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Nucleic acid-based therapies can be used to target the genetic basis of a disease and have 
been explored for the treatment of wide range of medical conditions, including cancer. However, 
many of these therapies have largely been ineffective in the clinic due to off-target toxicities and 
poor targeting properties, resulting in poor safety and efficacy outcomes. To address these 
challenges, there has been a strong effort over the past decades to develop delivery vehicles for 
targeted nucleic acid delivery. A high degree of targeting is particularly critical when delivering 
cytotoxic therapies for cancer cell killing, as off-target toxicities can lead to dangerous or deadly 
adverse events. In the case of liver cancer, off-target toxicity has a high risk of liver failure due 
to the prevalence of severe underlying liver disease in these patients. 
The aim of this thesis is to investigate multiple methods for targeted DNA delivery to 
hepatocellular carcinoma, the most common form of liver cancer. Polyplex nanoparticles (NPs) 
synthesized using poly(beta-amino ester) (PBAE) serve as a delivery vehicle to deliver plasmid 
DNA to target cells. This thesis uses PBAE NPs to explore multimodal targeting using (1) 
anatomical targeting of tissues, specifically HCC tumor vasculature, (2) optimization of delivery 
vehicle biomaterials for HCC cell-specific transfection, and (3) an HCC-specific promoter to 
restrict therapeutic gene expression. These methodologies are explored independently and in 
combination to specifically deliver DNA to HCC cells in vitro and in vivo. Importantly, these 
targeting principles are applied to develop two targeted therapeutics for HCC, which show 
therapeutic efficacy in preclinical rodent models of HCC. Altogether, these results highlight the 
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Chapter 1: Introduction to the thesis1 
1.1 DNA Delivery 
Many important cancer-associated genes have been identified in recent years, underpinning 
new molecular therapeutics, including recent cancer gene therapy efforts1. The delivery of DNA 
and other types of nucleic acid allows cells to be altered at the genetic level, allowing for 
sequence-specific regulation of disease-associated gene expression2. By changing the gene 
expression profile of target cells, researchers can directly address the cause of diseases that have 
a genetic component, including cancer. Malignant cells with dysregulated gene expression 
patterns can be treated by inducing overexpression of genes that induce apoptosis or by 
decreasing the expression of genes that promote cancer cell survival. However, effective and safe 
intracellular delivery of nucleic acids to cancer cells remains a challenge. The ability to target 
cancer cells is crucial to maximize the efficiency of anti-cancer treatment as well as to avoid 
causing unwanted toxicity to healthy tissues.  
1.1.1 Barriers to Nucleic Acid Delivery 
 A major challenge in developing nucleic acid-based therapeutics is achieving successful 
delivery to target tissues and cells (Figure 1.1). Nucleic acids on their own are vulnerable to 
degradation and various mechanisms of clearance. In order to reach cells intact, they must be 
loaded or condensed into nano-sized structures that can protect them from the environment and 
 
This chapter contains material modified from the following published articles.  
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020). Cancer‐targeting nanoparticles for combinatorial nucleic acid 
delivery. Advanced Materials, 32(13), 1901081. 
Karlsson, J.*, Vaughan, H. J.*, & Green, J. J. (2018). Biodegradable polymeric nanoparticles for therapeutic cancer 





facilitate their trafficking to target sites. Polymer nanoparticles can be engineered into a variety 
of formulations, such as solid nanoparticles, core-shell structures, polymeric micelles, and 
polyplexes (Figure 1.2). The preferred nanoparticle formulation and synthesis method depends 
on the properties of the chosen polymer and cargo, and they are generally formed by either self-
assembly or an emulsion polymerization method. Self-assembly methods involve inter- and 
intramolecular interactions between the polymer itself and its cargo, such as complexation of 
cationic polymers with anionic nucleic acids to form polyplexes, as well as spontaneous micelle 
assembly when amphiphilic block copolymers reach a critical micelle and form particles owing 
to hydrophobic interactions. For emulsification synthesis methods, nanoparticles are formed as 
droplets of one phase dispersed in a second phase. Typically, the polymer is dissolved in an 
organic phase that is then mixed with a surfactant and sonicated in an aqueous phase with high 
intensity to form nanodroplets3. The emulsion is stirred until the solvent evaporates, leaving 
behind hardened polymer nanoparticles. These hard nanoparticles can also be coated with 
another material to form core-shell nanoparticles with favorable surface properties4,5. 
Nanoparticles administered intravenously must avoid rapid clearance by the mononuclear 
phagocyte system6,7. Macrophages in the liver and spleen phagocytose and degrade nanoparticles 
in the 10-200 nm size range, reducing circulation time and minimizing nanoparticle 
accumulation in the tumor. This process can be slowed by reducing interactions between 
nanoparticles and macrophages. One common method is to shield the surface of the 
nanoparticles by coating them with poly(ethylene glycol) (PEG), a hydrophilic molecule that 
prevents adsorption of serum proteins and non-specific binding to cells8.  
Nanoparticles must be internalized by target cells to deliver the nucleic acid payload to the 
cytoplasm. Because the glycocalyx and lipid bilayer cell membrane have a net negative charge 
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on the extracellular surface, cationic nanoparticles facilitate cellular binding and uptake via 
electrostatic interactions9–12. Surface modification with certain moieties, such as cell-penetrating 
peptides (CPPs) or active targeting ligands, can be used to further improve overall cellular 
uptake of nanoparticles13–17. Nanoparticles are taken up by endocytic vesicles, then the 
endosomal pH is lowered as the vesicle progresses to the late endosome stage. Polymeric 
nanoparticles often incorporate H+ buffering polyamines into the polymer to promote the 
endosomal rupture through the proton sponge effect18,19. The amines of the cationic polymer are 
protonated as the pH decreases, causing accumulation of Cl− and osmotic swelling within the 
endosome, which generates a 140% increase in endosome volume in a process known as the 
proton sponge effect18. This volume increase facilitates endosomal rupture, releasing the 
nanoparticle cargo into the cytoplasm. Additionally, cationic or fusogenic components can 
interact with the anionic endosomal membrane and destabilize the compartment, causing release 
of the cargo into the cytoplasm20.   
Once nanoparticles are released from the endosome, the nucleic acid cargo must be released 
from the nanoparticle, which can occur by a decrease in binding between cargo and delivery 
material and/or degradation of the material itself21,22. Plasmid DNA must enter the nucleus, and 
diffusion of large biomacromolecules like plasmid DNA through the cytoplasm to the nucleus is 
very slow This can be improved upon by the attachment of a nuclear localization signal (NLS) to 
the plasmid or the nanocarrier23, promoting the binding of the DNA cargo to import proteins that 
can actively facilitate nuclear transport and entry24. It is therefore unsurprising that plasmid DNA 
delivery by non-viral nanocarriers has often been found to be much more efficient in dividing 
cells25–27. While non-mitotic mechanisms of nuclear entry have been demonstrated28, nuclear 
transport remains a key challenge for non-viral delivery of plasmid DNA. Given the long history 
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of using uncontrolled cell division as a method of targeting cancer cells while they are in 
mitosis29, however, this nuclear barrier to plasmid DNA delivery could in fact serve as an avenue 
to improving the selectivity of an anti-cancer gene therapy. 
Because of the complex sequential barriers that nucleic acid delivery nanoparticles must 
overcome, the properties described here should be considered together. For example, while 
cationic materials are convenient for encapsulation or complexation of anionic cargo, positively 
charged materials can also cause toxicity by disrupting the cell membrane30. On the other hand, 
decreasing the molecular weight31 or introducing biodegradable functional groups32 into the 
polymer materials has been shown to increase the safety of the nanomaterial33–35. Further, 
different types of nucleic acid cargos have distinct delivery challenges, so their delivery vehicles 
require different properties (Table 1.1). Thus, a combination of optimized parameters should be 
used to design an ideal nanoparticle delivery vehicle. 
1.1.2 Biomaterials 
Many types of materials exist as constituent building blocks of nanocarriers, including both 
natural and synthetic materials (Figure 1.3). Synthetic strategies include inorganic nanoparticles, 
such as those composed of gold36,37 or iron oxide38, which have intrinsic ability for imaging, 
sensing, and diagnostic applications39,40 but can have significant limitations for drug loading and 
drug release for therapeutic applications41. Organic materials such as lipids have had a relatively 
long history of use for delivering biomolecules for therapeutic purposes. These include 
therapeutics such as DOXIL®, liposomal doxorubicin surface-coated with PEG, which has been 
used to treat multiple cancers, including breast and ovarian cancers42–44. Many types of polymer 
materials have also been developed for drug delivery and have multiple benefits, including the 
ability to tailor the physical, chemical, and biological properties of the nanocarrier. 
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Biodegradable polymers are especially appealing because they break down in physiological 
conditions, which generally both reduces the toxicity of the carrier and facilitates drug 
release45,46. 
1.1.3 Natural Polymers 
Many naturally derived polysaccharide and protein-based polymers (Figure 1.4) have 
already been approved for diverse food, cosmetic, and medical applications47. They show 
excellent biocompatibility since they are broken down by enzymatic degradation into easily 
metabolized peptides or polysaccharides in the body, and this degradation rate can be tuned for a 
desired release profile48. However, these polymers are more variable batch to batch, often require 
chemical modification to act as efficient nanocarriers, and must be extensively purified to avoid 
immunogenicity. 
Chitosan is a linear polysaccharide derived from chitin, an abundant natural biopolymer 
found in the exoskeleton of insects and crustaceans49. Chitosan is synthesized by the 
deacetylation of chitin, which forms primary amine groups, making the polymer cationic in 
dilute acidic solutions. As a result, chitosan electrostatically binds to and complexes with 
negatively charged macromolecules such as nucleic acids to form polyplexes50,51. Chitosan’s 
positive charge increases cell uptake and adhesion to negatively charged mucosal surfaces, 
making it well-suited for oral drug delivery52. Degradation is highly tunable and can be 
optimized for biomedical applications by varying molecular weight, degree of deacetylation, and 
chemical modifications53. 
Dextran is a branched polysaccharide composed of simple repeat units of α-D-glucose joined 
by glycosidic bonds54. Dextran is hydrophilic and water soluble but can be acetylated to create a 
hydrophobic polysaccharide (AcDex)55. For drug delivery, it is typically combined with 
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crosslinkers to form a hydrogel or coating. Further, dextran can be linked to a hydrophilic 
polymer such as PEG, poly(ε-caprolactone) (PCL), or polylactide (PLA) as a block copolymer to 
form amphiphilic micelles, which can be loaded with hydrophobic therapeutic agents56. 
Alginate is an inexpensive, naturally derived hydrophobic polymer purified from algae. It is 
linear and unbranched, consisting of blocks of β-1,4-linked mannuronic acid and α-(1–4)-linked 
guluronic acid residues57. Alginate is anionic, and introducing divalent cations such as calcium 
induces gelation58. It is easily functionalized owing to hydroxyl and carboxyl groups on the 
backbone, so its chemical and biological properties can be tuned59. Alginate is biocompatible and 
nonimmunogenic and is used in a range of Food and Drug Administration–approved products, 
from food additives to wound dressings59. 
Gelatin is a mixture of peptides and proteins derived from partial hydrolysis of animal 
collagen. It is biocompatible, nonimmunogenic, and widely used in food and cosmetic products. 
Gelatin nanoparticles have been investigated for both nucleic acid and small-molecule drug 
delivery to tumors60,61. However, natural gelatin generally binds therapeutic cargos too loosely, 
so it is thereby chemically modified for drug delivery applications. Carboxyl and hydroxyl 
groups allow for modification, including the introduction of thiol for direct conjugation of gelatin 
to the therapeutic cargo and redox-responsive degradation and release60,61. The isoelectric point 
of gelatin can be modified to optimize loading of charged drugs, and gelatin molecular weight 
and crosslinking density can be altered to control drug release62. 
Poly(L-lysine) (PLL) is the polymerized form of lysine, a cationic amino acid, with L 
stereochemistry for natural enzymatic degradability. High positive charge density of the polymer 
allows PLL to efficiently condense negatively charged molecules into nanoparticles. Further, its 
positive charge improves particle uptake, so PLL is often used as a coating on core-shell 
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nanoparticles. PLL can be synthesized in linear and dendritic forms, with dendritic PLL 
exhibiting enhanced buffering capability and improved nucleic acid delivery63. 
1.1.4 Synthetic Polymers 
Synthetic polymers (Figure 1.4) are engineered with desirable properties, such as charge, 
hydrophobicity, and degradation profile, which are optimized for particular cargos, delivery 
routes, and disease targets. Synthesis is controlled for low batch-to-batch variability, and 
production is typically scalable for large-scale manufacturing. However, unintended degradation 
products or metabolites can cause synthetic polymers to be cytotoxic or immunogenic. 
PLA exists in two optically active forms, because the lactide molecule is chiral: L-lactide and 
D-lactide. The degradation of poly(L-lactide) is too slow for drug delivery systems; hence, 
poly(DL-lactide) is the preferred candidate owing to its faster degradation rate64. PLA undergoes 
hydrolytic degradation as random scission of the ester bonds occurs, releasing the particle cargo. 
To improve its use for gene delivery, tertiary amines are grafted onto the PLA backbone and 
serve as a source of positive charge to promote electrostatic interactions with nucleic acids65. The 
charge density can hence be adjusted through varied degrees of functional groups to the polymer 
structure. 
Poly(lactide-co-glycolide) (PLGA) is a copolymer of lactic acid and glycolic acid. PLGA is 
an attractive delivery material because of its high stability and low toxicity and a degradation 
rate that is easily tuned by varying the ratios of the constituent monomers. PLGA nanoparticles 
are typically synthesized by emulsion methods and are used to encapsulate small-molecule 
drugs. Surface modification with the addition of cationic ligands promotes efficacy of gene 
delivery, for example, using cationic lipids for small interfering RNA (siRNA) delivery66. 
PCL is a hydrophobic, semicrystalline biodegradable polymer with a high capacity for drug 
8 
 
binding and biodegradable properties due to the fact that ester bonds break under physiological 
conditions67. PCL is a hydrophobic, semicrystalline biodegradable polymer with a high capacity 
for drug binding and biodegradable properties because ester bonds in the polymer backbone are 
hydrolyzed under physiological conditions67. PCL exhibits high colloidal stability in a biological 
fluid, facile cellular uptake by endocytosis, low toxicity in vitro and in vivo, and controlled cargo 
release68. Thus, this polymer has been used in tissue engineering scaffolds, biomedical devices, 
and drug delivery devices, such as the implantable contraceptive Capronor®69. PCL is often 
blended with other biodegradable polymers to speed degradation rate. In cancer nanomedicine, 
PEG–PCL block copolymers have been used to form micelles encapsulating 
chemotherapeutics70,71. 
Cyclodextrins are water-soluble synthetic carbohydrates composed of six to eight glucose 
units in a ring structure. Cyclodextrins form an amphiphilic cup shape with a hydrophilic exterior 
and hydrophobic interior. Adamantine-PEG (AD-PEG) functionalization is used for nanoparticle 
stabilization without disturbing the electrostatic interactions to anionic cargos. Functionalized 
cyclodextrins have thereby been shown to form stable complexes with DNA and high 
transfection efficiency with low cytotoxicity72,73. 
1.1.5 Poly(β-amino ester) (PBAE) 
Poly(-amino ester) (PBAE) libraries are synthesized by reacting diacrylates with amine 
monomers, including different structures of backbone, side-chain, and endcapping monomers, to 
form polymers with diverse properties, including size, charge, and hydrophobicity74,75. By using 
high-throughput screening, PBAE formulations have been selected for high transfection efficacy, 
low toxicity, and cell-type specificity for targeted gene delivery to cancer cells76,77. For example, 
specific PBAE structures can provide a preferential DNA and siRNA delivery to patient-derived 
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glioblastoma cells over healthy human progenitor neural cells78,79. 
PBAEs are cationic, contain ester bonds that are hydrolytically cleavable, and can be 
engineered with primary, secondary, and tertiary amines80. These properties enable the polymers 
to bind anionic cargos and facilitate endocytosis, endosomal escape, and intracellular release of 
cargo, enabling efficient gene delivery77. To further promote cytoplasmic degradation, 
bioreducible disulfide linkages have been introduced into the polymer structure, enabling more 
efficient, triggered siRNA release in the reducing environment of the cytosol compared with 
release from ester bond hydrolysis alone79,81. 
1.2 Approaches for Tumor Targeting   
An overarching challenge in cancer therapeutics, including in nanomedicine, is achieving 
sufficient concentrations of an anti-cancer agent in the tumor while minimizing off-target 
toxicities in healthy tissues. Targeting methods take advantage of features that differentiate 
cancer from healthy tissue, including properties of the tumor microenvironment, overexpressed 
molecules on the cancer cell surface, and dysregulated gene expression. Nano-scale delivery 
vehicles are uniquely capable of passive targeting, active targeting via ligand functionalization, 
and controlled or triggered release. Additionally, nucleic acid cargos can themselves be 
engineered to take advantage of aberrant gene expression in cancer cells and achieve cancer 
specificity through their mechanism of action. Tumor targeting must be carefully considered 
when developing these delivery vehicles to maximize cargo delivery to cancer cells while 
avoiding dangerous off-target effects.  
1.2.1 Passive Targeting 
Hypervasculature, enhanced vascular permeability, and decreased lymphatic drainage are all 
hallmarks of rapidly growing tumors. The abnormal architecture of angiogenic tumor blood 
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vessels underlies the enhanced permeability and retention (EPR) effect, which describes the 
tendency for systemically administered macromolecules within a 10-200 nm size range to 
accumulate in solid tumors82. Nanoparticle formulations of chemotherapies, such as Doxil® (for 
doxorubicin) and Abraxane (for paclitaxel), were developed in response to this phenomenon and 
have improved pharmacokinetics, an increased maximum tolerated dose, less systemic toxicity, 
and improved therapeutic efficacy compared to their free drug counterparts43. Nanoparticle size 
is a key predictor of passive targeting because size affects clearance rate and route, extravasation 
into tumor tissue, cellular uptake, and interactions with the immune system. The range for 
passive targeting by the EPR effect is around 10-200 nm, although tumor accumulation has been 
described for slightly smaller or larger particles. Particle accumulation in the tumor compartment 
is in competition with clearance, either by the renal system or the MPS, which is comprised of 
macrophages predominately in the liver and spleen. Particles smaller than 10 nm are rapidly 
cleared by the renal system and tend to accumulate in the kidney, while larger particles 
accumulate in the liver and spleen83. Both clearance routes compete with accumulation in tumor 
tissue, so developing particles with low clearance rate and high circulation time is the primary 
goal for passive targeting by EPR.  
Inspired by the cylindrical or filamentous shapes of many viruses, non-spherical geometries 
have been explored for therapeutic drug and nucleic acid delivery. Long cylindrical, rod-like, 
disk-shaped, or filamentous particles have been shown to evade phagocytosis by resident 
macrophages. There is evidence that the contact angle between macrophages and particles affects 
phagocytic uptake; contact with a flatter surface such as a rod or disk causes macrophage 
spreading rather than phagocytosis84. Additionally, in dynamic fluid flow, filamentous particles 
elongate and align with flow, and hydrodynamic shear forces pull particles off of 
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macrophages85.These effects slow the uptake of filamentous particles by the MPS and can 
dramatically increase circulation times. For example, Geng et al. developed filamentous micelles 
(filomicelles) which remains in circulation 1 week after injection, while spherical versions are 
cleared within 2 days (Figure 1.5)86. Increased circulation time is correlated with enhanced 
therapeutic efficacy of paclitaxel-loaded filomicelles in a subcutaneous xenograft model. Micelle 
length appears to be a critical factor: an eight-fold increase in filomicelle length had the same 
therapeutic benefit as an eight-fold increase in paclitaxel dose.  
Along with size and shape, surface properties are a key parameter affecting biodistribution 
and cellular uptake. For example, nanoparticles with a strong charge or a hydrophobic surface 
attract serum proteins, which adsorb to the surface and form a protein corona. Adsorption of 
opsonins, such as IgG or complement factor, tag the protein for clearance by the immune system. 
A protein corona can also block targeting ligands that have been conjugated to the particle 
surface. Therefore, a neutral hydrophilic charge is typically desirable for systemically 
administered nanocarriers. PEGylation of particles is often used to reduce non-specific protein 
adsorption87,88. PEG can be incorporated into block co-polymers, conjugated to the surface of 
inorganic particles, or incorporated into liposomal formulations, making it an attractive option 
for a variety of delivery applications. PEGylation reduces uptake by the MPS and dramatically 
extends circulation time, particularly when particles are coated with high-molecular weight PEG 
at a high density45,89. Thus, many nanocarriers for cancer targeting are coated with PEG to 
increase blood circulation half-life and enhance passive targeting. However, bioinert hydrophilic 
carriers, due to their reduced binding to proteins and cellular components, also tend to have poor 
intracellular uptake and endosomal escape, and this related but unintended consequence is 
known as the PEG dilemma90. 
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While EPR has been a significant discovery in preclinical models, passive targeting is a 
complex and highly variable process that depends on the size, degree of vascularization, and 
location or the tumor91,92.There is also often a high degree of heterogeneity within tumors, with 
changes in cell density, interstitial pressure, and extracellular matrix composition affecting how 
nanoparticles move through different regions of tumor tissue93. These parameters are not easily 
recapitulated in vitro, and screening nanoparticles for in vivo delivery is traditionally low 
throughput and expensive.  
1.2.2. Active Targeting 
The large surface-to-volume ratio inherent to nanocarriers facilitates their interactions with 
biomolecules and cells. While methods described above have been employed to minimize this, 
thus extending the circulation time of nanocarriers, such interactions can also be leveraged as an 
advantage. Particles may be functionalized with active-targeting molecules that will specifically 
interact with the target and enrich particle accumulation in that site94–96. Nanoparticles have been 
functionalized to target various surface macromolecules on cancer cells, including overexpressed 
or mutated proteins, altered glycoproteins or glycolipids, and cancer-associated fetal proteins. 
Particles can also target molecules overexpressed in the tumor microenvironment, such as 
integrins, which are overexpressed on tumor vasculature97,98. Optimizing active molecular 
targeting of nanocarriers requires careful selection of a conjugation chemistry by which to attach 
targeting molecules to the particle surface. Different conjugation strategies can be selected 
depending on the bulk particle material, targeting ligand, and desired application. It is possible to 
harness hydrophobic or electrostatic interactions to functionalize nanoparticles by nonspecific 
adsorption, which enables functionalization without chemical modifications or complex 
reactions99. However, this requires the use of large amounts of targeting molecule and targeting 
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ligands may be displaced by other biological molecules in a physiological environment. Thus, 
covalent conjugation is commonly used for irreversible attachment of targeting ligands. 
Biological molecules such as proteins or peptides contain primary amines, which react with 
activated carboxylic acid groups on a nanocarrier to form an amide bond100. Common carboxylic 
acid-activating compounds include carbodiimidazole (CDI), as well as carbodiimide compounds, 
such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), often in combination with N-
hydroxysuccinimide (NHS), or dicyclohexylcarbodiimide (DCC)101. Alternatively, cysteine 
residues in proteins or peptides contain thiol groups that can be reacted with maleimide-
containing particles102. Proteins can also be functionalized with biotin for reaction with 
streptavidin-coated particles. To control ligand orientation on the particle surface, these reactive 
groups can be introduced at specific locations on the protein, either during synthesis or after 
protein purification96,103. Particles can also be coated with Protein A or Protein G, which bind the 
Fc region of antibodies and facilitates properly oriented conjugation. Conjugating targeting 
molecules via a flexible linker, such as PEG, allows the conjugated ligand or antibody to rotate 
and move freely in space for optimal binding with a target104. 
Conjugation methods can also dictate ligand density on the particle surface, which has 
proven an important parameter for optimization. For example, using various ratios of ligand-
functionalized and unfunctionalized PEG for particle coating can significantly affect uptake by 
target cells105. While enriching the targeting ligand can lead to multivalent complexation and 
enhanced affinity, a saturation effect or even reduced binding has been reported106,107. This effect 
has been attributed to multiple factors, including steric hindrance or suboptimal receptor 
clustering. Nanoparticle size and shape also dictates surface curvature and contact surface area, 
which can affect interactions between particles and target cells108. Therefore, although ligand 
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density has been optimized in detail for particular nanocarriers109, optimal parameters vary 
greatly depending on the size, shape, and material composition of the particle as well as size, 
chemistry, and avidity of the particular targeting ligand110,111. These parameters are summarized 
in (Figure 1.6). 
A.  Antibodies and Fragments 
Antibodies have been extensively explored as therapeutics because they can be engineered to 
target almost any antigen with a high degree of specificity112. Monoclonal antibodies have been 
used in cancer therapy for over 20 years, and patient responses are well-understood, so they are a 
natural choice for nanoparticle targeting113. While antibody therapies work by blocking or 
binding a receptor on a cancer cell, nanoparticles harness the specificity of antibodies while 
incorporating additional therapeutic modes of action by encapsulating a drug or imaging agent or 
acting as a therapeutic itself. For example, trastuzumab is a monoclonal antibody for HER2 that 
is used clinically for breast cancer, and conjugating this antibody to gold nanoparticles showed 
promise as a photodynamic therapy, a strategy to ablate tumor tissue with a high degree of 
precision114. Antibodies can also bind to endocytic receptors on target cells and facilitate cellular 
uptake, which is necessary for functional nucleic acid delivery115,116. However, antibodies are 
bulky and significantly increase the size of conjugated nanoparticles. Safety concerns have also 
been raised, even with clinically approved monoclonal antibodies, regarding their 
immunogenicity117. 
With the clinical success of antibody therapies came interest in developing molecules with 
the same specificity but smaller size. That initiative sparked the invention of next-generation 
antibodies, including single chain antibodies, domain antibodies, and nanobodies118–120. Single-
chain antibody fragments have been extensively explored for active targeting, since they 
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maintain the antigen-binding capability, are one fifth the size of full antibodies, and are 
considered safer than antibodies121. Antibodies and fragments are developed through display 
libraries, which preferentially and rapidly select for candidates which bind target cells and are 
internalized122,123. Because fragments can be screened for intracellular uptake, functionalized 
particles have been explored for nucleic acid delivery. For instance, liposomes surface-
conjugated to a melanoma-targeted antibody fragment showed a significant therapeutic benefit in 
melanoma lung metastases, while non-targeted control particles had no significant effect124. 
Because of their small size, antibody fragments targeting EGFR have been conjugated to very 
small particles (quantum dots and 10-nm iron oxide nanoparticles) for high-sensitivity diagnostic 
imaging125.  
B. Ligands 
Another approach to cancer cell targeting is functionalizing nanocarriers with ligands for 
overexpressed receptors, such as epidermal growth factor receptor (EGFR) and transferrin 
receptor. Many of these surface receptors are well-characterized cancer biomarkers, and ligands 
for these receptors have been identified and studied, which has led to their extensive 
development for active targeting. The natural ligands for overexpressed receptors range from 
proteins to carbohydrates to small molecules, such as vitamins126. Alternative small molecule 
ligands may also be developed using computational modeling and binding experiments, which 
expands targeting possibilities beyond the native ligand for a receptor127. 
Cancer-specific receptors can have a variety of functions, but nucleic acid delivery benefits 
from active targeting to endocytic receptors, which facilitate cancer-specific uptake and 
intracellular delivery. The transferrin receptor is a commonly overexpressed endocytic receptor 
on cancer cells and can be targeted by transferrin (Tf) protein-coated particles128. In another 
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example, hyaluronic acid (HA) functionalization facilitates uptake via overexpressed CD44 
receptors. HA can serve as a bulk scaffold material for self-assembled nanoparticles or as a 
coating to functionalize particles composed of alternate materials, such as mesoporous silica129. 
Small molecule ligands also offer specificity to overexpressed receptors with minimal 
increase in particle size. Folic acid has been extensively studied as a targeting ligand due to its 
high affinity of the folate receptor, which is overexpressed in approximately 40% of cancer 
types, including breast, lung, ovarian, and colorectal cancers130,131. Small molecule 2-[3-[5-
amino-1-carboxypentyl]-ureido] pentanedioic acid (ACUPA) is a high-affinity small molecule 
ligand of PSMA which has shown targeting properties in vivo and in vitro132,133. BIND-14, a 
PEG-PLGA nanoparticle with ACUPA active targeting for docetaxel developed by BIND 
Therapeutics, was evaluated in clinical trials for PSMA-targeted docetaxel delivery to prostate 
cancer111. ACUPA has recently been employed for PSMA-targeted delivery of siRNA to prostate 
cancer cells. For example, Xu et al. developed a nanocarrier comprised of a pH-responsive 
polymer blend coated with PEG-ACUPA for PSMA targeting to deliver siRNA targeting 
prohibitin (Figure 1.7)134. ACUPA-targeted NPs significantly suppressed tumor growth over 
non-targeted NPs after 30 days, showing the benefit of active targeting in this case134. 
Diseased or cancerous cells often display a different array of surface glycans compared to 
healthy cells, offering another targetable feature135,136. Lectins can be used to target drugs or 
nanoparticles specifically to cells displaying these abnormal features137. One useful example is 
targeting asialoglycoprotein receptors on liver cancer cells with galactosamine-conjugated 
nanoparticles138–140. Lectin conjugation can also facilitate transport across the blood-brain 
barrier, which typically serves a major hurdle for delivery to brain tumors. For example, 
nanoparticles modified with wheat germ agglutinin enhanced delivery to the brain two-fold over 
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unmodified nanocarriers141.  
 An alternative to direct ligand conjugation is coating nanocarriers with cancer cell 
membranes. Recent research describes homotypic cancer cell binding—a phenomenon where 
cancer cells preferentially bind to membranes which carry the same surface antigens142. To 
harness this feature, researchers have coated nanoparticles with modified and unmodified cancer 
cell membranes, which provides a stealth coating as well as tumor homing properties143. This 
straightforward approach enables particle functionalization with the complete range of tumor 
ligands in a biomimetic manner and facilitates cancer-specific accumulation and uptake. 
C. Aptamers 
As discussed, many ligand-based active targeting systems are restricted to a biological ligand 
binding its natural target receptor. Aptamers are single-stranded DNA or RNA oligos that serve 
as attractive targeting alternatives. These nucleic acid molecules form sequence-specific three-
dimensional structures and can be engineered to bind virtually any target, from small molecules 
and single amino acids to proteins, carbohydrates, and whole tumor cells. Aptamers are attractive 
for nanoparticle targeting because they have low molecular weight and can include chemical 
modifications for particle conjugation.144.  Targeted aptamers are selected from a large library of 
random sequences using systematic evolution of ligands by exponential enrichment (SELEX)145. 
In each round of this process, the aptamer library is exposed to the desired target, unbound 
sequences are washed away, and bound sequences are selectively eluted and amplified using 
PCR. The process is repeated in subsequent selection rounds with more stringent binding 
conditions to generate tightly binding aptamers with antibody-like affinity and specificity.  
Aptamers have been extensively explored in the past decade and have yielded novel selection 
methods for cancer targeting. Cell SELEX selects for aptamers that bind to a monolayer of 
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cultured cancer cells, rather than purified antigen146. This selection method generates a diverse 
pool of targeting aptamers that bind to or are internalized by the target cell population (Figure 
1.8)146–148 Methods have also been developed for in vivo SELEX, where aptamers are selected by 
binding tumors in situ in animal models149. This has resulted in aptamers with minimal off-target 
binding to healthy tissues that can bind multiple cell types in heterogeneous tumors150. Because 
aptamers can be generated for a range of molecules expressed in tumors, this targeting approach 
circumvents the problem of resistance, which is common when targeting a single receptor151.  
D. Integrins 
The integrin profile of tumors is distinct from that of healthy tissues, and several integrins are 
upregulated on tumor endothelial cells and cancer cells152,153. The αVβ3 integrin is significantly 
upregulated in many cancers and can be targeted with a simple RGD peptide motif. RGD-
targeted nanoparticles bind selectively to αVβ3 integrins, and this interaction facilitates selective 
endocytosis into angiogenic endothelial cells and cancer cells154. This approach has been used to 
efficiently deliver nucleic acids to tumor vasculature, for example to deliver siRNA against 
VEGF-R2 and inhibit both angiogenesis and tumor growth155. Because αVβ3 is expressed on 
both endothelial cells and cancer cells, RGD facilitates cancer cell targeting in addition to 
endothelial targeting. This dual targeting is a major advantage of RGD-functionalized 
nanocarriers. RGD-targeted chitosan nanoparticles containing siRNA have been used to 
successfully downregulate drug efflux transporter P-glycoprotein expression and reverse 
multidrug resistance in a breast cancer model156. Other integrins can serve as therapeutic targets, 
including arresten (α1β1), canstatin (αvβ3 and αvβ5), angiostatin (αvβ3), tumstatin (αvβ3), 
endostatin (αvβ3, αvβ5, and α5β1), and endorepellin (α2β1)157.  Nanoparticles have been used to 
deliver these anti-angiogenic agents158 or the genes that encode them159. 
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Despite promising preclinical data for active targeting in nanomedicine, no FDA-approved 
nanocarriers have employed active targeting strategies. Active targeting increases the complexity 
and potential immunogenicity of a drug delivery system, which makes it more difficult, time 
consuming, and expensive to develop. Further complicating their optimization is the binding site 
barrier effect, where antibodies or nanoparticles bind target cells with high affinity and cannot 
penetrate throughout the tumor160,161. BIND-014 was an early targeted nanocarrier to enter 
clinical trials, and it benefitted from rigorous and systematic optimization of particle properties 
(size, surface properties, drug loading etc.) in preclinical studies and biodistribution validation in 
multiple animal models (mouse, rat, and monkey)111. This rigor is essential when increasing the 
complexity of a platform and should be a model for active targeting in the future.  
Target identification remains a major hurdle, and even well-characterized targets are almost 
always heterogeneously expressed within tumors. Additionally, many of the receptors 
overexpressed on cancer cells, including transferrin and folate receptors, are also expressed on 
proliferating healthy cells, so targeting these receptors can lead to off-target side effects and 
systemic cytotoxicity162. Thus, efforts should be focused on developing companion diagnostic 
methods to characterize target expression and predict patient response. Radiolabeled tracers 
based on the RGD peptide sequence are already in clinical development for monitoring αVβ3 
integrin expression in patients163. Such advanced diagnostic tools are needed to study biomarker 
distribution within patient populations and assess the feasibility of actively targeted nanocarriers 
for personalized medicine. 
1.2.3 Stimulus-Responsive Targeting 
As tumors grow and develop, cancer cells exist in a constantly changing environment, 
influenced by high cell density and low blood supply. Solid tumors have an abnormally acidic 
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pH, are subjected to low oxygen, and have a high concentration of certain enzymes164. These 
properties of the tumor microenvironment are targetable features that can be exploited for 
nanoparticle targeting and controlled release (Figure 1.9). To respond to an environmental 
stimulus, nanocarriers must include responsive chemistries that change the properties of the 
particle when it encounters a trigger. This triggered response can expose binding domains, 
dismantle a protective coating, or change particle surface properties to facilitate cancer-specific 
uptake.  
Zwitterionic polymer nanoparticles are neutrally charged in physiological conditions, which 
confers stability, resists serum protein adhesion, and prevents clearance164. In the slightly acidic 
tumor microenvironment, the zwitterionic polymer becomes protonated and switches to cationic, 
facilitating uptake into cancer cells165. Cleavable PEG linkers can similarly be used to facilitate 
tumor cell uptake. Inert PEG coatings are commonly used in drug and gene delivery to enhance 
particle stability in circulation and increases the circulation half-life. However, as mentioned 
above, PEG coating also tends to decrease cellular uptake of particles90. To address this, 
researchers have coated particles with cleavable PEG, which is released in response to a trigger. 
For example, matrix metalloproteinases (MMPs), enzymes associated with angiogenesis and 
tumor growth, have been explored for triggered PEG de-shielding in a tumor-specific manner166. 
A multifunctional envelope-type nano-device (MEND) functionalized with MMP-cleavable PEG 
maintained the prolonged serum stability characteristic of PEG functionalized particles. Further, 
carriers conjugated with cleavable PEG exhibited superior in vitro and in vivo tumor transfection 
over carriers with non-cleavable PEG167,168.  
Responsive vehicles can also facilitate cytosolic release of nucleic acid cargo, which is 
particularly important for an efficient therapeutic response from RNA, since these molecules act 
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in the cytoplasm. Polymer nanoparticles often incorporate disulfide bonds, which degrade in the 
reducing environment of the cytoplasm and release their cargo. Using a bioreducible polymer 
reduces the toxicity of the nanocarrier while ensuring full protection of the easily degraded RNA 
cargo. pH can also trigger release in the acidic endosomal environment for site-specific cellular 
delivery. Acidic pH can trigger a shape change or expansion which disrupts the endosome and 
releases nucleic acid directly in the cytosol. Lipid-based liquid crystalline nanoparticles, termed 
nano-transformers, expand in a pH 5 environment from needle-like structures to nanospheres169. 
This shape transformation was proposed to have improved endosomal escape by promoting 
membrane fusion with the endosome. In another approach, Luo et al used miRNA-catalyzed 
release to specifically trigger payload release in the presence of miRNA-21, which is 
overexpressed in many cancers170. Similarly, the DNA “nanosuitcase” developed by Bujold et al. 
opens conditionally in the presence of a miRNA or mRNA and releases its therapeutic oligo 
cargo171. This approach allows triggered intracellular release in response to a genetic biomarker, 
limiting its effects to cancer cells. Responsive vehicles for intracellular delivery ensure efficient 
and specific cargo release to allow all components in a combinatorial system to act 
simultaneously, which is likely important to achieve synergistic effects.  
Systemically administered nanocarriers can also be triggered by an external stimulus to 
enhance gene delivery at the tumor site. The properties of thermoresponsive polymer particles 
change in response to externally applied heat or cold, which can be harnessed for tumor-specific 
gene delivery172. Poly(N-isopropylacrylamide) (PNIPAM)-based polymer nanocarriers undergo a 
hydrophilic to hydrophobic transition when temperature is raised from 37° C to 42°C, which 
causes the particles to aggregate and enhances endosomal escape, resulting in 2 orders of 
magnitude enhanced transfection at hyperthermic sites173. Light-responsive particles have also 
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been used to enhance endosomal escape in a spatially controlled manner174. To harness this for 
siRNA delivery, a photosensitizer was combined with siRNA and encapsulated using the 
Lipofectamine commercial transfection reagent, and cells stimulated with light showed 10-fold 
higher silencing than non-stimulated cells175. Though this strategy has shown efficacy in vitro, 
photodynamic therapy in vivo is limited by the penetration depth of visible light through tissue. 
Magnetic coating or encapsulation of magnetic material can be used for magnetically guided 
nucleic acid delivery to a targeted site176,177. An applied magnetic field is used to concentrate or 
retain gene delivery particles at the tumor site, which has been used to enhance the delivery of 
DNA and siRNA in a process termed magnetofection176,178.  
 Ultrasound has been extensively used in combination with microbubbles for regio-
specific delivery of anticancer agents. Briefly, a nucleic acid nanocarrier is co-delivered with gas 
microbubbles, which are clinically approved for use as a contrast agent179. Co-localization of 
microbubbles and nanocarriers is essential for successful transfection, so the nanocarriers must 
be coupled to the surface of the bubble using covalent conjugation. Then, ultrasound is applied to 
the target area, and passage of ultrasound through tissue creates pressure waves, which cause the 
microbubbles to undergo cavitation and release energy that opens transient pores in surrounding 
cells. The co-delivered nanocarrier enters the cell through these sub-micron pores, which leads to 
significantly enhanced transfection at the site where ultrasound was applied. DNA-containing 
PEI polyplexes conjugated to microbubbles combined with ultrasound stimulation enabled gene 
delivery to implanted tumors in a mouse kidney with 40-fold higher expression in tumor tissue 
than control non-sonicated tissue180. In a similar approach, liposome-bearing microbubbles 
enhanced the delivery of an anti-fibrotic miRNA to diseased liver in rats181. Microbubble 
cavitation can also be used to open the blood-brain barrier and allow systemically administered 
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nanocarriers to reach tumors in the brain182. Because nanocarriers enter through pores in the cell 
membrane, they bypass endosomal uptake and are delivered directly to the cytosol183. The 
method is also non-invasive and provides precise spatial and temporal control over nucleic acid 
delivery. However, the precise location of the tumor must be known to effectively apply the 
ultrasound to the target site. Image-guided focused ultrasound has been used to localize 
ultrasound signal more precisely, particularly for opening the blood brain barrier184,185. Still, this 
approach is limited to primary tumor sites rather than dispersed metastases.   
1.2.4 Local Administration 
 When possible, local administration can increase particle concentrations at the target site 
while decreasing healthy tissue exposure. Direct intratumoral administration is not an option in 
most cases, as accessing the tumor would involve an invasive procedure. Surgical tumor 
resection can be used as an opportunity to deliver a therapeutic directly to the site, where any 
remaining cancer cells can be treated to prevent recurrence. Implanted drug delivery depots can 
deliver a therapeutic at a controlled dose over the course of weeks or months with a single 
implantation surgery186. Nucleic acid therapeutics have been encapsulated in hydrogel depots for 
local delivery and reduced systemic toxicity. Naked DNA can be incorporated in hydrogels for 
regenerative medicine and anti-cancer applications, but only low levels of gene transfer have 
been observed due to the absence of a carrier187,188. DNA/PEI polyplexes have been successfully 
encapsulated in hydrogels and show effective gene transfer in vitro and in choriallantoic 
membrane assays189,190. siRNA-loaded micelles have similarly been encapsulated in injectable 
polyurethane scaffolds for sustained local gene silencing191. The bulk hydrogel can be tuned to 
achieve the desired release kinetics, including varying material, molecular weight, crosslinking 
density, size, and geometry. Another advantage of hydrogels is the ability to encapsulate multiple 
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separate agents in a single gel and simultaneously target cancer by multiple modes of action. 
Locally implanted hydrogel patches have been used to simultaneously deliver chemotherapy, 
siRNA, and gold nanoparticles for photothermal therapy192. This strategy can also be applied to 
deliver nucleic acid cargos with different properties, for example RNA and DNA, at the same 
site with particles optimized for each particular cargo. Nanocarrier properties can be 
independently tuned for efficient and targeted nucleic acid delivery, but maintaining stability and 
bioactivity of encapsulated particles is a significant hurdle to successful transfection. 
  Certain tumors can be accessed with non-surgical and non-invasive delivery routes, 
which reduces the potential for complications and enables frequent repeated particle dosing. 
Aerosol delivery provides direct access to lung tissue and can be used as a delivery route for lung 
cancer193,194. An inhalable cationic liposome formulation for plasmid DNA is in clinical trials to 
treat cystic fibrosis, and a hyperbranched PBAE nanoparticle recently was used for mRNA 
delivery to lung epithelium (Figure 1.10)195,196. Patel et al. reported that hDD90-118 polyplexes 
remained stable after aerosolizing with a vibrating mesh nebulizer, which produced micro-sized 
droplets ideal for distribution throughout lung tissue195. They were able to transfect 24.6% of 
lung epithelial cells after a single dose, with transfection seen in all five lobes of the lung195. 
Delivery to other tissues, including the liver, spleen, and heart, was negligible, and there was no 
observed local or systemic toxicity195.While this platform has not been employed in lung cancer 
models, cancer treatment is an obvious potential application of these new inhalable technologies. 
The skin is uniquely accessible for local delivery, so topical applications are being explored for 
nanoparticle gene delivery to skin cancer197. Nanocarriers can be used to control permeation 
through the skin, and transport properties can be controlled independently of the cargo198. 
Chitosan nanoparticles have been used for antisense oligonucleotide and plasmid DNA delivery 
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to skin, with reporter gene effects persisting on rat skin for 6-7 days199,200. Free nucleic acid had 
no measurable transfection, indicating that a drug silvery system is required to effectively protect 
and deliver topically applied nucleic acids. Finally, oral delivery of nanoparticles allows direct 
access to tumors of the gastrointestinal tract201,202. Chitosan nanoparticles have also been 
explored for this purpose, as they are stable upon oral administration, can encapsulate nucleic 
acid cargos, facilitate transport across the intestinal wall, and can be functionalized for active 
tumor targeting203. Delivery to different tissues requires overcoming different barriers, which can 
be physical (surfactant, mucous, stratum corneum), biological (enzymes, resident immune cells, 
blood brain barrier), and chemical (harsh pH of the GI tract). Future work in this area must focus 
on enhancing particle stability, controlling release kinetics, and improving transport and 
permeability across these tissue-specific barriers in orthotopic tumor models. 
1.2.5 Nucleic Acid Targeting 
Cancer is fundamentally a condition caused by dysregulated gene expression, and nucleic 
acid therapies can treat the genetic basis of the disease by counteracting observed genetic 
changes. Advances in high throughput sequencing, microarray technologies, and novel 
computational models have resulted in a rapidly growing understanding of the genetic basis of 
cancer. We are now beginning to understand how particular genetic mutations and expression 
profiles correlate with disease stage, drug resistance, and potential for metastasis. Therefore, 
selecting certain nucleic acid cargos can target disease that is more aggressive, drug resistant, or 
likely to metastasize. Combinatorial strategies greatly increase the number of possible nucleic 
acid combinations that may be used to target a heterogeneous tumor population. Additionally, as 
illustrated thus far, combinatorial approaches have been successful in slowing tumor growth in 
these aggressive and difficult to treat cases.  
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One common approach is restoring the function of a mutated tumor suppressor with 
exogenous nucleic acids. Mutations in tumor suppressors have been associated with resistance to 
chemotherapy and radiation204,205. Tumor suppressor function can be restored by introducing 
nucleic acids, including DNA and mRNA, that encode for the wild-type protein206. For example, 
systemic delivery of PTEN mRNA using polymer-lipid hybrid nanoparticles was shown to slow 
tumor growth in multiple models of prostate cancer207. Modified mRNA shows enhanced 
stability compared to plasmid DNA therapies in systemic circulation with more predictable and 
desirable protein kinetics. P53 is another tumor suppressor that has been targeted in many 
clinical and preclinical trials208,209. Studies have shown that introducing p53 induces apoptosis in 
many cancer cells, but healthy cells only experience cell cycle arrest, which suggests inherent 
cancer-specificity to p53 gene therapy210,211. However, certain healthy cell types, including 
epithelial and hemopoietic cells, are sensitive to p53-induced apoptosis212,213. Also, p53 is part of 
a complex interconnected web of factors, and the efficacy of these therapies is limited by 
mutations in downstream factors and epigenetic changes, as well as heterogeneous p53 
expression throughout tumors213. While p53 mutations have been explored most extensively due 
to their prevalence, other tumor suppressors (e.g., Rb7, PTEN, or mda-7) have also been 
targeted214. 
An alternative approach is silencing of overexpressed oncogenes using RNAi. Many 
strategies involving siRNA or miRNA have been developed to target oncogenes for cancer 
therapy. Ideal targets are upregulated in cancer cells, are vital for cancer progression, and do not 
have a rapid turnover rate. Examples of targeted pathways include angiogenesis (VEGF), 
proliferation (FAK), survival (Bcl-2, survivin), cell cycle (PLK1, cyclin B1), and resistance to 
chemotherapy or radiation (c-myc)215. Knocking down these pathways can have a potent anti-
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cancer effect but can also affect the viability of healthy cells and tissues, leading to systemic 
toxicity. Brummelkamp et al. approached this problem by developing siRNA that specifically 
targets the oncogenic K-RASV12 allele without any effect on wild-type K-RAS expression, 
which is required for normal cell survival216. They showed that knocking down K-RASV12 with 
a viral vector completely prevented CAPAN-1 pancreatic cancer cell growth in vitro as well as in 
a subcutaneous tumor model. This approach is promising for specifically targeting cancers with 
mutations or chromosomal translocations that produce mRNA transcripts distinct from those 
expressed in healthy cells.  
Cancer cells are also more vulnerable to cell death through certain proapoptotic pathways, 
including TNF217, Fas218, and Bcl219. Tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand (TRAIL) induces apoptosis with a strong cancer selectivity, due to overexpression of 
TRAIL-binding death receptors on cancer cells220. Because recombinant TRAIL proteins have 
poor pharmacokinetics and a short circulation half-life, nucleic acid therapies are a promising 
approach to achieve sustained TRAIL expression. Co-delivery with small molecule sensitizers, 
including clinically approved chemotherapies, has been shown to reverse TRAIL-resistance and 
improve antitumor efficacy in a synergistic manner. A dendrimer nanocarrier co-encapsulating 
doxorubicin and a plasmid DNA expressing human TRAIL induced synergistic growth inhibition 
in U87 glioma cells221. This treatment administered intravenously induced observable apoptosis 
in an orthotopic murine glioma model, and the co-delivery vehicle extended median survival to 
57 days, compared to 34 days with doxorubicin alone. Another strategy for TRAIL therapy is to 
transfect or transduce tumor-homing stem cells ex vivo to secrete TRAIL in the vicinity of the 
tumor222. This strategy combines regio-selective delivery of the stem cells with the cancer-
specific TRAIL therapy and shows significant survival benefit in an aggressive brainstem glioma 
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model223. A secretable TRAIL construct has also been developed to enhance the bystander effect 
to neighboring cancer cells and further potentiate the antitumor effect224.  
Gene expression in cancer cells is modulated by differential expression of transcription 
factors, which can be exploited to restrict the expression of therapeutic genes to tumor cells. By 
placing transgenes under the control of certain promoters, it is possible to achieve tissue-specific, 
cell-specific, or exogenously stimulated expression225. For example, hTR and hTERT promoters 
drive telomerase activity, which is a common feature of most cancers and can activate genes in a 
cancer-targeted manner226. Tumor-specific promoters ideally have strong expression in cancer 
cells and little to no expression in healthy cells. For example, alpha fetoprotein (AFP) is 
transcriptionally silent in adult liver but is expressed in 70-80% of hepatocellular carcinoma 
cases227. When potent pro-apoptotic genes are placed under the control of the AFP-promoter, cell 
death is restricted to AFP-producing HCC cells, and no acute systemic toxicity is observed228. 
Transcriptionally targeted BikDD DNA delivered by DOPC-cholesterol liposomes prolonged 
survival in multiple xenograft and syngeneic orthotopic murine HCC models (Figure 1.11)228. 
Histological staining indicated that treatment-induced apoptosis was restricted to liver tumor 
cells, and cell death was not observed in healthy liver228. Many other tumor-specific promoters 
have been identified for particular cancer types, each with a different prevalence, expression 
profile, promoter strength, and tumor target. Another approach is to use promoters that respond 
to the tumor microenvironment. Hypoxia response elements (HREs) can be used to drive gene 
expression in hypoxic tumor environments, where cells are typically resistant to chemotherapy 
and radiation. Glucose-responsive promoters, such as hexokinase 2 and GRP78, respond to low 
glucose and high catabolism in tumors229–231. Finally, inducible promoters have been developed 
to respond to exogenous stimulation. Examples of stimuli include radiation, hyperthermia, and 
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small molecule drugs232–234. These promoters do not depend on the expression profile of the 
tumor, so the strength and duration of activation can be controlled. Ultimately, transcriptional 
targeting offers an opportunity to control expression at the cellular level, which can dramatically 
reduce off-target toxicity. 
Combinatorial delivery can also be used to counteract phenotypic changes in a particular 
subset of cancer cells, such as drug resistant or stem-like cells. A combination of miRNAs can be 
used to target multiple pathways involved in the stem-like phenotype of brain tumor initiating 
cells. This minor population of glioblastoma cells has been associated with tumor reoccurrence 
and drug resistance. Using pooled miRNAs to revert the stem-like traits in these cells has proven 
successful in inhibiting growth, neurosphere formation, and shrinking orthotopic xenografts in 
mouse glioblastoma models235,236. Therefore, particular combinations of nucleic acids can target 
certain phenotypes associated with aggressive or reoccurring disease. Pooled siRNAs have also 
been used as a treatment strategy to overcome multiple drug resistance. In one example, two 
siRNAs (anti-Pgp and anti-Bcl-2) were combined with epirubicin in a calcium phosphate 
inorganic nanoparticle as a treatment for drug-resistant liver cancer cells and tumors237. The 
study concluded that the combination therapy was effective due to simultaneous targeting of two 
drug resistance mechanisms: pump (anti-Pgp) and non-pump (anti-Bcl-2)237. Therefore, pooled 
nucleic acid combination therapies can act synergistically and address tumor heterogeneity by 
acting on multiple pathways with spatial and temporal synchronization.  
1.2.6 Multifunctional Targeted Nanocarriers 
The use of a cancer-specific cargo reduces the burden of developing a perfectly targeted 
nanocarrier, since off-target delivery will have minimal effect in normal cells. Further, 
combinatorial nucleic acid therapies can be selected to address tumor heterogeneity or to target a 
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particular cancer cell subtype. The targeting methods described here work at different levels: 
local delivery to the tissue of interest, responsive uptake in the tumor microenvironment, active 
targeting to certain cell types, and genetic targeting to particular expression profiles. Thus, these 
orthogonal targeting mechanisms can be combined into highly targeted multifunctional 
nanocarriers. The multifunctional envelope-type nano-device (MEND) developed by 
Hatakeyama et al. integrates multiple strategies for successful cancer-specific nucleic acid 
delivery168. MEND is a nanocarrier comprised of nucleic acid condensed by a cationic polymer 
coated with a lipid envelope, which has been functionalized with various combinations of 
responsive and targeting features. For example, one iteration of the platform combines MMP-
cleavable PEG and pH-sensitive fusogenic peptides to overcome the PEG dilemma and 
specifically enhance cellular uptake of siRNA in solid tumors20. Combining transcriptional 
targeting with particle targeting is another promising dual-targeting strategy, demonstrated by 
Cocco et al.238 They developed a PLGA-PBAE blend nanoparticle functionalized with tumor 
targeting c-CPE peptides and used these particles to deliver a diphtheria toxin subunit A (DT-A) 
gene under the control of the cancer-specific p16 promoter. The dual-targeted particles 
efficiently transfected primary patient cells and significantly slowed tumor growth in 
chemotherapy-resistant ovarian cancer models.  
Multifunctional particles also have the potential to achieve stepwise release of therapeutic 
agents. For example, core-shell particles can release siRNA molecules from an outer polymer 
layer in a glutathione-responsive manner followed by slow release of a chemotherapy to 
overcome multi-drug resistance239. While multifunctional targeted particles show promise in 
preclinical studies, the lack of targeted particles in clinical trials for nucleic acid delivery is a 
testament to the complexity of implementing active targeting in a translational and scalable way. 
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Developing targeted nanocarriers requires additional testing, time, and expense, and the resulting 
product is often expensive to manufacture. Despite these hurdles, several next-generation 
actively targeted nanomedicines for nucleic acid delivery have entered clinical trials.  As more 
potent nucleic acid therapies are developed, particularly immunotherapies, a high degree of 
specificity will be essential to avoid dangerous off-target effects. Thus, these targeting strategies 
may serve as enabling technologies to bring nucleic therapies to patients. 
1.2.7 Clinical Results 
In recent years, several polymer nanoparticle formulations have been tested in the clinic with 
promising results, as outlined in Table 1.2. 
CALAA-01 (Calando Pharmaceuticals) was the first nanocarrier for siRNA delivery to reach 
clinical development in 200882. CALAA-01 is a cyclodextrin particle decorated with PEG for 
biological stability and transferrin ligands to target transferrin receptors overexpressed on cancer 
cells240. This carrier is used to deliver siRNA targeting the M2 subunit of ribonucleotide 
reductase. Tumor biopsies showed evidence of gene silencing by RNA interference, suggesting 
that targeted cyclodextrin nanoparticles are promising delivery vehicles for nucleic acids241. The 
therapy was shown to be safe in phase I trials, with minimal liver and kidney toxicity242. In the 
phase I trial, the most promising response was stable disease in one melanoma patient for four 
months242. 
Dr. Robert Langer of the Massachusetts Institute of Technology and Dr. Omid Farokhzad of 
Harvard Medical School developed a promising targeted and controlled release polymeric 
nanoparticle tested in humans. Their company, BIND Therapeutics, was founded around BIND-
014, a prostate-specific membrane antigen (PSMA)-targeted PLGA nanoparticle containing 
docetaxel111. The treatment was well tolerated with no unanticipated toxicities in phase 1 clinical 
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trials, and 6 of 52 patients responded to the treatment, one with a complete response243. 
Responses occurred in both PSMA-expressing and non-expressing tumors, indicating that 
passive targeting played a significant role. 
NanoCarrier Co. has completed phase I clinical trials with NC-6004, a polymeric micelle 
made of PEG-poly(amino acid) block copolymers. These particles have been tested in clinical 
trials to deliver cisplatin for lung, bladder, bile duct, pancreatic, and head and neck cancers. In 
phase I trials, the use of the nanocarrier increased the dose-limiting toxicity of cisplatin 34-fold, 
and stable disease was observed for longer than 4 weeks in 7 of 17 patients with solid tumors 
treated with NC-6004244. 
CRLX101 (NewLink Genetics Corporation) particles are formed with alternating units of 
cyclodextrin and PEG, which improves circulation time, and camptothecin is chemically linked 
to the polymer for pH-dependent release245. Phase I clinical trials showed acceptable safety and 
pharmacokinetics246. In phase II clinical trials, a measurable reduction in tumor size was 
observed in 74% of 22 patients with platinum-resistant ovarian cancer, and most recent results 
report a 16% response rate according to internationally recognized Response Evaluation Criteria 
in Solid Tumors (RECIST) criteria247. Preclinical and preliminary clinical studies suggest a 
synergistic effect with anti–vascular endothelial growth factor therapy bevacizumab, which will 
be further evaluated in future trials247,248. 
NK105, developed by Nippon Kayaku Co., is a micellar form of paclitaxel formulated from 
PEG-polyaspartate block copolymers. This nanoparticle formulation demonstrated preclinical 
success in increasing circulation time, reducing off-target toxicity, and improving the antitumor 
effect of paclitaxel249. Phase I trials showed a maximum tolerated dose 15 times higher than that 
of free paclitaxel250. In phase II trials, two full responses and 12 partial responses were observed 
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for a 25% overall response rate251. 
1.3 Specific Aims 
 The goal of this thesis is to explore several methods for targeting DNA delivery. The thesis 
begins by evaluating PBAE NPs for targeted delivery in vivo, exploring both systemic delivery of 
DNA (Chapter 1) and local delivery via the hepatic artery (Chapter 2). Then, biomaterial targeting 
is employed to deliver a pro-apoptotic cDNA to HCC cells (Chapter 3). Finally, transcriptional 
targeting is employed to restrict theranostic gene expression to HCC cells (Chapter 4).  
 
Specific Aim 1: Analyze and optimize tissue-specific DNA delivery by systemically and locally 
administered nanoparticles 
a) Develop a barcode DNA system as an enabling technology for high throughput analysis 
of biodistribution and transfection by systemically administered nanoparticles.  
b) Evaluate tumor-specific gene delivery by loco-regional delivery via the hepatic artery. 
Specific Aim 2: Apply cancer specific PBAE nanoparticles to deliver a novel secretable TRAIL 
(sTRAIL) therapy to human hepatocellular carcinoma  
a) Construct and characterize a vector and nanoparticle non-viral delivery vehicle for 
secretable TRAIL therapy 
b) Characterize cancer-specific apoptosis in vitro with combination sTRAIL nanoparticles 
and small molecule sensitizer treatment 
c) Assess tumor killing properties of sTRAIL therapy in vivo in a xenograft tumor model of 
human HCC 
Specific Aim 3: Engineer cancer specific PBAE nanoparticles to deliver theranostic 
transcriptionally targeted DNA to human hepatocellular carcinoma and achieve targeted cancer 
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cell killing and PET imaging 
a) Construct a clinically compatible theranostic vector harboring a cancer-specific promoter 
and SR39 suicide gene 
b) Evaluate transcriptional HCC targeting via in vitro delivery of SR39 for AFP-specific 
cancer cell killing and radiotracer uptake 
c) Deliver theranostic vector to orthotopic hepatocellular carcinoma, followed by systemic 
administration of a radiotracer and prodrug GCV to enable simultaneous PET/MRI imaging 
and tumor killing 
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1.5 Figures and Tables 
 
 
Figure 1.1 Challenges of nucleic acid delivery to tumors. Effective and specific delivery of 
nucleic acids to tumors requires encapsulation or condensation of the cargo into nanoparticles. 
Nanoparticles must then remain stable in circulation, evading clearance and avoiding aggregation 
with other particles, and then leave the circulation to accumulate at the tumor site. Once there, 
particles must enter cells, and various intracellular barriers must be overcome depending on the 






Figure 1.2 Schematic of various polymer nanoparticle formulation types. A. solid 





Figure 1.3 Types of nanomaterials used for nucleic acid delivery Broad classes of materials 
and nanostructures used as nucleic acid delivery vehicles are summarized, including A. lipid‐
based nanoparticles B. cationic polymer‐based nanoparticles, C. nanoparticles based on other 
polymer types, D. inorganic nanoparticles, and E. nanostructures that use DNA itself as a 





Figure 1.4 Chemical structures for natural and synthetic polymers used as drug delivery 
materials for anticancer drugs. Abbreviations: PBAE, poly(beta-amino ester); PCL, 






Figure 1.5 Shape effects of spherical vs filamentous micelles. Filomicelles are self-assembled 
from diblock co-polymers (a) with nano-scale diameter and micro-scale length. The filomicelles 
extend in flow (b) and evade phagocytosis while spherical micelles in flow are internalized. 
When the micelles are injected systemically in mice, they persist in circulation for days, and 
longer micelles have a longer circulation half-life than shorter micelles. Filomicelles are 
efficiently internalized (d) by lung epithelial cells in static culture. Reproduced from Geng et al., 
“Shape effects of filaments versus spherical particles in flow and drug delivery” Nature 





Figure 1.6 Optimization parameters for cancer-specific nanocarriers. Physical and chemical 
properties of delivery vehicles affect tumor accumulation, particle internalization and cargo 
delivery, and ultimately the therapeutic outcome. Classes of targeting moieties and their sizes are 




Figure 1.7 A prostate cancer ligand-targeted multifunctional envelope‐like nanodevice 
(MEND) A. The nanocarrier is synthesized by siRNA self‐assembly with two block copolymers: 
sharp oligoarginine functionalized pH responsive Meo‐PEG‐b‐P(DPA‐co‐GMA‐Rn) and PSMA 
targeted ACUPA‐PEG‐b‐PDPA. Schematic shows targeted intracellular siRNA delivery after IV 
administration of MENDs. B. This strategy enables efficient gene silencing and significantly 
slows LNCaP tumor growth compared with control and nontargeted NPs. C. Representative 
images of tumor bearing mice on day 18 and D. photographs of harvested LNCaP tumors after 





Figure 1.8 Aptamer-conjugated nanoparticles for prostate cancer cell targeting. A. 
Schematic illustrating the selection process for prostate cancer‐specific internalizing RNA 
aptamers. B. Nanoparticles coated with prostate cancer‐specific internalizing aptamers are 
specifically taken up in target PC3 cells to a higher degree than in nontarget HeLa cells. Bare 
particles without aptamer are taken up at low levels in both target and nontarget cells, so aptamer 
conjugation is necessary for target‐specific uptake. C. Uptake is distributed throughout the 
cytosol of targeted cells. D. When particles are loaded with docetaxel, the aptamer conjugated 
particles (Dtxl‐NP‐Apt) are significantly more potent nontargeted particles (Dtxl‐NP) at killing 





Figure 1.9 Tumor targeting by stimuli-responsive biomaterials. Polymeric materials can be 
engineered to transform their properties in response to intracellular stimulus, extracellular 
stimulus, or external triggers to provide release of the active agent at the desired site. A. Delivery 
materials for nucleic acid therapeutic agents are designed to protect the cargo during transport 
and subsequently provide an efficient intracellular release upon cell entry, often using pH 
responsiveness to enable endosomal escape to the cytosol. B. The nanocarrier can be designed to 
enable an environmentally sensitive stimuli-responsive release of therapeutic agents based on 
local changes to pH, temperature (T), concentration of reactive oxygen species (ROS), and 
concentration of enzymes in the tumor microenvironment. C. To obtain selective release at a 
specific site, external triggers, such as light, near infrared (IR) laser, ultrasound, and magnetic 
field, can be applied to achieve spatial and temporal controlled release of anticancer agents from 




Figure 1.10 Aerosol administration of polyplex nanoparticles for mRNA delivery to the 
lungs. A. A vibrating mesh nebulizer was used to prepare luciferase mRNA delivery vectors for 
aerosol administration. Nanoscale polyplexes were encapsulated in micrometer‐sized droplets 
and administered to a whole‐body chamber. B. Hyperbranched PBAE hDD90‐118 polyplexes 
enabled high levels of luciferase delivery in the lungs after 24 h. C. Local delivery by inhalation 
resulted in highly specific delivery to lung tissue and negligible off‐target luciferase measured by 
bioluminescence. D. Particles maintained a similar size and morphology before and after 
nebulization, characterized by electron microscopy. E. Particles also have a narrow size 
distribution before and after nebulization. Reproduced with permission195. Copyright 2019, 





Figure 1.11 Transcriptionally targeted DNA restricts therapeutic gene expression to HCC 
cells DOTAP‐cholesterol liposomes loaded with transcriptionally targeted eAFP‐VISA‐BikDD 
or nontargeted CMV‐BikDD were I.V. injected in orthotopic ML‐1 tumor‐bearing mice. A. Both 
particles significantly reduced tumor burden, and representative photos are shown from 1 week 
after the last treatment. B. Mouse survival was significant on treatment groups, and the 
transcriptionally targeted DNA therapy extended survival significantly compared with the 
nontargeted DNA. C. Tissue samples were fixed and stained for apoptosis using a TUNEL assay. 
The percentage of apoptotic cells were quantified in random fields from both tumor and healthy 
liver. While the targeted and nontargeted therapies induced similar numbers of apoptotic cells in 
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the tumor, the transcriptionally targeted DNA induced less apoptosis in the healthy liver tissue. 
Reproduced with permission228. Copyright 2011, Nature Research. 
 
 











Chapter 2: High-throughput evaluation of polymeric nanoparticles 
for tissue-targeted gene expression using barcoded plasmid DNA2 
2.1 Introduction 
 Gene therapy using exogenous DNA or RNAi is a powerful tool with the potential to 
address and even cure the underlying genetic origin of disease. However, efficient delivery of the 
genetic cargo across biological barriers remains a major bottleneck to successful gene therapy1. 
Multiple sequential obstacles exist from the formulation of delivery vehicle for injection to the 
expression of a target protein in cells2,3. At the systemic level, delivery vehicles must protect the 
genetic cargo from enzymatic degradation in biological fluid, circumvent clearance by the renal 
and mononuclear phagocyte system (MPS), and efficiently accumulate in the target tissue. At the 
cellular level, barriers include cell-specific targeting, cellular uptake, endosomal escape, and 
cargo release4.  
 Non-viral nanoparticle (NP) delivery systems can be engineered to overcome these 
specific challenges of delivery, while avoiding the design constraints and safety concerns of viral 
vectors5–7. Cellular uptake and endosomal escape can be tuned by modulating the vector’s 
chemical structure and buffering capacity, among other factors8–10. Cell and tissue level active 
targeting is possible through conjugation targeting ligands, including peptides or small 
molecules11. Passive tissue targeting modification is enhanced by coating NPs with polyethylene 
glycol (PEG), but PEG may simultaneously prevent cellular uptake12,13. Multifunctional NPs 
 
This chapter contains material modified from the following article in press  
Kim, J.*, Vaughan, H.J.*, Zamboni, C.G., Sunshine, J.C., Green, J.J., High-throughput Screening of Polymer 
Structure on Tissue-targeted Gene Expression In Vivo Using Barcoded Plasmid DNA. (2021) Journal of Controlled 




may be designed to sequentially overcome delivery barriers, but they are complex to develop, 
have interactive effects that are difficult to predict, and are challenging and costly to 
manufacture. Further, a vector optimized for cellular transfection in vitro may not show efficacy 
in vivo due to systemic factors, such as non-specific protein adsorption, that change the physical 
and chemical properties of the carriers14. For these reasons, rational design of NPs to overcome 
all in vivo delivery barriers is a major challenge. 
 An alternative approach is to screen large libraries of biomaterials for transfection in the 
target cell or tissue type. This approach has been used broadly, resulting in large libraries of 
polymer and lipid biomaterials for nucleic acid delivery15–18. Poly(beta-amino ester) (PBAE) is a 
class of biodegradable ionizable polymer that electrostatically complexes with negatively 
charged nucleic acids to form NPs19. Monomer units with distinct structures may be combined 
during synthesis to create a library of polymers with differential structures and properties, which 
have been used to successfully transfect multiple types of cells in vitro and in vivo20–25. Our 
group has previously performed high-throughput in vitro screening to demonstrate structure-
function relationship of PBAE polymer at the cellular level, including the effect of monomer and 
end-group structures on cell-type specificity, cellular uptake, and endosomal escape8,10,20,26,27. 
While ligand- or PEG-modified PBAE NPs have been developed for enhanced tissue targeting28–
30 or penetration13,21,31, respectively, the significance of differential molecular changes to PBAE 
chemical structure on biodistribution and transfection in vivo is still unclear. 
 Screening a wide range of biomaterials for tissue-specific in vivo transfection within the 
context of the entire gene delivery process requires high throughput methods, as in vivo study of 
multiple vectors is cost- and time-ineffective. Recently, high-throughput in vivo screening 
methods have been developed to study biodistribution of mRNA-loaded lipid NPs in major 
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organs using “genetic barcode”32–34. In this approach, NPs with distinct lipid compositions are 
used to encapsulate a unique, secondary nucleotide barcode sequence in addition to the siRNA or 
mRNA payload. This barcode technology enables sensitive quantification of each nanoparticle 
biodistribution in vivo by deep sequencing methods. However, unlike the previously reported 
methods that measure the accumulation of the oligonucleotide cargo, a DNA barcode system 
enables quantification of both plasmid DNA (pDNA) accumulation and its transcribed mRNA 
expression levels as an elegant way to screen multiple NP formulations, within the same animal, 
for in vivo transfection to a target tissue. Moreover, by using the actual pDNA cargo as the 
barcode sequence, the N/P ratio of barcoded NP remains unaltered in comparison to the non-
barcoded NP with pDNA of interest, thereby minimizing potential change in NP’s 
physicochemical properties. 
 In this study, we develop a high-throughput method for screening in vivo gene delivery 
efficiency of a library of PBAE NPs using a single pDNA that harbors a barcode sequence. Both 
biodistribution and transfection can be analyzed by detecting the primary barcode and the 
transcribed mRNA of the barcode through qPCR and RT-qPCR analysis, respectively. Also, by 
inserting the barcode sequence in the pDNA, we eliminate any potential change to the 
nanoparticle’s physicochemical properties from the addition of a secondary barcode payload. 
Using the platform, we evaluate specific structures of PBAE polymers and their accumulation 
and transfection of pDNA in major organs following systemic administration.  
2.2 Materials and methods 
Materials  
1,4-butanediol diacrylate (B4) (Alfa Aesar, Ward Hill, MA), 1,5-pentanediol diacrylate 
(B5) (Monomer Polymer & Dajac Labs), 3-amino-1-propanol (S3) (Alfa Aesar) ,4-amino-1-
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pentanol (S4) (Alfa Aesar), 5-amino-1-pentanol (S5) (Alfa Aesar), 2-methylpentane-1,5-diamine 
(E4) (TCI America, Portland, OR), 2-(3-aminopropylamino)ethanol (E6) (Sigma-Aldrich, St. 
Louis, MO), and 1-(3-aminopropyl)-4-methylpiperazine (E7) (Alfa Aesar) were purchased and 
used as received. pEGFP-N1 was purchased from Elim Biopharmaceuticals and amplified by 
Aldevron (Fargo, ND). pfLuc Luciferase-pcDNA3 was a gift from William Kaelin (Addgene 
plasmid # 18964) and amplified by Aldevron (Fargo, ND). Purelink Genomic DNA Extraction 
kit (Thermo Fisher Scientific), PowerUp SYBR Green Master Mix (Applied Biosystems, Foster 
City, CA), Label IT®-Tracker™ Cy™3 and Cy™5 kit (Mirus Bio LLC, Madison, WI) were 
obtained from commercial vendors and used per manufacturer’s instructions. 
Polymer synthesis 
 PBAE polymers are synthesized via a two-step Michael addition reaction as previously 
described (Figure 2.1A). First, acrylate-terminated base polymer is created by reacting a 
diacrylate monomer with a primary amine-containing side chain monomer at a stoichiometric 
molar ratio of 1.2:1 for 24 h at 90 °C. Then, the base polymer is reacted with 20-fold excess 
molar amount of primary amine-containing end-capping molecule in THF for 3 h at room 
temperature. The final polymer is ether-precipitated and stored in DMSO at 100 mg/mL in -20 
°C. For this study, a total of 8 PBAE polymers were synthesized using 2 different diacrylate 
monomers, 1,4-butanediol-diacrylate (B4) and 1,5-pentanediol-diacrylate (B5), 3 side chain 
monomers, 3-amino-1-propanol (S3), 4-amino-1-butanol (S4), and 5-amino-1-pentanol (S5), and 
3 end-capping molecules, 2-methylpentane-1,5-diamine (E4), 2-(3-aminopropylamino)ethanol 
(E6), and 1-(3-aminopropyl)-4-methylpiperazine (E7) (Figure 2.1B). Nomenclature for the final 
polymer follows the label of each monomer used. For example, a polymer synthesized with B5, 
S3, and E6 is named 536. The molecular weights of the 8 PBAE polymers were determined by 
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gel permeation chromatography (GPC) on a high-performance liquid chromatography (HPLC) 
system (Agilent) equipped with UV-Vis (Agilent), refractive index (RI) (Wyatt Technology), 
and Multi-Angle Light Scattering (Wyatt Technology) detectors. Molecular weight information 
(Mn, Mw, and PDI) was determined for each polymer using a specific refractive index (dn/dc) of 
0.06, which was calculated by injecting a known polymer mass, assuming 100% recovery (Table 
2.1).  
Plasmid preparation 
 A total of five plasmids were used, three encoding for fluorescent proteins and two 
encoding random nucleotide sequences. In order to ensure that all plasmids were similar in size 
and had the same backbone, pEGFP-N1 was used as the base plasmid and genes encoding other 
fluorescent proteins, mOrange and iRFP, or two random sequences were cloned in to replace 
EGFP gene. The two random plasmids were designed as a proof-of-concept that more plasmids 
with unique random barcode sequences can be used in a similar high-throughput study. These 
five plasmids are referred to as pDNA A (GFP), B (mOrange), C (iRFP), D (Noncoding 1), and 
E (Noncoding 2). All gene sequences can be found in Table 2.2. 
 For two plasmids with random noncoding sequences, two random 1500–base pair 
sequences with 25% fraction each of A, C, G, and T nucleotides were generated using the  
Aarhus University, Bioinformatics Research Centre, Denmark online tool  (URL - http://users-
birc.au.dk/~palle/php/fabox/random_sequence_generator.php) Sequences for mOrange and iRFP 
genes were acquired from Addgene. Restriction cloning sites for NheI and HindIII were encoded 
on the 5’ and 3’ ends of the DNA fragments, respectively. The double-stranded linear DNAs 
were custom ordered using gBlock Gene Fragments (IDT, Inc, Skokie, IL). Plasmids were 
cloned into the pN3 backbone using restriction digestion by NheI-HF and HindIII-HF restriction 
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enzymes (New England Biolabs, Ipswitch, MA), following the manufacturer’s instructions. 
Purification of DNA fragments was performed by gel electrophoresis and extraction using the 
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany), following the manufacturer’s 
instructions. DNA ligation was performed by combining 100 ng of digested backbone DNA with 
700 ng of digested insert, then performing an overnight ligation at 16 °C with T4 DNA ligase 
(New England Biolabs). Ligated cloned were selected for and amplified using 5-alpha 
Competent E. coli (New England Biolabs) and Qiagen Maxi Kits. mOrange and iRFP plasmids 
were also amplified by Aldevron. All plasmids were stored at 1 mg/mL in sterile water at 4 °C. 
Primer optimization 
 In order to generate forward and reverse primers specific to each pDNA and avoid non-
specific amplification of other plasmids or murine genomic DNA, Basic Local Alignment Search 
Tool (BLAST) from the National Institute of Health’s National Center for Biotechnology 
Information was used to extensively check for homology. First, Primer-BLAST was used to 
generate 50 primer candidates for each plasmid that match the conditions listed in Figure 2.2A. 
Then, the primer candidates for each plasmid were used as the input query sequence in BLASTn 
to check for homology against other plasmids as well as the mouse genome (Figure 2.2B). 
Primer candidates that showed undesired homology (matching sequence) in the last 6 base pairs 
or in more than 10 base pairs total were excluded (Figure 2.2C). Lastly, the top-scoring 
candidate for each plasmid was checked for hairpin, self-dimerization and hetero-dimerization 
using IDT OligoAnalyzer 3.1. The final primer sequences were custom ordered (IDT, Inc, 




 Primer sequences were experimentally checked for their specificity toward the 
corresponding plasmids by quantitative real time polymerase chain reaction (qPCR) and gel 
electrophoresis. Briefly, 100 ng of each plasmid was amplified against each of the five primer 
pairs to determine CT values and generate the melt curve. 2 μL of pDNA, 2 μL of 3 μM forward 
primer, 2 μL of 3 μM reverse primer, and 14 μL of PowerUp SYBR Green Master Mix solutions 
were mixed for qPCR amplification. PCR reaction consisted of initial polymerase activation 
stage at 95 °C for 2 min, followed by 40 cycles of denaturation at 95 °C for 15 sec, annealing at 
55 °C for 15 sec, and elongation at 72 °C for 1 min. After PCR amplification, the 25 qPCR 
products along with DNA ladder were also run through gel electrophoresis in 1% agarose gel.   
Validation of qPCR protocol using fresh tissue lysates spiked with pDNA 
 A 5–7-week-old female BALB/c mouse was euthanized and major organs – liver, 
kidneys, spleen, lungs, and heart – were harvested. Organs were washed with 1X PBS three 
times, cut into small pieces with a razor blade, and minced between the frosted ends of two 
microscope slides. Then, 10 mg of liver sample and 5 mg of samples from all other organs were 
separately placed into 1.5mL tubes. Tissues were digested using digestion solution provided in 
the Purelink Genomic DNA Extraction kit. Following the digestion, 10 ng to 10 pg of each 
pDNA were spiked into digested tissue. Subsequent steps of DNA extraction were followed as 
instructed and the final purified DNA was then diluted with water ten-fold for liver samples and 
two-fold for all other organ samples. The same qPCR reaction protocol was followed as 
described above.  
 Nanoparticle formulation and characterization 
 NPs were formed by bulk mixing of PBAE polymer and pDNA in aqueous conditions to 
allow electrostatic interaction and particle self-assembly. PBAE polymer in DMSO at 100 
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mg/mL and pDNA in water at 1 mg/mL were diluted to 12.5 mg/mL and 0.5 mg/mL, 
respectively, using 25 mM sodium acetate (NaAc) buffer at pH 5.0. Equal volume of polymer 
and DNA solutions were mixed and incubated for 10 min to form NPs. This ensures the mass 
ratio of polymer to DNA to be consistent at 25 w/w across the different NPs evaluated. 
 Hydrodynamic diameter was measured by dynamic light scattering, and zeta potential 
was measured by electrophoretic mobility using the Zetasizer Pro (Malvern Instruments, 
Malvern, UK). Immediately before these measurements, NPs were diluted 1:10 in a 1:1 ratio of 
25 mM sodium acetate and 1X PBS to a final volume of 1 mL. Encapsulation efficiency of 
pDNA in NPs was assessed by gel electrophoresis. NP prepared at 25 w/w with 0.03 mg/mL 
pDNA was combined with 6X Gel Loading Dye with no SDS. Samples were loaded into a 0.8% 
agarose gel containing 1 μg/mL ethidium bromide. Free unencapsulated pDNA at the same dose 
was used as a positive control. The gel was run with 90 V applied for 30 min and visualized by 
UV exposure.  
Förster resonance energy transfer (FRET) between Cy3- and Cy5-labeled NPs 
 FRET analysis was conducted to investigate any intermixing between different NPs co-
dispersed in a single solution, as would occur during a co-injection. pEGFP DNA was labeled 
with Cy3 and Cy5 fluorophores following a protocol by Wilson et al35. Labeling density was 
measured using a determined using a NanoDrop spectrophotometer (ThermoFisher Scientific, 
Waltham, MA). Three different pairs of NPs were tested: PBAE 447 with Cy3-labeled pEGFP 
DNA and PBAE 457 with Cy5-labeled pEGFP DNA, PBAE 457 with Cy3-labeled pEGFP DNA 
and PBAE 536 with Cy5-labeled pEGFP DNA, and PBAE 536 with Cy3-labeled pEGFP DNA 
and PBAE 447 with Cy5-labeled pEGFP DNA. NPs were prepared separately and incubated 
together at 1:1 v/v ratio with gentle pipette mixing, and peak emission intensities of Cy3 (565-
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570 nm) and Cy5 (665-675 nm) was read following Cy3 excitation at 540 nm using 
spectrofluorophotometry (Shimadzu RF-5301). A positive control NP batch was formulated by 
complexing either PBAE polymer 447, 536 or 457 with 1:1 mixture of Cy3-labeled and Cy5-
labeled DNAs.  
2.8 In vitro transfection with mixture of PBAE NPs 
 HepG2 cells were purchased from ATCC (Manassas, VA), cultured in Minimum 
Essential Media (MEM) supplemented with 10% FBS, 100 U/mL Penicillin, 100 μg/mL 
Streptomycin, 100 M of MEM non-essential amino acids solution, and 1 mM of sodium 
pyruvate, and maintained in a humidified incubator at 37°C with 5% CO2. Cells were seeded in a 
96-well plate at 10,000 cells / well and allowed to adhere for 24 hr. For in vitro screening (Fig 
S6), PBAE NPs were freshly prepared with equal amounts of each DNA barcode plasmid (A-E) 
at 25 w/w for a final DNA concentration of 0.3 μg/μL. For Fig S7, PBAE NPs were synthesized 
with pDNA A or a mixture of three NPs with pDNA A, D, or E at the same total pDNA dose 
each for a final DNA concentration of 0.3 or 0.1 μg/μL. 20 μL NPs were added to cells and 
allowed to incubate for 2 hours at 37oC. RNA was isolated and reverse transcribed using a Cells-
to-CT kit from ThermoFisher Scientific (Waltham, MA) according to the manufacturer’s 
instructions. For qPCR analysis, 6 μL of sample DNA, 2 μL of 3 μM forward primer, 2 μL of 3 
μM reverse primer, and 10 μL of PowerUp SYBR Green Master Mix (Applied Biosystems, 
Foster City, CA) solutions were mixed for qPCR amplification. qPCR was performed using a 
StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA) with the cycling 
parameters described above. Threshold and baseline values were standardized across all samples 
and all runs to ensure accurate comparison. The comparative CT method was used to quantify 
relative expression levels36. Barcode amplification was normalized to the housekeeping gene 
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GAPDH to quantify NP accumulation of each PBAE with each barcode relative to the genomic 
DNA content. Then, this value was normalized to non-specific background amplification in 
untreated cells, by subtracting the ΔCT of amplification in untreated animals from animals which 
received barcoded NPs, thereby obtaining ΔΔCT.  
ΔΔCT = (CTbarcode x −  CTGAPDH)treated − (CTbarcode x −  CTGAPDH)untreated 
High throughput biodistribution analysis 
 All in vivo procedures were approved and overseen by the Johns Hopkins Institutional 
Animal Care and Use Committee (IACUC). Biodistribution of 8 different PBAE polymers was 
tested in 5–7-week-old female BALB/c mice (The Jackson Laboratory, Bar Harbor, ME). For 
each mouse, a single 200 μL cocktail solution containing five different PBAE NPs was prepared 
for tail-vein injection. Each of the five NPs was formulated by pairing one of 8 PBAE polymers 
with one of the five pDNAs to serve as the identifier barcode (Figure 2.3). Each NP formulation 
contained 10 μg of pDNA for a total of 50 μg pDNA in the cocktail solution. Biodistribution of 
PBAE 447 NPs from the high-throughput samples was compared against that from additional 
mice injected only with NPs prepared from PBAE polymer 447 and 50 μg pEGFP DNA to 
validate accuracy of the high-throughput method. Mice were sacrificed 30 min post injection for 
DNA extraction. Major organs – liver, kidneys, spleen, lungs, and heart – were harvested, 
washed with PBS three times, cut into small pieces with a razor blade, and minced between the 
frosted ends of two microscope slides. Then, approximately 10 mg of liver sample and 5 mg of 
samples from all other organs were separately placed into 1.5 mL tubes, and pDNA was 
extracted from minced tissues following the manufacturer’s instruction from the Purelink 
Genomic DNA Extraction kit (Invitrogen, Waltham, MA). Once DNA was purified through the 
extraction column, it was diluted with water ten-fold for liver samples and three-fold for all other 
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organ samples. The differences in the amount of minced tissues used to extract pDNA between 
organs was normalized by the total amount of genomic DNA content during qPCR analysis using 
the comparative CT method and GAPDH as a housekeeping gene.  
High-throughput in vivo transfection analysis 
 5–7-week-old female BALB/c mice (The Jackson Laboratory) were injected via tail-vein 
with the same cocktail solutions as the biodistribution study (Figure 2.3). Mice were sacrificed 6 
hours post injection for RNA extraction. Organs were harvested and washed in 1X PBS, then cut 
into small pieces using a razor and minced between frosted microscope slides. 50 mg of each 
sample was suspended in Trizol and homogenized. A 20% volume of chloroform was added, and 
tubes were vortexed briefly to emulsify. Samples were incubated at room temperature for 5 
minutes, then centrifuged at 12,000 g for 15 minutes at 4 °C. The aqueous phase was transferred 
to a new tube, then isopropanol was added at 50 % of the original Trizol volume. Samples were 
inverted to mix, then incubated for 10 minutes at room temperature to allow for RNA 
precipitation. Samples were centrifuged at 12,000 g for 30 minutes at 4 °C. Isopropanol was 
decanted, and pelleted RNA was washed with 75% ethanol. After vortexing, samples were 
centrifuged at 7,500g for 5 minutes at 4 °C. Ethanol was carefully decanted, and the RNA pellet 
was air dried for 5-10 minutes. The dried pellet was resuspended in 30 µL water, and RNA 
concentration was determined using a NanoDrop spectrophotometer (ThermoFisher Scientific, 
Waltham, MA). RNA was purified of DNA using the TURBO DNA-free kit (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions. Using the High-Capacity RNA-to-
cDNATM kit (Invitrogen, Carlsbad, CA), 20 μg of RNA was reverse transcribed according to the 
manufacturer’s instructions. Reverse transcription was performed at 37 °C for 1 hour, followed 
by 5 minutes at 95 °C to stop the reaction. PCR reactions were comprised of 10 μL PowerUp 
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SYBR Green Master Mix (Applied Biosystems, Foster City, CA), 2 μL forward primer (3 μM), 2 
μL reverse primer (3 μM), and 1 μL cDNA. Baseline and thresholds were standardized across all 
samples. ΔΔCT values were calculated as previously described. If there was no amplification for 
a given sample primer combination, the sample was assigned a CT of 40, corresponding to the 
maximum amplification cycle, in order to compute ΔΔCT value.  
In vivo transfection using pfLuc 
 To form luciferase NPs for in vivo use, pfLuc DNA was complexed with PBAE 456, 536, 
and 546 at a 25 w/w ratio in 25 mM sodium acetate (pH = 5.0) for a final DNA concentration of 
0.25 µg/µL. 200 μL of NPs (50 μg DNA) was injected via the tail vein in 5–7-week-old BALB/c 
mice. After 30 minutes, 1 hour, 3 hours, or 6 hours, animals were injected intraperitoneally with 
150 mg/kg D-luciferin (Gold Biotechnology, St. Louis, MO). After 10 minutes, the animals were 
anesthetized using isoflurane and bioluminescence was imaged using the IVIS Spectrum 
(Xenogen, Alameda, CA). Images were analyzed using Living Image® 4.7.3 software 
(PerkinElmer, Waltham, MA). 
Statistical analysis 
 All statistical analysis was performed with GraphPad Prism 8 software package. For in 
vivo experiments, statistically significant barcode amplification was calculated by one-tailed 
Student’s t-test between the experimental -ΔΔCT values and zero. Statistical significance was 
defined as p < 0.05 after correcting for multiple comparisons using the Holm-Sidak method.  
2.3 Results  
Primers’ specificity to DNA barcodes 
 Primers were selected via BLAST with the most conservative conditions to ensure highly 
selective binding to barcoded plasmid used in the study. Three of the five plasmids used in the 
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study each contained an insert serving as the barcode, which can be detected directly as protein 
or in its transcribed mRNA form (Figure 2.3).   
 The forward and reverse primer pairs for each barcode gene were designed to produce an 
approximately 100-basepair long amplicon. Every possible combination of the primer pairs and 
the plasmids were mixed for qPCR reaction to confirm the primers’ specificity to the 
corresponding plasmids. As shown in Figure 2.4A, only conditions with correctly matched 
primers and plasmid resulted in amplification. Also, each set of primers run either alone or 
mixed with other primer sets did not yield any false positive PCR results from self- or hetero 
dimerization. The melt curves also showed a clean single peak only for correctly matched 
conditions, which indicates that there is no off-target amplification occurring in the PCR reaction 
(Figure 2.5). qPCR of fresh tissue lysates from all major organs of a BALB/c mouse showed no 
amplification from the primers, indicating no off-target amplification of genomic DNA. PCR-
amplified products were run on gel electrophoresis to confirm that the amplicons had the 
expected length, based on our primer design. The gel image shows bands appearing for primer-
plasmid matching conditions only at the height level of approximately 100-basepair mark on the 
DNA ladder (Figure 2.4B). These observations validate the specificity of each primer set to its 
corresponding plasmid. 
 We also evaluated whether the CT value from qPCR varies linearly with pDNA mass. A 
range of pDNA mass from 10 pg to 10 ng was spiked into fresh tissue lysates and subjected to 
DNA extraction for qPCR. As shown in Figure 2.4C, each of the 5 barcode plasmids has a linear 
correlation with R2 > 0.96 between its mass and CT values in the 5 major organs tested. All CT 
values collected in the experiments and used in the analysis were within the linear region of these 
curves. Amplification of each barcode plasmids was not affected by the type of tissue lysates, as 
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demonstrated by the overlapping standard curves in each panel of Figure 2C. Interestingly, 
however, amplification of 5 barcode plasmids showed varying degree of sensitivity in each type 
of tissue lysates, as demonstrated by the non-overlapping standard curves in each panel of 
Figure 2.6. This requires each unique barcode plasmid to be tested for linearity between CT 
value and a range of plasmid mass. In this study, each PBAE NP formulation is tested with 5 
different barcode plasmids, and the biodistribution and in vivo transfection data are averaged to 
mitigate the small difference in sensitivity across barcode plasmids.  
Nanoparticle characterization 
 PBAE NPs formulated with 8 different PBAE polymers were characterized based on 
hydrodynamic diameter and surface charge. As shown in Figure 2.7A, PBAE NP hydrodynamic 
diameter measured by dynamic light scattering ranged from 100 – 200 nm for all NP 
formulations. All NPs showed positive zeta potential between 15 – 22 mV, due to the exposure 
of positively charged polymer on the surface. While positive charge of NPs could cause toxicity, 
previous literatures on PBAE NPs with similar positive surface charge report minimal toxicity 
both in vitro and in vivo20,35. Also, all NPs showed 100% encapsulation of pDNA, with no 
evidence that barcode sequence or polymer structure significantly affects encapsulation 
efficiency (Figure 2.8). 
FRET analysis showing the absence of nanoparticle intermixing 
 The high-throughput in vivo screening method is based on different PBAE NPs being 
injected as a cocktail solution into a single animal and subsequently individually identified in 
tissue lysates. While inorganic nanoparticles (such as gold NPs) and lipid-based NPs (such as 
liposomes) form discrete NPs, it is conceivable that polyplex NPs, which are formed from 
molecular interactions between polyelectrolytes of opposing charge, could intermix components 
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together. Such potential intermixing of PBAE polyplexes has not been previously investigated 
and could conceivably prevent the barcodes from staying matched to a specific NP. Each PBAE 
NP formulation is formulated with one barcode pDNA, which serves for NP identification. Thus, 
the capability of PBAE polyplex NPs to resist exchange of  
DNA cargo in a cocktail solution to ensure that mixed NPs encapsulate only their original 
defining barcode plasmids. To evaluate this, we formulated two separate batches of NPs 
encapsulating pDNAs labeled with either Cy3 or Cy5 fluorophores, then mixed the two batches 
into a single solution. Exchange of Cy3-labeled DNA from a NP with Cy5-labeled DNA from 
another NP in the mixture brings the fluorophores in close proximity to each other within a NP 
and causes emission of a FRET signal. Negative control NPs were separately prepared with each 
of Cy3- or Cy5-labeled DNA alone and positive control NPs were prepared with a 1:1 mixture 
Cy3- and Cy5-labeled DNA within the same NPs. 
 Each NP sample was excited at the excitation wavelength for Cy3 (540 nm), and 
emission was measured at the emission wavelength for Cy3 (565-575 nm) and Cy5 (665-675 
nm), shown in Figures 2.7B/C and 2.9.  Cy3 NPs alone showed emission at 565-575 nm, and 
Cy5 NPs alone showed no emission, because there is minimal excitation of this fluorophore at 
540 nm. The positive control NPs showed FRET activity, with 35% decreased signal at 565-575 
nm (Cy3 emission) in comparison to Cy3 NP alone, and an increase in signal of  >3 RFU at 665-
675 nm (Cy5 emission) in comparison to Cy5 NP alone (~1 RFU). This suggests that part of Cy3 
emission was able to excite neighboring Cy5-pDNA encapsulated in the same nanoparticle. In 
the test case, where NPs were formulated separately then combined, minimal FRET activity was 
observed as indicated by the similar signal intensity at 565-575 nm compared to Cy3 NPs alone. 
The signal intensity at 665-675 nm for the test case was similar to the negative control at ~1 
93 
 
RFU. Given the high labeling density of Cy3 and Cy5 DNAs (1 fluorophore per 63.4 base pairs 
and 54.9 base pairs respectively) and high density of plasmid DNA in PBAE NPs reported in 
previous work37, we determined that there was not substantial intermixing of plasmid DNAs 
between PBAE NPs. While these results do not exclude the possibility of small amounts of 
exchange, the lack of FRET signal in a cocktail solution indicates that the Cy3 and Cy5 
fluorophores mostly maintain separation in distinct NPs. Therefore, we can correlate 
accumulation of unique barcode DNA with its corresponding unique NP. 
In vitro transfection of PBAE NPs with mixed barcoded pDNAs 
 HepG2 cells were transfected in vitro with 8 PBAE NPs with 120 ng each of barcoded 
pDNAs A, B, C, D, and E. After 48 hours, qRT-PCR results show significant differences in 
transfection between NP formulations, with PBAE 447 as the most effective formulation for 
transfection and PBAE 546 as the least effective (Figure 2.10). To evaluate differential 
expression between the barcodes, the percentage of variation from the mean was calculated for 
each barcode (Figure 2.11). Barcode A and B had significantly increased expression over C, D, 
and E within the same NP formulations. This indicates a difference in expression which is 
sequence dependent. To control for any bias from these differences, we formulated each PBAE 
NP with each barcode in subsequent studies. This redundancy ensured that variation in 
biodistribution, transfection efficiency, PCR amplification efficiency, transcript half-life, or 
plasmid immunogenicity due to the difference in barcode sequences would not bias the results. 
 To verify that screening results from mixed barcode formulations are representative of 
transfection results from a single pDNA, NPs were formulated at either a full dose of pDNA A or 
a mixture of 1/3 dose each of pDNA A, D, or E. RT-qPCR results showed a decrease in -ΔΔCT 
of Barcode A mRNA from 9.1 for the single, full dose NP to 7.4 for the mix, 1/3 dose NPs, 
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corresponding to a 1/3 decrease in mRNA concentration (Figure 2.12). This indicates that RT-
qPCR results from mixed barcode NPs are predictive of transfection with a full dose NP. 
Interestingly, decreasing the total DNA concentration by 1/3 from 0.03 µg/µL to 0.01 µg/µL 
does not result in a similar decrease in transfection measured by RT-qPCR, suggesting that 
changing the overall DNA concentration may affect transfection levels. 
High-throughput screening of tissue targeting 
 Utilizing five barcoded pDNAs and their specific primers, we developed a scheme to test 
biodistribution of five PBAE NP formulations per animal. In each animal, all PBAEs were paired 
with a different barcode to distinguish the polymers from one another. Further, each PBAE NP 
was tested separately in 5 animals, and it was paired with a different barcode in each replicate, as 
shown in Table 2.4. NPs were freshly prepared by separately combining barcode DNA and 
PBAE for each formulation, then mixing the five formulations for each animal immediately prior 
to injection, to minimize exchange of pDNA between NP formulations. The NPs were 
administered intravenously via the tail vein in BALB/c mice.  
 30 minutes after NP injection, the animals were sacrificed and the heart, lungs, spleen, 
liver, and kidneys were collected. DNA was isolated and purified from the organs, then qPCR 
was performed for each sample using primer sets for each barcode. By matching each barcode to 
its corresponding PBAE NP in a particular animal, we calculated the average relative 
accumulation of each formulation in the major organs (Figure 2.13). The plots show 
accumulation of any given PBAE NP across organs to screen for PBAEs that direct NPs to 
specific organs over others. Statistically significant barcode accumulation over untreated samples 
was observed in organs involved in clearance, including the spleen (PBAE 546), liver (PBAE 
456, 534, 546), and kidneys (PBAE 534). Although not statistically significant, higher barcode 
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accumulation was also observed in the lung, which presents the first capillary bed that the NPs 
are exposed to once injected intravenously. Accumulation in the heart was negligible for all 
formulations. The mean highest levels of barcode DNA were detected in the liver and spleen for 
7 out of 8 formulations. This is consistent with rapid MPS clearance of NPs in the range of 100-
200 nm.  
High-throughput screening of tissue-specific gene expression 
 While NP accumulation in the target tissue is necessary for gene delivery, cellular uptake, 
endosomal escape, and nuclear localization are critical steps for transfection that are not captured 
by biodistribution studies alone. To this end, we further explored the use of barcoded pDNA to 
directly quantify PBAE NP transfection in the major organs. Transfection was quantified by 
performing RT-qPCR on transcribed barcode mRNA isolated from treated animals. Animals 
were treated with the same NP mixtures as described in Table 2.4, and organs were harvested 
after 6 hours, a timepoint that shows a notable increase in in vivo expression signal and therefore 
captures transfection efficacy (Figure 2.14). The isolated RNA was purified of any 
contaminating DNA and reverse transcribed into cDNA. RT-qPCR was performed using each set 
of primers for each sample, and ΔΔCT values were calculated as previously described.  
 Barcode transfection of each PBAE across organs is shown in Figure 2.15. Transfection 
was predominantly observed in the kidney, spleen, and liver. For the heart and lungs, there was 
no detectable transfection as PCR amplification was equivalent to amplification in untreated 
samples for all NP formulations. Transfection was primarily localized to the liver and spleen, 
with statistically significant spleen transfection detected for 447, 457, and 536 PBAEs, and liver 
transfection detected for 546 PBAE. Transfection in the kidneys was relatively low / not 
significant, despite similar levels of barcode DNA accumulation to the liver and spleen. This 
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may be because small, fragmented particles or free pDNA ineffective for transfection may 
preferentially be cleared by the renal system. Interestingly, PBAEs showing similar level of 
accumulation in an organ did not necessarily resulted in similar level of transfection. For 
example, comparable amounts of pDNA were delivered to the liver by both 456 and 546 PBAEs, 
however 546 PBAE NP showed a significant level of transfection in the liver while 456 did not. 
This difference in transfection efficiency could be explained by the differential effect of each 
PBAE polymer structure following tissue accumulation in the downstream intracellular delivery 
steps, including interaction with cell surface, internalization, endosomal escape, and pDNA 
release. These differences are particularly striking as the chemical structures of 456 and 546 are 
so similar. In the repeating unit of the polymer, 456 contains 4 carbons between acrylate groups 
and 5 carbons between the amine group and the alcohol group in the side chain, whereas 546 
contains 5 carbons between acrylate groups and 4 carbons between the amine group and the 
alcohol group in the side chain. Yet, this small molecular difference generates a dramatic 
biological difference in the ability of the polymer to facilitate gene delivery in a tissue-specific 
way, in this case transfection of liver. This result highlights the utility of a high-throughput in 
vivo assay to evaluate differential activity of gene delivery effectiveness between closely related 
materials from a nanoparticle library. While it is difficult to identify a single parameter from the 
properties of a given PBAE polymer that directs specific accumulation or transfection in an 
organ (Table 2.1), a thorough statistical correlation analysis can elucidate the structure-function 
relationship of gene delivery polymers(26).  
 It is also important to note that PBAE NP that showed significant transfection in the liver 
in vivo was not the optimal candidate from in vitro transfection screening (Figure 2.10). While 
there were significant differences in in vitro transfection efficacy with all 8 PBAE NP 
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formulations in HepG2 liver cancer cells, these differences were not predictive of in vivo 
performance. For example, PBAE 546 showed the lowest in vitro expression in these cells but 
showed a high degree of liver targeting in vivo as shown by barcode screening and luciferase 
imaging. This further highlights the significance of the in vivo high-throughput screening 
method. 
Validation of liver- and spleen-specific gene delivery by 536 PBAE NPs 
 To verify that this system accurately predicted transfection patterns for a particular NP 
formulation, we delivered a reporter plasmid, firefly luciferase (fLuc) intravenously using 456, 
536, and 546 PBAE and imaged bioluminescence after 6 hours. Luciferase expression was 
localized primarily to the spleen for 456, liver and spleen for 536, and liver for 546 PBAE NP 
(Figure 2.16). Bioluminescence in heart, lung, and kidney were negligible in all three 
formulations. These gene expression results from singular injection agree with high-throughput 
transfection screening results for each of the respective PBAE NPs. The agreement between 
high-throughput screening and singular injection results suggests that the barcode method is 
predictive of NPs functional outcome based on specific polymer composition regardless of the 
nucleic acid sequence of pDNA. In addition, 456 and 536 PBAE NPs exhibited conflicting 
patterns between the biodistribution and gene expression results, where 456 PBAE NP showed 
highest accumulation in the liver but highest expression in spleen, and 536 PBAE NP showed 
similar levels of accumulation across organs but significant expression only in the spleen and 
liver. This again highlights the importance of directly quantifying transfection at the level of 




Many different polymers and lipids libraries have been synthesized to formulate NPs by 
combinatorial methods. These NPs have extensively been characterized to elucidate structure-
function relationships15,19,38. This often requires high-throughput methods for standardized and 
efficient screening for optimization. Multi-well plates and automated pipetting robots have 
enabled fast and efficient in vitro analysis of cytotoxicity, cellular uptake, and transfection39. 
Because these in vitro cell culture studies are rapid and reproducible, they are often used to 
identify optimal formulations from the library for further in vivo testing. However, many studies 
have found that in vitro transfection efficacy is a poor predictor of in vivo efficacy because cell 
culture conditions do not recapitulate the many barriers to systemic gene delivery40,41. Cost, time, 
and loss of animal life are bottlenecks preventing in vivo screening of large numbers of NP 
formulations. A high-throughput strategy for in vivo gene therapy experiments with novel 
methods to investigate multiple NPs in a single animal reduces the labor, cost, and use of 
animals. The study showed how only 8 mice could be used to perform a biodistribution 
experiment of 8 NP formulations with n=5, which would otherwise have required 40 mice 
without high-throughput methods. The barcode strategy also mitigates variability between 
individual animals unduly influencing observed differences in NP behavior. While each PBAE 
NP formulation is still evaluated in five separate mice, variability between animals across the 
five different PBAE NP formulations is reduced, as a complete set of five NP formulations is 
evaluated in a single mouse and thus different NPs are being evaluated in the same animals 
instead of in unique animals. Furthermore, just as automation adds efficiency to high throughput, 
this in vivo screening approach could be adapted for additional NP types per animal and further 




 Several methods for high-throughput in vivo screening using nucleic acid barcodes have 
been recently reported. Dahlman et al. used deep sequencing methods to simultaneously 
characterize biodistribution of dozens of lipid NPs harboring barcoded oligonucleotides32,33. This 
innovative approach highlights the power of barcoding methods to impact the field of drug and 
gene delivery. While oligonucleotide barcodes offer flexibility and versatility due to their small 
size, they are used as a passive tag to measure biodistribution rather than functional delivery. We 
chose to incorporate DNA barcodes in plasmid vectors to assess biodistribution (extracellular 
barriers) and transfection (intracellular barriers) in target tissues using the same barcodes. 
Because properties of NPs may be affected by the properties of their cargo depending on the NP 
system, including potentially by adding a noncoding nucleic acid barcode tag or conjugating 
labeling molecules to the nucleic acid cargo, the presented strategy also allows us to evaluate 
NPs specifically formulated for delivery of their standard pDNA cargo without an additional 
labeled component. We show that directly measuring transfection is critical, as biodistribution 
results did not accurately predict in vivo transfection. Particles that accumulate in tissues may 
become entrapped in mucosal or extracellular matrix barriers42, sequestered in vesicles43, or 
exocytosed into the interstitial space44. Successful gene therapy is dependent on overcoming all 
extracellular and intracellular barriers, ultimately resulting in the transcription and translation of 
a therapeutic protein.  
The type of genetic cargo, including DNA, mRNA, siRNA, and short oligonucleotide, 
can interact with the vectors differently and affect the NP’s physicochemical properties as well 
as biodistribution profile. For example, Guimaraes et al. showed that NPs with the same lipid but 
either mRNA or DNA oligonucleotide exhibited different levels of accumulation in liver and 
spleen34. We simplified NP’s nucleic acid cargo to a single plasmid vector harboring both the 
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barcode and a functional gene, eliminating the need for a secondary barcode oligonucleotide and 
the possibility of its differential molecular interaction with various vectors. This strategy also 
allows broad utilization of the technology with other NP formulations. Moreover, our study 
shows that randomly generated nucleotide sequences can function well as barcodes, which 
indicates that many NPs with similar random barcodes can be evaluated simultaneously as a 
larger NP cocktail within a single animal. Increased number of barcodes would increase the 
utility of the high-throughput screening strategy. In contrast to prior work, our system uses qPCR 
for barcode quantification, which is routinely used with well-established analysis methods. 
Therefore, this strategy is easily adaptable to different NP systems and laboratories to 
characterize gene delivery.  
Quantifying transfection at the cellular level would add further value to this approach for 
gene therapy development. To achieve this degree of granularity, cell types of interest could be 
sorted using immunocytochemistry and flow cytometry or other single cell methodologies, then 
barcode accumulation and transfection could be quantified in the population of interest. This 
would enable identification of NPs that target individual cancer cells within a heterogeneous 
population, specific immune cells, and other phenotypes affected by genetic disease.  
Our reported biodistribution results from high-throughput barcode NP screening agree 
with the current understanding of NP pharmacokinetics, which has been extensively reported in 
the literature45,46. Particles with diameter < ~10 nm are rapidly cleared by the renal system and 
accumulate in the kidneys, bladder, and urine47. NPs larger than ~20 nm are cleared by the MPS 
in the liver and spleen48. Our characterization of PBAE NPs by DLS sizing confirms that all 
PBAE NPs tested are between 100 and 200 nm, suggesting that MPS clearance would dominate 
their pharmacokinetics. In agreement with these principles, we found by high throughput barcode 
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screening that PBAE NPs accumulate in the liver and spleen at 30 min post administration. 
Biodistribution was evaluated at 30 min post administration due to short half-life (10 min) of 
PBAE NPs in the blood49 and potential DNA degradation, while in vivo transfection was 
quantified at 6 hours based on similar methods reported by previous literature on luciferase gene 
expression using PBAE NPs24,50. Interestingly, we also observed barcode accumulation in the 
kidneys, despite the average NP size being far above the maximum for renal clearance. Because 
transfection in the kidney was negligible, we hypothesize that barcode DNA accumulating in the 
kidney was unencapsulated DNA or very small, degraded NP fragments. We also observed 
consistent NP accumulation in the lung. NP entrapment in the lung capillaries has been observed 
and well-characterized in the literature1. Aside from NP size, aggregation with serum proteins 
may also play a role in lung accumulation, so the effects of PBAE NP physicochemical 
properties on protein adsorption should be further studied in future work51. Across the PBAE 
NPs evaluated in this study, while we found lung accumulation, we found that these entrapped 
NPs were not successful for gene delivery, potentially due to cell-specific transfection efficacy 
often demonstrated with PBAE polymers20,23,24. Success for gene delivery depended on polymer 
structure, with small, seemingly insignificant changes to structure of one or two carbons, making 
a significant difference to gene therapy performance, from tissue-specific accumulation to cell-
specific transfection. This proof-of-concept study demonstrates that there is much to be learned 
by extending higher throughput nanobiotechnology studies from in vitro to in vivo, to better 
understand differential nanomaterial function in biological systems. 
2.5 Conclusion 
With gene therapy emerging as a viable and versatile approach to treat or potentially cure 
various diseases, optimizing non-viral delivery vectors has become an active area of research. In 
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this study, we explored the role of a polymer’s chemical structure to direct tissue-specific 
nanoparticle targeting and gene transfection. To this end, we also successfully developed an 
innovative high-throughput method using pDNA itself as a barcode that consequently reduces 
the number of animals used and mitigates variability between animals. Using the method, we 
demonstrated certain PBAE polymeric nanoparticles are capable of delivering and transfecting 
pDNA in the liver and/or spleen. We also showed that tissue accumulation of PBAE NPs does 
not necessarily correlate with in vivo gene expression, emphasizing the importance of in vivo 
transfection screening to predict the therapeutic efficacy of gene therapy. Both polymer structure 
and tissue type were important to determine transfection efficiency. Finally, we validated the 
high-throughput screening method by showing correlation between its mRNA result and in vivo 
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2.7 Figures and Tables 
 
 
Figure 2.1 PBAE polymer synthesis. (a) PBAE polymer was synthesized using a two-step 
Michael addition reaction. Acrylate-terminated PBAE base polymer, synthesized by reacting a 
diacrylate monomer with a primary amine-containing alkanolamine monomer in the first step, is 
end-capped during the second step with a primary amine-containing molecule. (b) Monomers 




















Figure 2.2 Primer design with BLAST (A) Generating forward and reverse primer candidates 
through Primer-BLAST based on minimizing homology against the plasmid backbone, 
restricting the amplicon size, and ensuring a window of melting temperature. (B) Checking 
specificity of primer candidate for a plasmid through BLASTn by comparing its homology 








Figure 2.3 High-throughput screening of PBAE NP biodistribution and transfection via 






Figure 2.4 Primer optimization. (a) CT values from qPCR reaction of all possible 
combinations of 5 plasmids and 5 corresponding primers (n=3, mean ± SEM). (b) Gel 
electrophoresis of PCR-amplified product, showing specific amplicons’ size of approximately 
100 base-pairs. For each plasmid, there are 6 conditions with specific primers for pDNA A, B, C, 
D, E, or no primers going from left to right, as indicated by the index numbers 1-6, respectively. 
DNA ladder: 1 kbp left and 100 bp right. (c) CT values from qPCR reaction of tissue lysates 






Figure 2.5 Melt curve from qPCR of barcode plasmids and primers. Single-peak melt curve 
for the qPCR conditions with matching barcode plasmid and primers (red: plasmid A, yellow: 
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plasmid B, cyan: plasmid C, dark green: plasmid D, light green: plasmid E) confirms specificity 




Figure 2.6 Primer Standard Curves CT values from qPCR reaction of tissue lysates from major 







Figure 2.7. PBAE NP properties. (a) Hydrodynamic diameter and zeta potential of 8 PBAE 
NPs, measured by dynamic light scattering (n = 3, mean ± SEM). (b) Cy3 and (c) Cy5 emission 
following Cy3 excitation of a solution consisting of either 447 PBAE NP with Cy3-labeled 
pDNA, 457 PBAE NP with Cy5-labeled pDNA, 447 PBAE NP with a mixture of Cy3- and Cy5-
labeled pDNAs, or a mixture of 447 PBAE NP with Cy3-labeled pDNA and 457 PBAE NP with 





Figure 2.8. Gel electrophoresis of 8 PBAE NPs. Gel electrophoresis of NPs formulated with 
barcoded plasmids A-E with a final concentration of 0.03 mg/mL pDNA and 25 w/w ratio of 
PBAE polymer. Free unencapsulated plasmid DNA at the same dose was used as a positive 





Figure 2.9. FRET analysis of a mixture of barcoded NPs. Cy3 (A) and Cy5 (B) emission of 
PBAE 536 NPs with Cy3 pDNA, PBAE 447 NPs with Cy5 pDNA alone, the mixture of these 
two NPs, and a positive control PBAE 536 NP formulated with equivalent concentrations of Cy3 
and Cy5 pDNA. Emissions from PBAE 457 and PBAE 536 NPs are also shown (C, D). Data is 
shown as mean ± SEM from 3 replicates. Significant differences in Cy5 emission between mixed 
NPs and NPs formulated with both pDNAs were determined by one-way ANOVA and Sidak’s 






Figure 2.10. In vitro barcode screen of 8 PBAE NPs in HepG2 cells. Cells were transfected in 
96-well plates at a dose of 600 ng DNA per well, and RT-qPCR was performed 48 hours later. 
Data represent mean ± SEM of n = 3. Statistical differences between NP formulations were 
calculated by one-way ANOVA with Holm Sidak’s multiple comparison test. *: p < 0.05, **: p < 
0.01 
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Figure 2.11. Variance in barcode amplification. Variance in barcode amplification from in 
vitro transfection of Hep3b cells with all PBAE NP formulations. Variance from mean indicates 
the percent deviation of the -ΔΔCT values from each barcode by the average -ΔΔCT value from 







Figure 2.12. In vitro transfection of Hep3b cells with barcoded NPs. Hep3b cells were 
transfected with 0.03 or 0.01 µg/µg barcode pDNA A or a mixture of barcode pDNAs A, D, and 
E. Expression of barcode A mRNA was determined using RT-qPCR (-∆∆CT of barcoded pDNA 







Figure 2.13. High-throughput screening of NP biodistribution. Pooled biodistribution data in 
major organs (liver, spleen, heart, lungs, kidneys) of each PBAE NP formulation with 5 distinct 
DNA barcodes from 5 different mice. 30 min post administration of barcoded PBAE NPs, the 
amount of DNA accumulated was quantified by the amplification of DNA barcodes in qPCR (-
∆∆CT of barcoded plasmid DNA in each PBAE NP normalized to GAPDH). Data represent 
mean ± SEM of n = 5 for each PBAE NP from a total of 8 mice (one-tailed Student’s t-test 







Figure 2.14. Time-course in vivo gene expression. In vivo bioluminescence after intravenous 
administration of PBAE 536 NPs (25 w/w) harboring 50 μg fLuc pDNA and subsequent IP 
injection of 150 mg/kg D-luciferin. Data represent mean ± SEM of n = 3. Statistical differences 
between time points were calculated by one-way ANOVA with Holm Sidak’s multiple 






Figure 2.15. High-throughput screening of in vivo transfection. Pooled transfection data in 
organs with detectable transfection signal (liver, spleen, and kidneys) of each PBAE NP 
formulation with 5 distinct DNA barcodes from 5 different mice. 6 hours post administration of 
PBAE NPs, mRNA was extracted from organs and relative expression was quantified by RT-
qPCR (-∆∆CT of mRNA transcription of barcoded plasmid DNA in each PBAE NP normalized 
to GAPDH). Data represent mean ± SEM of n = 5 for each PBAE NP from a total of 8 mice 
(one-tailed Student’s t-test between the experimental -ΔΔCT values and zero with Sidak’s 





Figure 2.16. Luciferase expression after intravenous administration of PBAE NPs 
harboring fLuc plasmid DNA. Quantification and representative images of organ 
bioluminescence 6 hours after intravenous administration of PBAE 456 (A,D), PBAE 536 (B,E), 
and PBAE 546 (C,F) NPs. Data represent mean ± SEM of n = 3. Statistical differences between 
organ luminescence were calculated by one-way ANOVA with Holm Sidak’s multiple 





Table 2.1 Properties of PBAE polymers. Total numbers of carbons and tertiary amines are 
estimated from the molecular weight of each polymer. 
  
 
PBAE polymer 446 447 454 456 457 534 536 546 
Molecular weight: 
Mn (kDa) 
4.38 14.8 3.85 3.05 5.99 7.37 4.73 6.02 
Molecular weight: 
Mw (kDa) 
9.40 103 9.50 10.6 20.5 14.7 10.8 11.9 
PDI 2.15 6.96 2.47 3.48 3.42 2.00 2.27 1.97 
# of carbons between 
diacrylates in diacrylate 
monomer group 
4 4 4 4 4 5 5 5 
# of carbons in side chain 
between amine and 
hydroxyl group 
4 4 5 5 5 3 3 4 
Total # of carbons 210 734 197 150 306 365 237 299 
# of primary amines 0 0 2 0 0 2 0 0 
# of secondary amines 4 2 2 4 2 2 4 4 


















































































































Table 2.4 Barcode NP administration scheme. Each animal (1-8) listed in the row title was 
injected with a mixture of 5 NPs, where each NP is comprised one of 5 barcode pDNAs 




Chapter 3: Non-Viral Gene Delivery to Hepatocellular Carcinoma 
Tumors via Intra-Arterial Injection 
3.1 Introduction 
 Liver cancer is the fifth most prevalent type of cancer globally, and the third most 
common cause of cancer death1. Hepatocellular carcinoma (HCC) is the most common type of 
primary liver tumor, accounting for >80% of cases2. Patients with early-stage disease are eligible 
for tumor resection or liver transplantation, which can be curative. However, many HCC patients 
are diagnosed at a later stage when treatment options are generally limited to palliative care3. 
Treatment regimens for these patients are complicated due to the high prevalence of underlying 
liver disease. Globally, approximately 80% of HCC cases can be attributed to chronic hepatitis 
infection, and in the United States, non-alcoholic fatty liver disease underlies 10-20% of HCC 
cases4. These comorbidities cause inflammation and cirrhosis, significantly damaging the normal 
function of the liver. Therefore, systemic or non-targeted treatments such as general 
chemotherapy have a high risk of liver failure for these patients5. 
 Locoregional approaches are preferable to target tumor tissue while avoiding off-target 
toxicity to the liver6. Ultrasonography or computed tomography are used to directly access HCC 
tumors and deliver a cytotoxic agent. Radiofrequency and microwave ablation use high energy 
waves directed at the tumor to cause tissue damage and cell death7,8. Percutaneous ethanol or 
acetic acid injection similarly induce ablation of smaller lesions9. These treatments are most 
successful in small tumors, but the rate of recurrence remains high. 
 Another locoregional approach for intermediate stage HCC is trans arterial 
chemoembolization (TACE)10. This is an interventional radiology procedure which involves 
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accessing the hepatic artery non-invasively, then delivering chemotherapy followed by an 
embolic agent. Because the hepatic artery preferentially supplies blood to HCC tumor while the 
rest of the liver is fed by the portal vein, embolizing the hepatic artery cuts off blood supply to 
the tumor. Local chemotherapy is a standard component of TACE, but clinical trials have shown 
no benefit to adding chemotherapeutic agents over the embolic agent alone11. This may be due to 
the poor pharmacokinetics of small molecule drugs. Another solution is drug eluting bead TACE 
(DEB-TACE), in which microspheres are used to embolize the artery and release drug over an 
extended period, resulting in sustained chemotherapy in the tumor. This procedure carries a 
higher risk of hepatic artery and biliary injuries, but reduced incidence of other complications, 
including abdominal pain, due to the controlled chemotherapy release12. However, in terms of 
effectiveness, DEB-TACE has not shown proven benefit over conventional TACE.  
 There is great interest in improving the therapeutic benefit of TACE by incorporating 
newer generations of therapeutics. Nanoparticles have different pharmacokinetics from small 
molecule drugs and benefit from the enhanced permeation and retention (EPR) effect13. Further, 
nanoparticle may be modified for enhanced targeting by optimizing the material of the delivery 
vehicle or adding targeting ligands to the surface14. Additionally, nanoparticle delivery vehicles 
have been developed for targeted delivery of nucleic acids, which can specifically target genetic 
abnormalities of HCC tumors. Poly(beta-amino ester) PBAE nanoparticles have been optimized 
for targeted DNA delivery to HCC cell lines in vitro and in vivo15. Therefore, we sought to 
develop a protocol for intra-arterial injection of PBAE nanoparticles in a rat xenograft liver 





All in vivo procedures were approved and overseen by the Johns Hopkins Institutional 
Animal Care and Use Committee (IACUC). RNU athymic rats were purchased from Charles 
River Laboratories (Wilmington, MA) or bred at Johns Hopkins from two homozygous RNU 
athymic rats. For all surgical procedures, animals were be anesthetized with 3% isoflurane in 
100% oxygen until a sufficient plane of anesthesia was reached as gauged by rapidity and 
thoracic nature of breathing. Anesthesia was confirmed by monitoring response to stimuli (toe 
pinch). Ophthalmic ointment was applied while animals were under anesthesia. During surgical 
procedures, rats were placed onto a 37°C heated surface to ensure optimum thermoregulation and 
minimize post-op recovery time. The hair was removed from the surgical site (abdomen) using 
clippers or depilatory cream and prepared using a wash of povidone-iodine soap then rinsed with 
70% ethanol. After surgery, the peritoneum was closed using simple continuous suturing of the 
muscle layer with absorbable sutures and skin layer was closed using wound clips or simple 
interrupted suturing with non-absorbable sutures. Finally, Vetbond tissue adhesive was applied 
topically to prevent dehiscence and to improve post-procedure healing. Warm, sterile isotonic 
fluids at 3-5% of the body weight was injected subcutaneously prior to and at the end of surgery. 
Analgesia was administered as meloxicam (2 mg/kg) delivered subcutaneously prior to surgery 
and again at 24 and 48 hours after surgery. 
Liver tumor implantation surgery  
To access the liver, a laparotomy was performed extending caudally from the xiphoid 
process. Under direct visualization, 1 × 106 N1-S1 cancer cells in a 1:1 solution of HBSS and 
High Concentration Matrigel (Corning, Corning, NY) were injected under the liver capsule. 
Successful inoculation with cancer cells was verified by pale, white protrusion at the point of 
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injection. Gentle compression was applied for at least 15 seconds using a sterile cotton tipped 
applicator to prevent cancer cell leakage or bleeding.  
Nanoparticle Preparation 
Firefly luciferase (fLuc) DNA was amplified by Aldevron (Fargo, ND) and used for in 
vivo transfection studies. For biodistribution studies, fLuc DNA was functionalized using Label 
IT Nucleic Acid Modifying Reagent (Mirus Bio Madison, WI) and labeled with IRDye 800RS 
NHS Ester Infrared Fluorescent Dye (LI-COR, Lincoln, NE). 10% labeled DNA was used for 
biodistribution studies. PBAE 536 was synthesized by Michael addition as previously 
described15.  
PBAE 536 was diluted in sodium acetate (40.4 mM, pH 5), the added to 1 mg/mL 
plasmid DNA in water for a final DNA concentration of 0.25 mg/mL and polymer: DNA weight 
ratio of 25 w/w. DNA and polymer were allowed to complex for 10 minutes, then sucrose was 
added for a final concentration of 90 mg/mL to make the solution isotonic. Nanoparticles were 
frozen at -80°C and thawed immediately prior to injection. 
Jugular Injection 
Under careful dissection, the right or left jugular was visualized. A 27G insulin needle 
was inserted into the overlying muscle and then directed towards the rat’s head into the jugular 
vein lumen as it is visualized in vessel anterior to the trapezius muscle. Prior to injection, the 
plunger was pulled back, and proper placement was confirmed by visualizing blood in the 
syringe. Nanoparticles were injected slowly at 100 µL per minute in a total volume of 500 
microliters and were visualized intravenously in the jugular vein during delivery.  
Hepatic Artery Injection 
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After orthotopic liver tumor implantation described above, tumor-bearing animals were 
subjected to the following hepatic artery injection surgical procedure. Hepatic artery injection 
surgery was not performed sooner than two weeks after the orthotopic tumor implantation 
surgery, to minimize main and distress on the animals. The procedure was performed under a 
dissecting microscope to improve visualization of small delicate structures. Animals were 
prepared for surgery as described above, then an incision was made with a scalpel extending 
caudally from the xyphoid process ~3 cm. The peritoneum was cut with scissors along the linea 
alba. The lateral left lobe of the liver was externalized on a sterile piece of gauze soaked with 
saline and retracted. Similarly, the duodenum was externalized on gauze and retracted. The 
mesenteric connective tissues were dissected, and common bile duct was retracted using silk 
suture to allow visualization of the common hepatic artery, proper hepatic artery and 
gastroduodenal artery (GDA). The right GDA artery was freed from surrounding tissue and 
ligated at the distal end. A few drops of 2% lidocaine were applied to the GDA to promote 
vasodilation. The common hepatic artery was clamped using a bulldog clamp, occluding blood 
flow. A 27-gauge needle was inserted into the gastroduodenal artery, and 500 µL of 
experimental solution was slowly hand injected at a rate of ~100 µL per minute. Successful 
injection was confirmed by visualizing the displacement of blood in the proper hepatic artery.  
Following experimental injection, the needle was slowly withdrawn from the vessel. A suture 
was used to ligate the GDA proximal to the needle insertion site, and the clamp was removed 
from the common hepatic artery to restore blood flow through the proper hepatic artery. The 
duodenum and liver were replaced in the abdominal cavity, and the incision was closed as 
described above. 
In Vivo Imaging 
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Biodistribution and transection were monitored by IVIS (IVIS Spectrum imaging system, 
Perkin Elmer, Waltham, MA). 150 mg/kg D-luciferin (Gold Biotechnology, St. Louis, MO) was 
administered intraperitoneally to mice, then 8 minutes later animals were sacrificed, and livers 
were harvested. Bioluminescence and fluorescence images were acquired. Images were analyzed 
across regions of interest (ROI) using Living Image software (Perkin Elmer, Waltham, MA).  
3.3 Results 
 PBAE 536 NPs were specifically optimized to transfect HCC cell lines in previous work 
be Zamboni et al15. To evaluate biodistribution and transfection, firefly luciferase (fLuc) plasmid 
DNA was labeled with a near-infrared fluorophore. NPs were formulated with 10% labeled DNA 
and 90% unlabeled fLuc plasmid. DNA at 0.25 mg/mL was combined with PABE 536 polymer 
in sodium acetate (pH 5, 25 mM) and allowed to self-assemble. The tonicity of the solution was 
balanced using sucrose, for a final concentration of 90 mg/mL.  
A microsurgical procedure was developed to administer NPs via the hepatic artery. A 
laparotomy was performed, and the liver and duodenum were retracted on sterile gauze. The 
gastroduodenal artery (GDA) was located near the caudate lobe, anterior to the portal vein and 
posterior to the common bile duct (Figure 3.1). To prevent bleeding, the GDA was selected as 
the injection site, as the vessel may be ligated without complications (cite). The GDA was 
isolated and ligated at the distal end. Next, a few drops of 2% lidocaine were applied directly to 
the GDA to induce vasodilation. The common hepatic artery was clamped temporarily using a 
micro bulldog clamp. A 27G insulin needle was used to inject 500 µL of NPs into the GDA, and 
flow was directed to the common hepatic artery. Successful injection was confirmed by 
visualizing the displacement of blood in the proper hepatic artery. Injections were performed at a 
rate of 100 µL per minute to minimize risk of embolism. After injection, the needle was carefully 
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removed, and the proximal end of the GDA was ligated before removing the clamp on the 
common hepatic artery. A latex solution was injected using this procedure to visualize the 
injection route and anatomy (Figure 3.2). Injected solution was directed into the proper hepatic 
artery and into the left and right branches and into the liver. 
 To assess biodistribution and transfection, nanoparticles were synthesized with fLuc 
DNA labeled (10%) with near-IR fluorescent dye (NIR-fLuc NPs). NIR-fLuc NPs were 
administered intravenously or via hepatic artery, and biodistribution (fluorescence) and 
transfection (luminescence) were assessed 6 hours later. In healthy RNU rats, NPs administered 
by either route accumulated in the liver (Figure 3.3). No transfection was observed in the liver. 
To evaluate intratumoral delivery, rats were implanted with N1-S1 tumors in the liver. Two 
weeks later, NIR-fLuc NPs were injected. Intravenously injected NPs accumulated in the liver, 
excluding the tumor tissue (Figure 3.4). NPs administered via the hepatic artery accumulated in 
the liver but also in the tumor. In the intra-arterial injection case only, transfection was detected 
in the primary tumor. Interestingly, there was also measurable transfection outside the tumor 
area, suggesting that micrometasteses may be transfected throughout the liver.  
3.4 Discussion 
 Local delivery is an attractive option for targeting therapeutics directly to the tumor 
microenvironment. However, small molecule chemotherapies have poor pharmacokinetics and 
can still cause systemic toxicity with local administration. Nanoparticle formulations have 
superior retention in tumor tissue, which has been exploited in the development of many 
systemically administered therapeutic nanoformulations16. While passive targeting by the EPR 
effect has shown promise in preclinical studies, this effect has not translated to clinical trials in 
human patients with solid tumors17. In an orthotopic rat model of HCC, we showed that 
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intravenously administered PBAE nanoparticles do not accumulate in tumor tissue. With local 
delivery via the proper hepatic artery, intratumoral accumulation is increased. By taking 
advantage of the differential blood supply to tumor and liver tissue, nanoparticle biodistribution 
was improved.  
 Nucleic acid therapeutics may be used to target dysregulated oncogenes or tumor 
suppressor genes in cancer cells. Further, plasmid DNA may be targeted for cancer cell 
expression by employing a cancer-specific promoter for therapeutic gene expression18,19. 
Delivery efficiency is still a major barrier to DNA therapy for cancer, and local administration 
should lead to an increased concentration of nanoparticles at the target site20. Further, local 
administration routes lead to decreased exposure to systematic circulation, slowing clearance and 
reducing the risk of systemic toxicity21. We showed successful delivery of fLuc reporter DNA to 
HCC liver tumors with intra-arterial injection of PBAE NPs. Intravenous administration of NPs 
was not successful in transfecting tumor or liver tissue. Further investigation is necessary to 
characterize the cell populations targeted. 
 Local delivery is not a feasible option for many types of solid tumors. HCC tumors are 
uniquely accessible by the proper hepatic artery, and this has been harnessed in a clinical setting 
with the TACE procedure10. This procedure is minimally invasive, and specific branches of the 
artery can be accessed to target a patient’s tumor more specifically. By developing a preclinical 
surgical procedure to access this artery for nanoparticle delivery, this route may be explored for 
the delivery of alternative agents, such as mRNA and siRNA. Additionally, active targeting 
agents which specifically bind to tumor cells may be developed and tested for additional 
targeting22. This rat model recapitulates many of the barriers of delivery to HCC tumors. Further 
development should be focused on toxin-induced or genetic HCC models which may model the 
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vasculature of these tumors more accurately. Additionally, a syngeneic HCC model is needed to 
investigate the immunological response to therapeutic agents, particularly in the development of 
cancer immunotherapies.  
 In conclusion, we describe a method for accessing the proper hepatic artery in rats. We 
show that this route of administration provides a significant advantage over intravenous 
administration for the delivery of PBAE NPs, improving both accumulation of NPs in the tumor 
and successful delivery of a reporter gene. Future work should incorporate anti-cancer nucleic 
acid to assess the therapeutic benefits of this approach. 
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Figure 3.1 Intra-arterial Injection Procedure. A. Portal triad anatomy. The common biliary 
duct is retracted to visualize the hepatic artery. Arrow (yellow) indicates the injection site in the 
gastroduodenal artery. B. Intra-arterial injection to the hepatic artery visualized using a latex 
solution injection. Blue latex was injected into the gastroduodenal artery, then progresses into the 
common hepatic artery and into the liver. Images were acquired under magnification with a 






Figure 3.2 NIR-fLuc NP biodistribution and transfection following intra-arterial or 
intravenous injection in animals without liver tumors. Healthy rats were injected with 500 µL 
PBAE NPs harboring 125 µL of fLuc DNA, with 10% of DNA mass covalently labeled with 
near infra-red fluorophore. With both intravenous and trans arterial administration, NPs were 





Figure 3.3 NIR-fLuc NP biodistribution and transfection following intra-arterial or 
intravenous injection in animals with N1-S1 xenograft tumors (circled). 2 weeks after N1-S1 
tumor implantation, rats were injected with 500 µL PBAE NPs harboring 125 µL of fLuc DNA, 
with 10% of DNA mass covalently labeled with near infra-red fluorophore. NPs administered by 
intravenous injection accumulate in the liver but exclude the tumor. NPs administered via the 




Chapter 4: Poly(beta-amino ester) Nanoparticles Enable Tumor-
Specific TRAIL Secretion and a Bystander Effect to Treat Liver 
Cancer3 
4.1 Introduction 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a protein ligand that has 
been studied for over two decades as an anti-cancer agent.1,2 Upon TRAIL binding to death 
receptors DR4 and DR5, intracellular death domains cluster and initiate apoptotic signaling via 
assembly of the death-inducing signaling complex (DISC).3 DR4 and DR5 are overexpressed in 
many cancers, while healthy cells overexpress decoy receptors DcR1 and DcR2, which bind 
TRAIL protein but do not contain fully functional intracellular death domains required for 
apoptosis.4,5 These differences in death receptor expression, as well as abnormal regulation of 
apoptotic signaling, result in TRAIL initiating apoptosis selectively in cancer cells with limited 
toxicity to healthy cells and tissues.6 
Though TRAIL has shown promising therapeutic effects in vitro and in animal cancer 
models, it has failed to show significant anti-tumor efficacy in clinical trials.7,8 Recombinant 
TRAIL protein is rapidly cleared, with a serum half-life of approximately 30 minutes.9 This 
results in low TRAIL accumulation in the tumor, likely underpinning the lack of robust anti-
tumor response. Additionally, there is evidence of acquired and innate TRAIL resistance in many 
tumor types, which has inspired investigation into combination therapies and sensitizing 
agents.10  
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Lackluster clinical efficacy has motivated gene therapy approaches to improve TRAIL-based 
cancer treatment.11 TRAIL gene therapy directly delivers TRAIL-encoding cDNA to cancer 
cells, enabling cytokine production locally in the tumor. This approach maximizes the local 
concentration of TRAIL protein, while minimizing systemic exposure and toxicity. Several 
groups have employed viral vectors for TRAIL gene therapy and achieved efficient suppression 
of xenograft tumor growth in various cancer types.12–14 However, there are safety concerns 
inherent to viral gene therapy, including risk of immunogenicity,15 tumorigenicity.16 and 
cytotoxicity,17 as well as the practical limitations of limited cargo carrying capacity and 
manufacturing challenges.  
Non-viral gene delivery systems are generally safe and non-immunogenic but often have 
lower delivery efficacy than their viral counterparts.18 To address this limitation, we have 
developed cDNA encoding a secreatable form of TRAIL which we deliver to hepatocellular 
carcinoma (HCC) using poly(beta-amino ester) PBAE nanoparticles (NPs). We explored 
combining this TRAIL NP therapy with histone deacetylase (HDAC) inhibitors, which have 
shown promise in sensitizing resistant cells to TRAIL19–23. We hypothesized that the bystander 
effect of secreted TRAIL to non-transfected cells combined with HDAC inhibitor sensitization 
could result in a potent yet cancer-specific non-viral TRAIL gene therapy (Figure 4.1). 
4.2 Methods 
Polymer Synthesis 
1,5-pentanediol diacrylate (B5) (Monomer-Polymer and Dajac Labs, Trevose, PA), and 3-amino-
1-propanol (S3) (Alfa Aesar, Ward Hill, MA) were combined in  a 1:1.1 molar ratio of backbone 
to sidechain monomer and polymerized at 90°C under stirring for 24 hours. The resulting 
acrylate-terminated polymer (B5S3) was dissolved in THF, and 2-(3-aminopropylamino)ethanol 
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(E6) (Sigma-Aldrich, St. Louis, MO) was added at a 10-fold molar excess. The end capping 
reaction was allowed to proceed for 1 hour at RT under stirring. Endcapped PBAE polymer 536 
was purified twice in diethyl ether to remove unreacted monomer and short oligomers, then dried 
under desiccant for approximately 48 hours to remove traces of ether. PBAE 536 was dissolved 
in anhydrous DMSO and stored at -20°C with desiccant. Molecular weight was characterized by 
Gel Permeation Chromatography (GPC, Waters 2414 Refractive Index Detector, Milford, MA). 
Plasmid DNAs 
pEGFP-N1 (eGFP) DNA was purchased from Clontech Laboratories Inc. (Mountain View, 
CA) and amplified by Aldevron (Fargo, ND). pEGFP‐TRAIL (mTRAIL) was a gift from 
Bingliang Fang (Addgene Plasmid #10953) (Cambridge, MA). Luciferase-pcDNA3 was a gift 
from William Kaelin (Addgene plasmid # 18964) and amplified by Aldevron (Fargo, ND).  
A non-viral plasmid encoding sTRAIL was designed and synthesized based on published 
work.24 Coding sequences from the extracellular domain of Flt3L (a.a. 1– 81), an isoleucine 
zipper sequence from the pFETZ vector, and the apoptosis-inducing sequence derived from the 
N-terminus of the human TRAIL sequence (a.a. 114 –281) were combined in-frame. sTRAIL 
cDNA was synthesized using custom gene synthesis from Integrated DNA Technologies, Inc. 
(IDT) (Coralville, IA). The empty pN3-Control backbone was a gift from Guntram Suske 
(Addgene plasmid # 24544). sTRAIL cDNA was cloned into pN3-control backbone by 
restriction enzyme digest and amplified using ZymoPURE Plasmid Gigaprep kit (Zymo 
Research, Irvine, CA).  
Nanoparticle Synthesis and Characterization 
Plasmid DNA and PBAE 536 polymer were separately dissolved in pH 5 25 mM sodium 
acetate and combined at equal volumes, with a 1:25 mass ratio of polymer to DNA. NPs were 
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allowed to assemble for 10 minutes, then diluted 5x or 10x in pH 7.4 PBS. Size was measured by 
dynamic light scattering (DLS) and zeta potential was measured by electrophoretic light 
scattering by a Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). To measure 
encapsulation efficiency PBAE NPs were combined with 6X loading dye without SDS. The 
samples were run through 0.8% agarose gel and using ethidium bromide staining and UV 
exposure to visualize the DNA bands.  
Cell Culture 
HepG2 and THLE3 cells were purchased from ATCC (Manassas, VA) and cultured 
according to the vendor’s specifications. HepG2 cells were cultured in MEM media 
supplemented with 10% FBS, 1% Pen/Strep, 100 μM MEM Non-Essential Amino Acids, and 1 
mM sodium pyruvate. THLE3 were cultured in Bronchial Epithelial Cell Growth Medium 
(BEBM) supplemented with 10% FBS, 1% Pen/Strep, 5 ng/mL human epithelial growth factor 
(EGF), 70 ng/mL O-phosphorylethanolamine, and the BEGM bullet kit (Lonza/Clonetics 
Corporation, Walkersville, MD) except Gentamycin-Amphotericin and Epinephrine. THLE3 
cells were grown on plates and flasks coated with 0.01 mg/mL fibronectin, 0.03 mg/mL bovine 
collagen type I, and 0.01 mg/mL bovine serum albumin dissolved in culture media. Coating was 
performed overnight at 37°C. 
In vitro transfection  
Cells were plated in tissue culture treated 96-well plates at 10,000 cells per well and allowed 
to attach overnight. PBAE 536 NPs were freshly prepared and added to wells at a final DNA 
dose of 0.6 μg per well. Cells were incubated with the NPs for 2 hours at 37°C, then replenished 
with cell culture media. In HDAC inhibitor experiments, vorinostat (Adipogen, San Diego, CA), 
sodium butyrate (Sigma-Aldrich, St. Louis, MO), and MS-275 (Sigma-Aldrich, St. Louis, MO) 
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were diluted from stock solutions in cell culture media and added to cells after NP incubation. 
For media transfer studies in Supplemental Figure 4B, transfected cells were cultured for 48 
hours, then conditioned media was spun down at 300 rcf  for 5 minutes to remove dead cells and 
debris. HDAC inhibitors were added to conditioned media and transferred to non-transfected 
HepG2 or THLE3 cells, seeded 24 hours prior.  
Viability and transfection analysis 
Brightfield images were acquired 48 hours after transfection using a Zeiss (Oberkochen, 
Germany) Axio Observer fluorescence microscope at 10X magnification. Flow cytometry was 
performed 48 hours after transfection using a BD Accuri™ C6 Flow Cytometer (BD 
Biosciences, San Jose, CA) outfitted with a HyperCyt™ autosampler (IntelliCyt Corporation, 
Albuquerque, NM) to enable high throughput analysis. Cells were prepared for flow by 
detaching in 0.25% trypsin-EDTA (HepG2) or 0.05% trypsin-EDTA (THLE3), then 
resuspending in 30 µL of 2% FBS solution in 1X PBS. To assess viability, cells were also 
stained with a 1:200 dilution of propidium iodide (PI). Data was analyzed using FlowJo v10 
(Ashland, OR). Events were gated on FSC-H and SSC-H to identify the cell population, then on 
FSC-H and FSC-A to exclude doublets. For transfection toxicity analysis, % cells were 
calculated by determining the percentage of cells stained positive for PI. For GFP transfection 
analysis, dead cells which stained PI+ (FL3-A) cells were also excluded. % GFP positive cells 
and normalized geometric mean fluorescence (FL1-A) were calculated. For TRAIL efficacy 
studies, viability was measured 24 hours after transfection using an MTT cell proliferation assay 




Total protein was extracted from tumor cells 24 hours following treatment with DMSO 
(Sigma Aldrich, USA), 0.1 µM and 0.5 µM of Vorinostat (Thermo Fisher Scientific, USA), and 
quantified using Bradford protein assay (Bio-Rad, USA). 10 µg of the protein lysates from these 
samples were loaded onto 10% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad, USA) 
and conducted at 110 V for 90 minutes. Following the separation step, proteins were transferred 
to a PVDF membrane at 100 V for 1 h. Membranes were blocked with 5% dry milk or 5% 
bovine serum albumin (BSA) and 0.1% Tween-20 in TBS for 1 h at room temperature (RT), and 
incubated with primary antibodies in TBS-T overnight at 4 °C. After treatment with HRP-
conjugated secondary antibodies in TBS-T for 1 h at RT, membranes were developed with Super 
Signal West Pico system (Thermo Fisher Scientific, USA) then, signals were visualized using 
autoradiographic films. Antibodies used: DR4 (ProSci 1139), DR5 (ProSci 2019), Vinculin 
(Sigma V4505), anti-rabbit IgG HRP-linked (Cell Signaling Technologies 7074), and goat anti-
mouse IgG H&L (HRP) (Abcam ab97023). Vinculin was used as a loading and internal control. 
Flow Cytometry Analysis of Cell Surface Receptors 
Cells were harvested with trypsin, washed, and resuspended in PBS, then stained with 
Zombie UV™ Fixable Viability Kit (Biolegend 423107) for 30 minutes at RT, followed by a 
wash and then incubated with primary antibody for 60 minutes at 4 ºC in the dark; then samples 
were washed and incubated with secondary conjugated antibody for 60 minutes at 4 ºC in the 
dark. Samples were then resuspended in PBS with 1% FBS (Gibco, USA). Flow cytometry was 
performed using FACS Fortessa (BD) cell sorter and data was analyzed using FlowJo (BD). All 
washes were performed with PBS. Antibodies used: APC anti-human CD262 (DR5, TRAIL-R2) 
(Biolegend 307407), DR4 (Santa Cruz Biotechnology, sc-32255), and IgG1 cross-adsorbed goat 
anti-mouse, Alexa Fluor® 488, (Invitrogen A21121). 
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Annexin V Stain 
Annexin V, FITC conjugate was purchased from BioLegend (San Diego, CA). 48 hours after 
transfection and/or sensitizer treatment, cells were resuspended in 100 μL staining buffer with 
1:200 dilution of PI. 5 µL of Annexin V stain was added per well, and cells were incubated at RT 
for 15 minutes. Cells were spun down, washed once in 1X PBS, then resuspended in 2% FBS for 
flow cytometry, as described above. Geometric mean fluorescence (FL1-A) was calculated and 
reported. Histograms from representative wells were created using FlowJo v10 (Ashland, OR). 
TRAIL ELISA 
To collect lysates, cells were washed 3X with ice-cold PBS, then treated with cell extraction 
buffer (Invitrogen, Carlsbad, CA) supplemented with 5% protease inhibitor (Sigma Aldrich, St. 
Louis, MO) for 30 minutes in ice. Lysates were thoroughly mixed by pipetting, then centrifuged 
for 10 minutes at 13,000 rpm at 4°C. Supernatants were transferred and stored at -80°C until 
used. Conditioned cell culture media was collected and centrifuged for 10 minutes at 1,500 rpm 
at 4°C. Supernatants were also stored at -80°C. Human TRAIL ELISA was purchased from 
Invitrogen (Carlsbad, CA), and the assay was run according to manufacturer’s instructions. 
Human TRAIL protein dilutions were used as standards and run in duplicate. Absorbance was 
measured at 450 nm using a Biotek Synergy 2 plate reader (Winooski, VT). Results from the 
standards were plotted and fit to a 5-parameter fit curve in GraphPad Prism 6 (San Diego, CA). 
Sample concentrations were calculated by interpolating the fit curve.  
Total protein contents of cell lysates were measured using a Pierce™ BCA Protein Assay Kit 
(Waltham, MA). Bovine serum albumin (BSA) standards were prepared and run in duplicate to 
create a standard curve. The kit was used following manufacturer’s instructions, and absorbance 
was measured at 562 nm on a Biotek Synergy 2 plate reader (Winooski, VT). Absorbance 
155 
 
measurements from the BSA standards were plotted and fit to a 5-parameter fit curve in 
Graphpad Prism 6 (San Diego, CA). Protein concentrations of samples were determined by 
interpolating the fit curve. TRAIL concentration in each sample was normalized to total protein 
content by BCA and was reported as pg of TRAIL per ug total protein.  
Animal Models 
All in vivo procedures were approved and overseen by the Johns Hopkins Institutional 
Animal Care and Use Committee (IACUC). To establish xenograft tumors, 1 million HepG2 
cells were resuspended in 100 μL of 50% Matrigel matrix HC (Corning, Corning, NY) and 50% 
HBSS. Cells were injected subcutaneously in the hind flank of female 6-8 week-old athymic 
nude mice (The Jackson Laboratory, Bar Harbor, ME). During implantation, animals were 
anesthetized with 2.5% isoflurane in oxygen. Tumors developed in ~80% of mice after 14 days.  
In vivo gene delivery to SC tumors 
To make NPs for in vivo gene delivery, PBAE 536 was diluted in pH 7.4 sodium acetate, 
then fLuc plasmid was added for a final DNA concentration of 0.1 μg/μL. The polymer to DNA 
weight ratio was maintained at 25 w/w, and final sodium acetate concentration was 25 mM. NPs 
were stored at -80°C and thawed immediately prior to injection. Animals were anesthetized 
under isoflurane, and 50 µL of NPs were injected into the tumor using an insulin syringe, for a 
final 10 μg DNA dose. After 24, 48, 72, and 96 hours, live in vivo imaging was performed using 
an IVIS Spectrum imaging system (Perkin Elmer, Waltham, MA). 150 mg/kg D-luciferin (Gold 
Biotechnology, St. Louis, MO) was administered intraperitoneally to mice, then imaging was 
performed 10 minutes later. Images were analyzed across regions of interest (ROI) using Living 
Image software (Perkin Elmer, Waltham, MA).  
Anti-tumor Efficacy and Survival Study 
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Mice were implanted with HepG2 tumors as previously described. PBAE NPs were 
synthesized with fLuc or sTRAIL plasmid in pH 7.4 sodium acetate at a DNA dose of 0.2 μg/μL 
and stored at -80°C. 14 days after tumor implantation, mice were randomized to three groups: (1) 
fLuc (control) NP + vehicle (N=7), (2) vorinostat only (N=3), (3) sTRAIL NP + vorinostat 
(N=8). Every four days, beginning on Day 14, mice received intratumoral injections of NPs and 
retroorbital injections of 100 μL vehicle or 150 μM vorinostat. Tumor dimensions were 
measured every other day using calipers, and area was calculated by multiplying the longest 
dimension (length) by its perpendicular width. An animal was sacrificed when its tumor area 
grew larger than 200 mm2.  
Statistical Analysis 
All data is presented as a mean ± standard error of replicate tests. Comparisons between 
two groups were performed using a student’s t test. Comparisons between multiple (>2) groups 
were performed using one-way ANOVA and Tukey or Dunnett post-hoc test for multiple 
comparisons. Tests between groups with multiple factors were performed using two-way 
ANOVA and Sidak’s multiple comparison test. All statistical analyses were performed using 
GraphPad Prism 6 (San Diego, CA).  
4.3 Results 
PBAE NPs Enable DNA Delivery to HepG2 In Vitro and In Vivo 
PBAEs are a class of biodegradable polyesters that have been employed for nucleic acid 
delivery to a wide range of cell types.25 To form DNA NPs, PBAE cationic polymer is combined 
with anionic plasmid DNA at varying weight/weight (w/w) ratios, and the polyelectrolytes self-
assemble electrostatically into polyplexes. These NPs facilitate efficient cellular uptake, 
endosomal escape, and expression of the encapsulated gene cargo.  Our lab has shown that by 
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varying the composition of PBAE polyplexes, we can tune transfection efficacy in a wide range 
of cell types, while minimizing NP cytotoxicity.26,27 Notably, we recently used high-throughput 
screening to optimize DNA delivery to an array of nine HCC cells lines and identified a polymer 
termed PBAE 536 (Figure 4.2A) as the superior candidate for gene delivery across these cell 
lines.28 Therefore, we selected PBAE 536 NPs as a non-viral DNA delivery vehicle for HCC 
cells in this study. 
PBAE NPs were characterized and evaluated for DNA delivery in both HCC cells and 
healthy human hepatocytes. PBAE 536 was synthesized via Michael addition in a two-step 
reaction (Figure 4.3). To form NPs, PBAE 536 was combined with eGFP-N1 plasmid DNA at 
25 w/w and allowed to self-assemble in sodium acetate (pH=5). Electrostatic interactions 
between the cationic polymer and anionic nucleic acid facilitated the formation of NPs with a 
hydrodynamic diameter of ~200 nm and a zeta potential of +16 mV. Gel electrophoresis was 
performed to quantify DNA encapsulation efficiency as a function of w/w ratio.  Encapsulation 
efficiency was ~100% for all formulations tested (Figure 4.4). Dynamic light scattering (DLS) 
measurements were performed on NPs formulated with various plasmid DNAs as well as PBAE 
polymer alone. We determined that NP size is independent of the plasmid sequence, and there is 
a significant decrease in particle size in the absence of plasmid DNA, demonstrating that 
electrostatic complexation drives the formation of the NPs (Figure 4.5). To evaluate these NPs 
for gene delivery, in vitro cultures of HepG2 human HCC cells and THLE-3 healthy human 
hepatocytes were incubated with varying doses of eGFP-N1 PBAE 536 NPs. Increasing doses of 
NPs caused increased toxicity in both HepG2 and THLE-3 cells (Figure 4.2B). Transfection 
efficacy was also dose-dependent, with increasing transfection with higher DNA doses in both 
cell types (Figure 4.2C). An intermediate dose of 600 ng DNA per well was selected for further 
158 
 
studies because this was the lowest dose tested with significantly increased transfection in 
HepG2 HCC cells over THLE-3 hepatocytes. At this dose, toxicity was maintained below 15% 
for both cell types, and transfection rates were 41±3% and 27±1% in HepG2 and THLE-3 cells, 
respectively. Therefore, PBAE 536 NPs enable specific transfection of HepG2 cells over healthy 
hepatocytes, without toxicity to either cell line. HepG2 cells transfected with empty pN3 
backbone plasmid showed similar toxicity profile to eGFP transfected cells and no significant 
fluorescence, indicating that transgene expression does not cause significant toxicity or 
background fluorescence in transfected cells (Figure 4.6). These results confirm a biomaterial-
mediated cancer-specificity of PBAE 536 NPs that has been previously reported.29 
PBAE NP Transfection with sTRAIL Plasmid Results in TRAIL Protein Secretion 
With the aim of developing a TRAIL gene therapy with a potent bystander effect, we 
engineered a secretable TRAIL (sTRAIL) plasmid (Figure 4.7A). The non-viral sTRAIL 
construct, based on a viral construct developed by Shah et al., is comprised of three components: 
1) A secretion signal derived from the extracellular domain of Flt3L, a ligand for the Flt tyrosine 
kinase receptor involved in protein secretion, 2) An isoleucine zipper trimerization domain to 
facilitate the assembly of a biologically active TRAIL homotrimer, and 3) The apoptosis-
inducing sequence derived from the N-terminus of the human TRAIL sequence.24 The coding 
sequences of these three domains were combined and inserted into the multiple cloning site of 
the pN3 backbone downstream of the CMV promoter-enhancer sequence.30 The full cDNA 
sequence can be found in Figure 4.8 (Addgene #154246). As a positive control, we utilized a 
plasmid encoding for the endogenous transmembrane human TRAIL protein in a pEGFP-C3 
backbone, which we refer to as mTRAIL (membrane TRAIL) to differentiate it from secretable 
TRAIL (sTRAIL).31,32  
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Next, we evaluated TRAIL protein expression and secretion in cells transfected with sTRAIL 
and mTRAIL plasmids. PBAE 536 NPs were fabricated with mTRAIL or sTRAIL DNA, and 
these NPs were used to transfect HepG2 cells. After 48 hours, lysates and media samples were 
collected from transfected cells, and an ELISA for human TRAIL was performed on these 
samples. These results showed that cells treated with sTRAIL-NPs had intracellular TRAIL 
expression of 530 pg per µg of total protein, an expression level similar to cells treated with the 
mTRAIL positive control plasmid (Figure 4.7B). However, there were striking differences in the 
conditioned cell culture media from mTRAIL and sTRAIL transfected cells. sTRAIL-treated 
cells secreted TRAIL protein extracellularly, with a concentration of 850 pg/mL after 48 hours 
(Figure 4.7C). However, cells transfected with mTRAIL showed no detectable protein secretion. 
Taken together, these results confirm that the sTRAIL sequence developed for these studies 
encodes for human TRAIL protein, as detected by ELISA. Additionally, the modifications made 
in the engineered sTRAIL cDNA enable secretion of this TRAIL protein.  
We next measured cellular viability to confirm that the protein secreted by sTRAIL 
transfected cells maintained the pro-apoptotic function of TRAIL. After 24 hours, HepG2 cells 
treated with sTRAIL NPs are sparser, rounded, and form smaller clumps than cells transfected 
with control eGFP-N1 NPs (Figure 4.7D). By MTT assay, the viability of sTRAIL transfected 
cells was reduced by 37% over untreated cells, while the loss in viability from control GFP NPs 
was only 1% (Figure 4.7E). Transfection with mTRAIL showed only 21% decrease in viability, 
although there is not a statistically significant difference in comparison to sTRAIL transfected 
cells. These results suggest that the modifications to the sTRAIL sequence did not mitigate the 
anticancer effect of TRAIL protein. 
HDAC Inhibitors Sensitize HepG2 cells to TRAIL-Induced Apoptosis 
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HDAC inhibitors have been explored as a cancer treatment as a monotherapy and in 
combination with chemotherapy or radiation.33 This class of drugs acts by inhibiting histone 
deacetylases, effectively opening chromatin and affecting gene expression at the epigenetic level, 
including key tumor suppressors and resistance genes.34 Some studies have also shown a 
synergistic anti-cancer effects between TRAIL and HDAC inhibitors.35–37 Western blot analysis 
shows that the HDAC inhibitor vorinostat alters death receptor expression in HepG2 cells 
(Figure 4.9A). After 24-hour treatment with vorinostat, DR4 and DR5 expression are increased.  
Flow cytometry confirms that surface expression of DR5 increases with vorinostat exposure in a 
dose-dependent manner (Figure 4.9B). However, surface DR4 is unchanged by vorinostat 
exposure, suggesting that trafficking of death receptors to the cell membrane remains a barrier. 
Receptor mutation studies have shown that DR5 has a greater contribution to TRAIL mediated 
apoptosis than DR4, so we hypothesized that increased DR5 expression alone could mediate a 
significant sensitizing effect.38–40 
We combined PBAE 536 sTRAIL NP treatment with low doses of three HDAC inhibitors as 
sensitizing agents: vorinostat, sodium butyrate, and MS-275. HepG2 cells were incubated with 
NPs for 2 hours, then sensitizers were added. While HDAC inhibitors have shown promise as 
anti-cancer agents, we used low doses with limited toxicity to cancer cells when used alone 
(Figure 4.10). After 48 hours, viability was measured by MTT assay, and treatment wells were 
normalized to wells treated with control GFP NPs and the same sensitizer dose to isolate TRAIL-
mediated apoptosis.  
HepG2 cells treated with HDAC inhibitors showed higher TRAIL-mediated cell death, 
compared with TRAIL NP treatment alone (Figure 4.9C-E). This sensitizing effect was dose-
dependent, with higher HDAC inhibitor concentration resulting in >70% loss in viability. This 
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suggests that the increased surface DR5 expression from HDAC inhibitor treatment effectively 
sensitize HepG2 cells to TRAIL-mediated cell death. Further, combination treatment with 
sTRAIL NPs was more potent than with mTRAIL NPs at most of the HDAC inhibitor doses 
tested. This demonstrates that the bystander effect enabled by TRAIL secretion increases the 
potency of TRAIL gene therapy.  
Combination Treatment of sTRAIL PBAE NPs and HDAC Inhibitors shows Cancer-Specific 
Apoptosis In Vitro 
We evaluated apoptotic cell death by quantifying phosphatidyl serine expression on the outer 
cell membrane using Annexin V staining. Apoptosis in HepG2 cells increases with sTRAIL 
transfection, as indicated by a shift in the Annexin V histogram curve (Figure 4.11A). Annexin 
V staining further increases with higher HDAC inhibitor doses, confirming that TRAIL-mediated 
apoptosis is dose dependent with HDAC inhibitor concentration. This increased Annexin V 
staining is not observed in GFP-transfected HepG2 cells treated with HDAC inhibitors (Figure 
4.11B). This confirms that treatment-mediated apoptosis is due to a synergistic effect from 
secreted TRAIL and HDAC inhibitors, not from the inhibitors alone or NP cytotoxicity.  
Next, we evaluated the cancer-specificity and off-target toxicity of our combination approach 
by comparing treatment effect in HepG2 HCC cells to THLE3 hepatocytes. While TRAIL-
induced apoptosis is generally considered cancer-specific, there is evidence that modified 
versions of TRAIL protein may cause hepatotoxicity in healthy human cells.41 Further, certain 
sensitizing drugs, including HDAC inhibitors, have shown hepatotoxicity when combined with 
TRAIL therapy.42 We treated both HepG2 HCC and THLE3 hepatocyte cell lines with sTRAIL 
NPs and HDAC inhibitors, then compared the treatment-mediated cell death in the healthy and 
cancer cell types (Figure 4.11C). sTRAIL NPs alone caused very low toxicity in hepatocytes, 
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with 5% cell death in THLE3 cells compared with 27% in HepG2 cells. When HDAC inhibitors 
were used to sensitize the cells, treatment-mediated cell death was increased to 80-90%. The 
combination treatment was significantly more toxic to HepG2 cells over THLE3 at all HDAC 
inhibitor doses, with up to 40-fold higher cell death in the cancer cells. At higher HDAC 
inhibitor concentrations, cell death was increased in both HepG2 and THLE3 cells, indicating 
that the sensitizer dose must be carefully balanced to achieve a potent anticancer effect but not 
cause hepatotoxicity.  
To deduce a mechanism of cancer-specificity, we used an ELISA to quantify TRAIL 
secretion from each cell type. HepG2 cells transfected with sTRAIL NPs secreted over 9-times 
more TRAIL protein than THLE3 cells (Figure 4.11D). To account for this difference in TRAIL 
secretion, THLE3 and HepG2 cells were treated with sTRAIL-conditioned media from 
transfected HepG2 cells. Without HDAC inhibitors, there was an 18% increase in HepG2 cell 
death with sTRAIL-conditioned media, indicating that the secreted TRAIL can potentiate a 
bystander effect to non-transfected cancer cells (Figure 4.12).  This effect was dose-dependent 
with HDAC inhibitor concentration, with the greatest effect of 37% TRAIL-mediated cell death 
at 2 μM vorinostat. The cancer-specificity of the sTRAIL NP treatment is predominantly due to 
higher and preferential transfection of HCC cells by PBAE 536 NPs leading to cancer-specific 
apoptosis. 
Locally Administered PBAE NPs Enable DNA Delivery to HepG2 Xenograft Tumors and Slow 
Tumor Growth 
To evaluate the translational potential of this approach in vivo, we assessed delivery of a 
reporter gene to HCC xenograft tumors. HepG2 tumors were established in the hind flank of 
athymic nude mice. PBAE NPs carrying a plasmid encoding firefly luciferase (fLuc)43 were 
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injected directly into the tumors at a 5 μg DNA dose. 24, 48, 72, and 96 hours later, D- luciferin 
was administered, and in vivo bioluminescence imaging was performed. Strong luciferase 
expression was detected as early as 24 hours after treatment (Figure 4.13A). The average total 
flux across the tumor area was significantly higher than background, with an average total flux of 
1.1 ± 0.3 x 106 p/s (Figure 4.13B). Radiance was greatest at 24 hours, then decreased over the 
course of four days, with the average total flux still 5-fold higher than background 96 hours after 
injection. All in vivo imaging can be found in Figure 4.14. This study confirmed that PBAE 536 
NPs enable efficient gene delivery to HepG2 tumors in vivo. 
Finally, to evaluate the in vivo efficacy of this system, subcutaneous xenograft HepG2 
tumors were randomly assigned to one of three treatment arms: control fLuc NPs, IV vorinostat, 
or sTRAIL NPs with IV vorinostat. Nanoparticles harboring fLuc plasmid were selected to 
control for potential immunogenicity or toxicity from expression of a foreign protein and isolate 
the TRAIL-mediated anti-tumor effect.44 Vorinostat was selected for in vivo testing because it 
showed promising in vitro anti-cancer activity in combination with sTRAIL NPs, and this drug is 
already clinically approved for human use to treat cutaneous T-cell lymphoma.45 Starting 14 days 
after tumor implantation, every four days animals received intratumoral injection of PBAE NPs 
at a 10 μg DNA dose and/or intravenous administration of vorinostat at an estimated blood 
concentration of 10 μM. Tumor measurements over the first four days of treatment indicated that 
sTRAIL NP with vorinostat showed significantly slowed growth compared with animals 
receiving control NPs, from  (Figure 4.15A). No antitumor effect was observed from vorinostat 
alone. Median survival with sTRAIL NP and vorinostat treatment was 39 days, compared to a 
median of 26 days in the control NP alone and vorinostat alone groups (Figure 4.15B), an 
increase of 50%. 
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4.4 Discussion  
Here we describe a novel non-viral TRAIL gene therapy that induces potent and cancer-
specific cell death in HCC. We utilize PBAE 536 NPs, a gene delivery vehicle which facilitates 
cancer-specific transfection in a wide range of HCC cell lines28. Structurally similar polymers 
have been optimized to specifically transfect brain, lung, and breast cancers, showing the 
versatility of this strategy in heterogeneous tumors and diverse cancer types.29,46–48 While the 
mechanism of cancer-specific uptake and transfection is not fully understood, work by Zamboni 
et al. indicates that it is not driven by differences in cell division rate or NP uptake alone28. Our 
group found that changes in PBAE endcap structure bias the route of endocytosis, thereby 
influencing NP uptake and transfection.26,49,50 Kim et al. showed that endocytosis route is 
predictive of transfection efficacy, with clathrin-mediated endocytosis of PBAE NPs 
disproportionately responsible for transfection over caveolae-mediated endocytosis and 
macropinocytosis.48 Because endocytosis is one of many pathways frequently dysregulated in 
cancer, a link between material properties and biological mechanism may provide a means for 
rational design of cancer-targeting biomaterials.51 
A non-viral plasmid was constructed to enable exogenous expression of a secretable 
trimeric TRAIL protein. We show that the HCC-targeted PBAE 536 NPs enabled therapeutic 
delivery of the new plasmid encoding for secretable TRAIL. Transfection of HepG2 HCC cells 
with sTRAIL plasmid results in high levels of TRAIL protein secretion, enabling cell killing of 
both transfected cells and non-transfected bystander cancer cells. Because non-viral delivery 
vehicles tend to have lower transfection efficacy than viral methods, and penetration of tumors 
can be difficult, this bystander effect is critical to achieve potent tumor killing. In this case, 
PBAE NPs enable 53% transfection, but >80% cell death by sTRAIL gene therapy. 
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Corroborative results by Shah et al. demonstrated that a cDNA encoding secretable TRAIL 
protein delivered virally to glioma cells also induced apoptosis in non-infected bystander cells.24 
Due to this bystander effect, transfection with sTRAIL cDNA produces a significantly enhanced 
therapeutic effect over non-secreted TRAIL. In contrast to previous work, the current research 
demonstrates that secretable TRAIL can be delivered efficaciously through non-viral NPs.  
One major barrier to TRAIL therapy for cancer is the well-documented innate and 
acquired TRAIL resistance in certain tumors.52  We used HDAC inhibitors vorinostat, sodium 
butyrate, and MS-275 to sensitize HepG2 cells to TRAIL gene therapy. With increasing 
concentrations of these small molecule drugs, there is a synergistic and dose-dependent increase 
in TRAIL-mediated cell death and upregulation of phosphatidyl serine on the outer cell 
membrane. Studies have shown that HDAC inhibitors caused upregulation of death receptors and 
Bcl-2 family proapoptotic factors while simultaneously downregulating inhibitors of apoptosis.53 
We found that vorinostat treatment induced upregulation of death receptor expression in HepG2 
cells, suggesting a mechanism for the observed increase in TRAIL sensitivity. While it remains 
to be seen whether this sensitizing mechanism is conserved between cancer types, these results 
are further evidence that clinically approved HDAC inhibitors may improve clinical efficacy of 
TRAIL therapies, including gene therapy. Future studies of sTRAIL combination therapy in cells 
derived from primary human tumors would be valuable to better understand the heterogeneity of 
TRAIL resistance in a clinical setting. These studies may also reveal biomarkers that can be used 
to select for patients who are more likely to respond to TRAIL treatment in a personalized 
medicine approach.46 
TRAIL is known to selectively initiate apoptosis in cancer cells while sparing normal 
cells, which has underpinned its investigation as a targeted cancer therapy.  Interestingly, we find 
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that TRAIL-conditioned media combined with HDAC inhibitors may have equivalent or greater 
toxicity to healthy hepatocytes than to HCC cells. This contrasts with historical studies showing 
that TRAIL has minimal off-target toxicity to normal cells.6,54 However, there have been 
published reports of elevated TRAIL toxicity in human hepatocytes relative to rodent or primate 
cells, which suggests that TRAIL sensitivity in normal cells is species-specific.55 Additionally, 
combination treatment with sensitizing drugs has been reported to also sensitize healthy cells to 
TRAIL.56 Therefore, the hepatotoxicity observed in these studies is consistent with the 
established literature. Death receptors have also been implicated in liver injury, including 
steatohepatitis and hepatitis.57  Elevated DR4 and DR5 expression in these conditions result in 
increased TRAIL-mediated hepatocyte apoptosis.  Because liver tumors often develop in patients 
with underlying liver disease, this highlights the importance of employing cancer-targeted 
delivery vehicles for TRAIL therapy to minimize off-target hepatotoxicity.58 In further 
development of sTRAIL NPs in orthotopic tumor models, it will be essential to evaluate the 
bystander effect to healthy hepatocytes and closely monitor toxicity to the surrounding liver 
tissue.  
The in vivo results demonstrate that PBAE NPs are effective for gene delivery to solid 
HCC tumors. A secretable TRAIL plasmid was constructed and validated to release sTRAIL to 
the supernatant, cause apoptosis of liver cancer cells, and synergize with small molecule drugs. 
PBAE NPs were validated to selectively transfect liver cancer cells over healthy hepatocytes, and 
via delivery of sTRAIL, enable liver cancer cell-specific killing. PBAE NPs shuttling a cDNA 
encoding for sTRAIL slow HepG2 tumor growth when combined with systemically administered 
vorinostat. To our knowledge, this is the first demonstrated application of PBAE NPs for the 
treatment of liver cancer. Successful development of a potent non-viral TRAIL gene therapy has 
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broad implications for cancer treatment. While subcutaneous tumors were used for these studies 
to allow direct access for intratumoral injection and measurement, they fail to accurately 
recapitulate the tumor microenvironment and interactions between cancer and stromal cells.59 
Further, intratumoral injection of therapeutic agents is not feasible in a clinical setting, and 
systemic delivery introduces additional delivery barriers, including serum aggregation or 
degradation, macrophage uptake, and intratumoral pressure.60 Therefore, future work should 
employ orthotopic HCC tumor models to study biodistribution, off-target transfection, and 
systemic toxicity of PBAE NPs. 
Because death receptors are upregulated on many cancer types, sTRAIL gene therapy is 
not limited to HCC. Tzeng et al. showed that PBAE NPs encoding for membrane-expressed 
TRAIL selectively induced > 60% cell death in lung and pancreatic cancers, suggesting that 
these cancer types may be suitable future targets for sTRAIL NPs.31 These NPs also have a 
promising safety profile, due to their rapid degradation in physiological conditions. Here we 
show that PBAE 536 NPs are non-toxic to hepatocytes, and PBAE NPs also have been proven 
safe in brain and retinal tissues in vivo.61,62 Further, PBAE 536 NPs are within the size range to 
potentially passively target tumors by the EPR effect. In addition, recent work shows that PEG-
conjugated PBAE NPs have enhanced stability and tumor penetrating properties.63 Thus, non-
viral PBAE sTRAIL NPs, with favorable pharmacokinetics and enabling sustained in vivo gene 
expression, may have therapeutic promise for various solid tumors. 
4.5 Conclusion 
 Non-viral delivery of cDNA encoding for secreatable TRAIL in combination with HDAC 
inhibitors results in in vitro and in vivo anti-tumor efficacy in hepatocellular carcinoma with 
168 
 
minimal toxicity to human hepatocytes. Considering the safety benefits of utilizing a non-viral 
gene therapy vector, this approach should be investigated further for clinical use. 
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4.7 Figures and Tables 
 




Figure 4.2 PBAE 536 NPs Enable Selective Intracellular Delivery of a Reporter Gene to 
HepG2 Cells In Vitro. A. Chemical structure of polymer 2-((3-aminopropyl)amino)ethanol end-
modified poly(1,5-pentanediol diacrylate-co-3-amino-1-propanol) (PBAE 536). B. Viability of 
HepG2 and THLE3 cells after treatment with PBAE 536 NPs at a range of eGFP DNA doses. 
Toxicity was determined by staining samples 1:200 with propidium iodide (PI) and measuring 
the percentage of PI+ cells by flow cytometry. C. In vitro eGFP transfection of HepG2 HCC 
cells and THLE3 hepatocytes by PBAE 536 NPs measuring the percentage of GFP+ cells by 
flow cytometry. Data represent mean ± SEM of three replicate wells. Statistically significant 
differences in transfection between HepG2 and THLE3 determined using two-way ANOVA 





Figure 4.3 Synthesis of polymer 2-((3-aminopropyl)amino)ethanol end-modified poly(1,5-
pentanediol diacrylate-co-3-amino-1-propanol) (PBAE 536). 1,5-pentanediol diacrylate (B5) 
is combined with 3-amino-1-propanol (S3) at a 1:1.1 ratio of B5 to S3 and reacted neat under 
stirring at 90° C for 24 hours. The resulting acrylate-terminated polymer is dissolved in THF and 
reacted with 2-(3-aminopropylamino)ethanol (E6) in 10-fold excess for 1 hour at room 
temperature. Endcapped polymer is ether purified and dried under vacuum. Resulting polymer 





Figure 4.4 Encapsulation efficiency of PBAE 536 NPs. Gel electrophoresis of 0.03 µg/µL 
eGFP plasmid and PBAE NPs formulated with eGFP plasmid and a 25, 50, and 75 w/w ratio of 
PBAE 536 polymer. 
 
Figure 4.5 Hydrodynamic diameter of PBAE 536 NPs. Diameter of electrostatically 
complexed NPs comprised of PBAE 536 and plasmid DNA at a 25 weight ratio (w/w). 





Figure 4.6 Viability and cellular fluorescence after transfection with empty pN3 backbone 
A. Viability of HepG2 and THLE3 cells after treatment with PBAE 536 NPs at a range of pN3 
DNA doses. Toxicity was determined by staining samples 1:200 with propidium iodide (PI) and 
measuring the percentage of PI+ cells by flow cytometry. B. In vitro pN3 transfection of GFP+ 







Figure 4.7 Transfection with PBAE 536 NPs Carrying the sTRAIL Plasmid Results in 
Production and Secretion of Human TRAIL Protein A. Map of the engineered sTRAIL 
plasmid. B. Intracellular and C. Secreted human TRAIL protein in HepG2 cells measured by 
ELISA after PBAE 536 NP treatment. D. Representative phase contrast images of HepG2 cells 
after transfection with PBAE 536 NPs containing eGFP, mTRAIL, or sTRAIL plasmid DNA. 
Scale bar = 200 μm. E. Treatment-mediated cell death in HepG2 cells measured by MTT, 
expressed as a percentage of metabolic activity normalized to untreated HepG2 cells. All data 
represented as mean ± SEM of n = 3 replicate wells. Significant differences between groups 













Figure 4.9 HDAC Inhibitors cause upregulation of death receptor expression and sensitize 
HepG2 cells to TRAIL NPs. HepG2 death receptor (DR4 and DR5) expression by A. Western 
blot and B. flow cytometry after 24-hour vorinostat treatment. HepG2 cell viability 48 hours 
after transfection with either mTRAIL or sTRAIL NPs and treated with varying doses 
of C. vorinostat, D. sodium butyrate, and E. MS-275. Data represented as mean ± SEM of n = 3 
replicate wells. Significant differences between sTRAIL and mTRAIL-treated cells are 
determined by two-way ANOVA and Sidak’s multiple comparison test. *P < 0.05, **P < 0.01, 





Figure 4.10 HDAC inhibitor cytotoxicity. Viability of HepG2 and THLE3 cells treated with 






Figure 4.11 Combination Treatment with sTRAIL NPs and HDAC Inhibitors Causes a 
Dose-Dependent and Cancer-Specific Apoptosis. A. Histograms of Annexin V staining (FL1-
A) in HepG2 cells transfected with sTRAIL NPs and treated with various doses of the HDAC 
inhibitors vorinostat, sodium butyrate, and MS-275. B. Quantification of Annexin V staining 
results by flow cytometry, showing HepG2 cells treated with HDAC inhibitors and with PBAE 
536 NPs containing GFP or sTRAIL. Comparisons between sTRAIL and control NP treatments 
were made by two-way ANOVA and Sidak’s multiple comparison test. C. Cell death 48 hours 
after transfection, normalized to negative controls treated with GFP NPs and corresponding 
HDAC inhibitor dose to calculate treatment-mediated cell death. Comparisons between HepG2 
and THLE3 were made by two-way ANOVA and Sidak’s multiple comparison test. D. Secreted 
human TRAIL protein in sTRAIL-transfected HepG2 HCC cells and THLE3 healthy 
hepatocytes, measured by ELISA 48 hours after transfection. Comparison of TRAIL 
secretion between HepG2 and THLE3 was made by unpaired t test with Welch’s correction. 






Figure 4.12 Effects of sTRAIL Conditioned Media Non-transfected HepG2 and THLE3 cells 
were treated with conditioned media from sTRAIL-transfected HepG2 cells (sTR-CM). After 48 
hours, a viability assay was performed, and data was normalized to control wells with matched 
HDAC inhibitor exposure. All data is represented as mean ± SEM of n = 3 replicate wells. **P < 
0.01, ****P < 0.0001. 
 
Figure 4.13 Intratumoral Administration of PBAE 536 NPs Results 
in Strong Gene Expression in Subcutaneous Xenograft Tumors. A.  Bioluminescence images 
of subcutaneous HepG2 tumors 24 hours after treatment with fLuc-PBAE 536 
NPs. B. Average bioluminescence over time in tumors injected with PBAE 536 NPs containing 
firefly luciferase plasmid DNA.  Data represent mean ± SEM of 4-5 animals. Statistically 
significant differences between tumors treated and untreated tumors were calculated using one-






Figure 4.14 Intratumoral transfection time course. Bioluminescence images of subcutaneous 
xenograft HepG2 tumors treated with intratumoral injections of PBAE 536 NPs containing 






Figure 4.15 sTRAIL NPs Administered Intratumorally with Systemic Vorinostat Slow the 
Growth of HepG2 Subcutaneous Xenografts A. Normalized subcutaneous HepG2 tumor size 
over 4 days in animals treated with control NPs only (N=7), vorinostat only (N=3), and sTRAIL 
NPs with vorinostat (N=8). Data is represented as mean ± SEM. Significant differences in 
average tumor size between groups determined by two-way ANOVA with Sidak correction for 
multiple comparisons. *P < 0.05 B. Kaplan-Meyer survival curves of tumor-bearing mice. 
Dotted line drawn to indicate 50% survival.  
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Chapter 5: Poly(beta-amino ester) Nanoparticles for 




Hepatocellular carcinoma (HCC) accounts for 90% of liver cancer and has an estimated 
overall 5-year survival rate of only 10%1,2. In the United States, incidence of HCC is increasing, 
and the mortality rate is rising faster than any other leading cancer3. While surgery or liver 
transplantation can be curative, most patients present with invasive HCC and are only eligible for 
palliative and locoregional treatments4,5. Broadly cytotoxic treatments, including chemotherapy 
and radiation, have off-target toxicities to healthy hepatocytes, which is particularly dangerous 
due to the high incidence of underlying liver disease6,7. Accordingly, there is a critical need for 
an effective, targeted treatment option for HCC.  
In contrast to chemotherapy, gene therapies can target tumors by multiple mechanisms, 
including targeting of the delivery vehicle, transcriptional targeting, and molecular targeting8. 
This has led to interest in developing nucleic acid therapies. For example, oncolytic viruses have 
reached late stage clinical trials for treatment of bladder cancer, glioblastoma, head and neck 
cancer9. However, viral gene delivery methods have elicited concern due to risk of insertional 
mutagenesis and acute immunogenicity, which can be life-threatening. Viruses also have 
limitations of cargo capacity and manufacturing challenges, which limits scale-up10.  
In contrast, nanoparticle (NP) delivery vehicles are typically safer but historically 
suffered from low transfection efficiency11. Poly(beta-amino-ester) (PBAE) is a synthetic 
polymer that was developed to overcome barriers to intracellular gene delivery12. PBAEs contain 
hydrolysable ester bonds in the backbone which degrade on the order of hours and reduce the 
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toxicity of the polymer13. They also contain titratable amines that buffer the endosomal pH and 
facilitate endosomal escape and intracellular cargo release14,15. Cationic PBAE polymer 
complexes with anionic nucleic acids can be formulated as ~100 nm particles, which is a 
desirable size range for intracellular delivery and for accumulation in solid tumors through leaky 
vasculature16,17. 
Transcriptional targeting employs promoters with specific activity in target cells to 
restrict therapeutic gene expression18,19. There has been great interest in investigating regulatory 
elements that may target gene expression selectively in cancer cells. While truly cancer-specific 
promoters are relatively rare, notable examples include the promoter of telomerase20, 
progression-elevated gene-3 (PEG-3)21 and prostate-specific antigen (PSA)22. Alpha fetoprotein 
(AFP) is the main biomarker of liver cancer, as expression is undetectable in healthy adults, yet 
high levels are detected in ~80% of HCC cases23. AFP promoter and enhancer sequences have 
shown efficient and selective expression in AFP-producing HCC cells24. 
One hurdle to gene therapy is reducing the host immune system response to therapeutic 
nucleic acids. One such response is the recognition of unmethylated CpG sequences, which are 
found in bacterial DNA, by toll-like receptor 9 expressed in plasmacytoid dendritic cells25,26. 
When activated, the dendritic cells release cytokines to recruit and activate natural killer cells 
and T cells, and this has been shown to induce inflammation and shorten the duration of gene 
expression27,28. Therefore, there has been interest in developing CpG-free plasmids for gene 
therapy, including CpG free backbones, genes, and promoters29–31.  
Another hurdle is safe and selective delivery of nucleic acids to target cancer cells. We 
recently reported that select PBAE formulations enable robust and cancer-specific plasmid DNA 
delivery to HCC cells32. However, that initial finding has not yet been extended to tumor-
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targeted therapy. Here we develop a completely CpG free transcriptionally targeted plasmid 
encoding for mutant herpes simplex virus type1 sr39 thymidine kinase (sr39) under the control of 
the AFP promoter and enhancer. Sr39 is a theranostic enzyme that 1) converts the prodrug 
ganciclovir (GCV) into a cancer-killing compound and 2) phosphorylates radiolabeled 
nucleoside analogs to enable PET imaging of gene expression (Fig 1). Combining two layers of 
selectivity, we show that an HCC-specific nontoxic, biodegradable nanocarrier (PBAE 536) with 
a transcriptionally targeted theranostic suicide gene therapy enables sr39 delivery to HCC tumors 
for safe and effective tumor control and molecular genetic imaging. 
5.2 Methods 
PBAE Synthesis 
1,5-Pentanediol diacrylate (B5) (Monomer-Polymer and Dajac Labs, Trevose, PA), and 
3-amino-1-propanol (S3) (Alfa Aesar, Ward Hill, MA) were combined neat at a 1:1.1 ratio for a 
1.5 g total mass and allowed to polymerize under stirring for 24 hours at 90°C. This polymer was 
then dissolved in anhydrous THF. 2-(3-aminopropylamino)ethanol (E6) (Sigma-Aldrich, St. 
Louis, MO) was added in 10-fold molar excess and stirred at room temperature (RT) for 1 hour. 
The resulting polymer was washed 2X in diethyl ether and dried under vacuum for several days. 
Polymer was dissolved in anhydrous DMSO and stored with desiccant at -20°C at 100 mg/mL. 
Molecular weight was measured by gel permeation chromatography (GPC) relative to 
polystyrene standards (Waters 2414 Refractive Index Detector, Milford, MA). 
NP Formation and Characterization 
Plasmid DNA and PBAE 536 polymer were diluted separately in sodium acetate (25 mM, 
pH=5), then combined at equal volumes for a final DNA concentration of 0.03 mg/mL and 
polymer:DNA weight ratio (w/w) of 25. For transmission electron microscopy (TEM), NPs were 
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added to a plasma-treated, carbon-coated copper grid, stained with 0.5% uranyl acetate, then 
dried for one hour at RT. Images were acquired using a Philips/FEI BioTwin CM120 
Transmission Electron Microscope. For aqueous analysis, NPs were diluted 5X in sodium 
acetate, then 1:1 in PBS. A Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) 
was used to measure hydrodynamic radius and zeta potential. 
Cell Culture 
Hep 3b (ATCC® HB-8064™), SK-HEP-1 (ATCC® HTB-52™), PC-3 (ATCC® CRL-
1435™), and THLE-3 (ATCC® CRL-11233™) cells were purchased from ATCC (Manassas, 
VA). Huh-7 was kindly provided by Dr. Phuoc Tran's laboratory from the Johns Hopkins 
University School of Medicine. Hep3b, SK-HEP-1 cells were cultured in Minimal Essential 
Medium (MEM) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 100 
μM of MEM non-essential amino acids solution, and 1 mM of sodium pyruvate. Huh7 and PC-3 
cells were cultured in high glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum, 1% penicillin-streptomycin. THLE-3 cells were cultured in 
bronchial epithelial cell growth Medium (BEBM) with the additives from the kit (BEGM Bullet 
Kit [CC3170]; Lonza/Clonetics Corporation, Walkersville, MD), except gentamycin-
amphotericin and epinephrine, 10% FBS and 1% penicillin-streptomycin. For THLE-3 culture, 
flasks and plates were coated with 0.01 mg/mL of human fibronectin, 0.03 mg/mL of bovine 
collagen type I, and 0.01 mg/mL of bovine serum albumin dissolved in BEBM basal medium 
and incubated overnight at 37°C. Coating solution was aspirated prior to seeding. THLE-3 cells 
were not used beyond passage 5. Cell cultures were maintained in a humidified incubator, at 37 
°C, with 5% CO2. 
In Vitro Transfection 
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Cells were seeded in 96-well plates one day prior to transfection. Media was changed 
immediately prior to transfection. NPs were formulated as described above at 25 w/w and a final 
DNA concentration of 0.03 mg/mL (600 ng/well) or alternate dosing as specified. After waiting 
10 minutes for assembly, 20 μL of NPs were added per well (100 μL of media). Cells were 
incubated with NPs for 2 hours, then media was changed. Viability was measured 24 hours after 
transfection using the MTS assay CellTiter 96 AQueous Nonradioactive Cell Proliferation Assay 
(Promega, Madison, WI). Transfection efficacy was determined 48 hours after using flow 
cytometry for GFP expression measurement. Cells were resuspended in 1X PBS with 2% FBS 
with a 1:200 dilution of propidium iodide, and a Attune NxT Flow Cytometer was used to 
measure GFP expression. Data was analyzed using FlowJo v10 (Ashland, OR). Events were 
gated on FSC-H and SSC-H to identify the cell population, then on BL1-A and YL1-A to gate 
for GFP expression in live cells. 
CMV-sr39 and AFP-sr39 
Geneious 8.0.4 (Biomatters, Auckland, New Zealand) was employed throughout the 
plasmid design process. The 1131 base pair sequence of the wild type herpes simplex virus (type 
1 /strain RH2) thymidine kinase (HSV-TK) gene, obtained from the European Nucleotide 
Archive, was modified to produce the sr39 mutant33, in which Leu, Ile, Phe, Ala, and Leu 
residues are replaced with Ile, Phe, Leu, Phe, and Met in the amino acid positions 159, 160, 161, 
168 and 169, respectively. The 2144 base pair composite AFP enhancer and promoter sequence 
was obtained from the pDRVE-AFP-hAFP plasmid (Invivogen, San Diego, CA catatog # pdrive-
afphafp). The sr39 gene was added to the 3’ AFP enhancer and promoter sequence, separated by 
a the KpnI (5’-GGTACC-3’) restriction endonuclease cutting site. A SbfI (5’-CCTGCAGG-3’) 
restriction endonuclease cutting site was placed on the 5’ end, and the NheI (5’-GCTAGC-3’) 
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restriction endonuclease cutting site was added to the 3’ end of the construct. This entire 
construct was then sent for custom synthesis by Genscript (Piscataway, NJ). 
To synthesize the AFP-sr39 plasmid, 10 μg each of the gene synthesis product from 
Genscript and pCpGRich-mcs backbone from Invivogen (catalog # pcpgr-mcs) were separately 
digested with SbfI-HF and NheI-HF (New England Biolabs, Ipswich, MA) according to the 
manufacturer’s instructions for 10 hours at 37°C. Digestion products were run on a 0.8% agarose 
gel and visualized under UV light. The bands of interest were excised from the gel, and DNA 
was recovered using the QIAquick Gel Extraction Kit (Qiagen catalog # 28704). DNA 
concentration from extraction products was assessed with a NanoDrop 2000 Spectrophotometer 
(Thermo Scientific), and ligation was carried out at a 1 to 7 vector to insert volume ratio. T4 
DNA Ligase and buffer (NEB catalog # M0202S) were mixed with DNA at 4°C, and the ligation 
reaction was incubated at 16°C overnight. ChemiComp GT115 E. coli, acquired frozen from 
Invivogen (catalog # gt115-11), were transformed via heat shock using 5μL of the ligation 
product. Bacteria was cultured in 450 μL of SOC outgrowth medium (NEB catalog # B9020S) 
for 1 hour at 37°C. The full 500 μL of the bacteria suspension was streaked in an LB agar plate 
with Zeocin at 100 μg/mL. The plate was placed in a 37°C dark incubator for 16 hours. A single 
colony was then harvested, and bacteria allowed to grow for additional 8 hours in LB Broth 
(Quality Biological catalog # 340-004-101). QIAprep Spin Miniprep Kit (Qiaqen catalog # 
27104) was used to isolate plasmid DNA, which was then sent for DNA sequencing (Sanger 





To eliminate all CpG dinucleotides within the sr39 gene, CpG-creating codons, i.e., 
containing a CpG or forming a CpG with the preceding or succeeding codons, were replaced 
with non-CpG-creating synonyms by following the degenerate human genetic code. The 
selection of the synonymous triplet substituting a CpG-creating codon was based on the Codon 
Usage Tabulated from GenBank (CUTG) and always prioritized synonyms with higher 
frequency of occurrence in humans. A 10 nucleotide construct containing the ScaI (5’-
AGTACT-3’) restriction endonuclease cutting site, and a 10 nucleotide sequence containing the 
NheI (5’-GCTAGC-3’) restriction site were designed to flank the 5’ and 3’ ends of the gene, 
respectively. This construct was synthesized by Integrated DNA Technologies (IDT), and a 10 
nucleotide overhang containing the ApaLI (5’-GTGCAC-3’) restriction site was subsequently 
incorporated into the 5’ end by PCR using FP: 
AATTCTGTGCACAGCTTAGACCAGTACTAT and RP: 
TGCTTATGCTTATATGGCTAATGCTAGCTC as primers. This CpG free sr39 insert was 
cloned into the pCpGfree-vitroNmcs backbone from Invivogen (catalog # pcpgvtn-mcsg) with 
the restriction enzymes ApaLI (NEB catalog # R0507S) and NheI-HF (NEB catalog # R3131S) 
as described above.  
CpGf-AFP-sr39 
To remove CpG dinucleotides from the AFP enhancer and promoter, the sequence 
evaluated for putative transcription factor binding sites using the TRANSFAC database (version 
8.3) through the PROMO website34,35. A 95% similarity between predicted regulatory site and 
transcription factor matrix was the established threshold for a hit to be reported. CpG sequences 
within the AFP enhancer and promoter sequences were identified (total of 6) and modified 
according to the following strategies: 1) Only one nucleotide was replaced within each CpG 
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dinucleotide, and their purine or pyrimidine identity was maintained, i.e., cytosines were 
replaced by thymidines and guanines by adenines; and 2) The selection of cytosine or guanine 
for substitution was based on the distribution of regulatory sites. In the AFP promoter and 
enhancer, there were no cases in which both nucleotides were identified as being a part of 
predicted transcription factor binding sites. Next, a designed construct consisting of the CpG free 
sr39 gene was added to the 3’ end of the CpG free AFP sequence. Also, a 1520 base pair 
sequence, corresponding to base pairs 4403 to 435 of the pCpGfree-vitroNmcs vector and 
containing the EcoRI restriction site, was added to the 5’ end of the CpG free AFP sequence. 
This entire construct was then sent for custom synthesis by Genscript (Piscataway, NJ). This 
CpG free AFP-sr39 insert was cloned into the pCpGfree-vitroNmcs backbone from Invivogen 
(catalog # pcpgvtn-mcsg) with the restriction enzymes EcoRI-HF (NEB catalog # R3101S) and 
NheI-HF (NEB catalog # R3131S). Cloning was performed as described above. 
TLR9 Activation Assay 
HEK-BlueTM hTLR9 cells were purchased from Invivogen (catalog # hkb-htlr9) and 
cultured according to manufacturer’s instructions. Plasmid DNA or CpG ODN (positive control) 
was added at a volume of 20 μL per well. Cells were prepared in HEK-BlueTM Detection 
medium, and ~80,000 cells were added to each well (180 μL volume). Cells were incubated 
overnight 37 °C, with 5% CO2. Absorbance was measured at 620 nm using a Biotek Synergy 2 
plate reader (Winooski, VT).  
In vitro sr39 expression PCR 
Transfection of Hep3b cells with sr39 plasmids was performed as described above. The 
mRNA was harvested 48 hours later, reverse transcribed, and prepared for PCR using a Cells-to-
CT 1-step Power SYBR Green kit from Invitrogen (catalog # A25600) according to the 
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manufacturer’s instructions. The optional DNase step was performed to remove plasmid DNA 
from the samples. The following primers were designed and used for sr39 detection: FP: 
GCCCTTCCTGAGGACAGACAC, RP: GGAGGCTGGGAGCTCACATG. qRT-PCR was 
performed using a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, 
CA) with the cycling parameters specified for the Cells-to-CT kit. Threshold and baseline values 
were standardized across all samples and all runs to ensure accurate comparison. The 
comparative CT method was used to quantify relative expression levels36. Barcode amplification 
was normalized to the housekeeping gene GAPDH to quantify NP accumulation of each PBAE 
with each barcode relative to the genomic DNA content. Then, this value was normalized to non-
specific background amplification in untreated cells, by subtracting the ΔCT of amplification in 
untreated cells, thereby obtaining ΔΔCT.  
ΔΔCT = (CT sr39 −  CT GAPDH)treated − (CT sr39 −  CT GAPDH)untreated 
In vitro sr39 Cell Killing Assay 
GCV was purchased from Invivogen (catalog # sud-gcv) and reconstituted according to 
the manufacturer’s instructions. Transfection of Hep3b, Huh 7, SK-HEP-1, PC-3 and THLE-3 
cells with sr39 plasmids was performed as described above. One day after transfection, media 
was prepared with GCV at the desired concentration, then added to the cells. For long-term 
studies, media with GCV was replenished every two days. To measure viability, the MTS assay 
CellTiter 96 AQueous Nonradioactive Cell Proliferation Assay (Promega, Madison, WI) was 
used according to the manufacturer’s instructions. 
Assessment of native AFP expression by cells lines 
 Huh-7, Hep 3b, SK-HEP-1, PC-3, and THLE3 cells were stained for native AFP 
expression using immunocytochemistry. Cells (~150,000) were fixed using BD Phosflow™ Fix 
199 
 
Buffer I (BD Biosciences catalog # 557870) at 37°C for 10 minutes. After washing with BD 
Pharmingen™ Stain Buffer (FBS) (BD Biosciences catalog # 554656), cells were permeabilized 
using cold BD Phosflow™ Perm Buffer III (BD Biosciences catalog # 558050) on ice for 30 
minutes and washed twice with stain buffer. Cells were stained with PE Mouse Anti-Human 
Alpha-fetoprotein (BD Biosciences catalog # 563002) at a 1:20 dilution in stain buffer for 20 
minutes. Cells were then washed twice with PBS then resuspended in a buffer solution (2% FBS 
in1xPBS).  Stained cells were run through a HyperCytTM autosampler (IntelliCyt Corporation, 
Albuquerque, NM) connected to a BD Accuri™ C6 Flow Cytometer (BD Biosciences, San Jose, 
CA). The collected data were analyzed using the FlowJoTM software v.10.1r7 (Ashland, OR) for 
percentage (AFP positive %) and intensity of AFP expression (geometric mean). Gating was 
performed using unstained samples and was adjusted to account for varying autofluorescence 
between cell types. Staining was performed in triplicate. 
In vitro 18F-FHBG Uptake Assay 
PET radiotracer 9-(4-18F-fluoro-3-hydroxymethylbutyl)guanine (18F-FHBG) was 
radiolabeled immediately prior to the study37,38. Cells receiving no treatment were used as 
controls. At day 2 post-transfection, 18F-FHBG uptake studies were performed. Huh-7, Hep3b, 
SK-HEP-1, and PC-3 cells were treated with serum-free media for 24 hours to sync cell cycles. 
THLE3 was not serum starved due to the sensitivity of this cell line. One hour prior to treatment, 
serum-free media was replaced with serum-containing media. Cells were incubated with 10 
μCi/mL of freshly-prepared 18F-FHBG for one hour at 37°C then washed 5x with RPMI media 
containing 10% serum to remove extracellular 18F-FHBG. RIPA buffer (50 μL 1x) was added to 
the cells and incubated on ice for 5 minutes until cells were completely lysed. Radioactivity of 
the cell lysate samples was measured using an automated gamma counter (LKB Wallace 1282 
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Compugamma CS Universal Gamma Counter). Fifteen serial dilutions of 18F-FHBG were used 
as standards to calculate radiotracer accumulation. Protein content for each sample was measured 
by Pierce™ BCA Protein Assay Kit (ThermoFisher catalog #23225) as directed by the 
manufacturer. Data were recorded as radioactivity (μCi) normalized to protein mass (μg). 18F-
FHBG uptake studies were performed in triplicate. 
Orthotopic Tumor Model 
All in vivo procedures were approved and overseen by the Johns Hopkins Institutional 
Animal Care and Use Committee (IACUC). Female athymic nude mice (NU/J) were purchased 
from Jackson Laboratory (Bar Harbor, ME) and were implanted with orthotopic liver tumors at 
6-8 weeks of age. Hep3b cells with or without constitutive firefly luciferase expression (fLuc+) 
were resuspended in a 1:1 mixture of HBSS and Corning Matrigel Matrix High Concentration 
(Corning, catalog # 354248) at 50 million cells/mL. Prior to implantation, animals were 
anesthetized with 2.5% isoflurane in oxygen, and the skin was cleaned with povidone-iodide and 
ethanol. An incision was made with a scalpel extending caudally from the xiphoid process. The 
left lateral liver lobe was visualized, and 1 million (20 μL) cells were injected under the liver 
capsule. Successful inoculation with cancer cells was be verified by pale, white protrusion at the 
point of injection. fLuc+ Hep3b tumor growth was monitored by IVIS (IVIS Spectrum imaging 
system, Perkin Elmer, Waltham, MA). 150 mg/kg D-luciferin (Gold Biotechnology, St. Louis, 
MO) was administered intraperitoneally to mice, then imaging was performed 8 minutes later. 
Images were analyzed across regions of interest (ROI) using Living Image software (Perkin 
Elmer, Waltham, MA).  
In vivo Gene Delivery to Orthotopic Tumors 
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NPs for intravenous delivery were formulated by combining DNA with PBAE 536 in 
sodium acetate (pH 5) for a final DNA concentration of 0.25 mg/mL and 25 w/w. NPs were 
allowed to assemble for 10 minutes before adding sucrose to a final concentration of 90 mg/mL, 
and a final solum acetate concentration of 25 mM. NPs were frozen at -80°C and thawed 
immediately prior to use. Four weeks after tumor implantation with non-fLuc expressing Hep3b 
cells, mice received a single retro-orbital injection of 100 μL NPs. For biodistribution, 10% of 
DNA was functionalized with amine groups using Label IT® Nucleic Acid Modifying Reagent 
(Mirus, Beltsville, MD, # MIR 3925), then labeled with IRDye® 800RS NHS Ester (Licor, 
Lincoln, NE). One hour after NP injection, fluorescence was measured in the organs of interest 
using IVIS imaging. For reporter gene transfection, fLuc expression was imaged using IVIS 24 
hours after NP injection, as described above. 
For qRT-PCR analysis, organs were harvested 24 hours after NP injection. Tissues were 
homogenized in Trizol reagent, then chloroform was added for phase separation. After 
precipitation with isopropanol and washing with 75% ethanol, the RNA was resuspended in 
water. Next, the samples were treated with RNase-Free DNase Set (Qiagen, Hilden, Germany) to 
remove plasmid DNA. Reverse transcription was performed using High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific, Waltham, MA). cDNA was amplified using Power 
SYBR Green (Thermo Fisher Scientific, Waltham, MA) and a StepOnePlus Real-Time 
Polymerase Chain Reaction (RT-PCR) System (Applied Biosystems) with sr39 primers: FP: 
GCCCTTCCTGAGGACAGACAC, RP: GGAGGCTGGGAGCTCACATG. Expression was 
quantified using the comparative CT method normalized to GAPDH expression. Fold expression 
was calculated as follows: 
𝐹𝑜𝑙𝑑 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  2−∆∆𝐶𝑇 
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 sr39 Therapeutic Efficacy Study 
Mice were implanted with fLuc+ Hep3b tumors, and tumor growth was monitored by 
IVIS beginning 2 weeks after implantation and every 4 days thereafter. NP treatment began 
when tumor luminescence (total flux) reached 109 p/s. Animals were randomly assigned to 
treatment groups to receive either fLuc NPs, CpGf-CMV NPs, or CpGf-AFP NPs. NPs were 
formulated for IV injection as described above and were administered every 4 days by retro-
orbital injection. GCV was administered daily at 50 mg/kg via intraperitoneal injection. 16 days 
after the start of treatment, animals were anesthetized, and blood was collected by cardiac 
puncture for liver enzyme analysis. Blood was incubated at RT to clot, then spun down to isolate 
the serum. Liver enzyme levels were analyzed using an Alanine Aminotransferase Activity 
Assay Kit and an Aspartate Aminotransferase Activity Kit from Sigma Aldrich (St. Louis, MO). 
After euthanasia, tumor area was measured using calipers. Outliers were identified and removed 
using the ROUT method with the most stringent criteria (Q = 0.1%). Significant differences 
between groups were identified by ordinary one-way ANOVA and Tukey’s multiple 
comparisons test.  
For histopathology, tissues were fixed in 10% formalin for 2 days, dehydrated and 
cleared, then embedded in paraffin. Paraffin sections were stained using hematoxylin and eosin, 
then mounted and imaged using a Zeiss AxioObserver.Z2 (Oberkochen, Germany). Sections 
were analyzed by a trained veterinary pathologist (KLG). T2 weighted MRI scans were 
performed using a Bruker 9.4T horizontal bore spectrometer and analyzed using ImageJ.  
sr39 PET Imaging Study 
Mice were implanted with fLuc+ Hep3b tumors. Four weeks after implantation, animals 
were imaged using IVIS to determine relative tumor size, then randomly assigned to receive 
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either fLuc NPs, CpGf-CMV NPs, or CpGf-AFP NPs. NPs were formulated for IV injection as 
described above and were by retro-orbital injection. The next day, 18F-FHBG was radiolabeled 
37,38, and a 150 μCi dose in an isotonic 10% ethanol solution was administered to animals via tail 
vein injection. Two hours after injection, animals were imaged using a 7T PET-MR  (Bruker, 
Billerica, MA). After imaging, animals were euthanized, and liver, tumor, spleen, kidneys, heart, 
and lungs were dissected, weighed, and measured using a Wizard 2 Automatic Gamma Counter 
(Perkin Elmer, Waltham, MA). Tissue radiopharmaceutical uptake values were calculated 
compared with 15 µCi 18F-FHBG as a standard. 
5.3 Results 
PBAE 536 (Figure 5.2A) was selected for DNA delivery based on its ability to 
specifically transfect HCC cancer cells in previous studies32. The polymer was synthesized by 
Michael addition as previously described32, with a final molecular weight of 5638 Da and a 
polydispersity index of 1.29 by GPC. PBAE 536 NPs harboring plasmid DNA had a 
hydrodynamic diameter of 137 ± 3 nm (PDI=0.064) and zeta potential of +18.5 ± 0.6 mV. TEM 
images showed that dried NPs have a spherical morphology and a diameter of ~50-100 nm 
(Figure 5.2B). Hep3b HCC cells were transfected in vitro with PBAE 536 NPs at doses of 300-
1200 ng GFP DNA per well to assess transfection efficacy. GFP expression was dose dependent 
with a maximal transfection rate of 47 ± 3% (Figure 5.2C and E). Viability was maintained at > 
80% for all formulations tested (Figure 5.2D).  
The HSV-TK system is a promising approach for cancer suicide gene therapy39. This 
enzyme catalyzes the phosphorylation of GCV, converting it into a nucleotide analog which 
inhibits DNA polymerization in dividing cells39. sr39 is a mutant form of HSV-TK with 
significantly increased affinity for GCV33. 18F-FHBG is a substrate of sr39 used for molecular 
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genetic imaging40,41. 18F-FHBG accumulates in cells transfected with sr39, and this activity may 
be imaged using PET to monitor therapeutic gene expression. This theranostic functionality 
allows for optimization of the treatment protocol, enabling precision dosing. 
The sequence of the wild type herpes simplex virus (type 1 /strain RH2) thymidine kinase 
gene was modified to produce the sr39 mutant33. The coding sequence for sr39 was placed under 
the control of a human elongation factor 1 (EF1) alpha core promoter with mouse CMV 
enhancer sequence (Figure 5.3A), enabling ubiquitous expression of the theranostic gene (CMV-
sr39). For a transcriptionally targeted vector, the sr39 sequence was placed under the control of a 
human AFP promoter and enhancer (AFP-sr39) (Figure 5.3B).  
CpG free versions of these plasmids were designed to reduce TLR9 activation and reduce 
the risk of inflammation31,42. In the sr39 coding sequence, codon redundancy was employed to 
eliminate CpG sequences while maintaining the amino acids translated. Codons were selected 
based on usage bias in the human genome to maximize translational efficiency. Regulatory 
elements were modified to maintain known transcriptional elements while removing CpG 
sequences. Known human transcription factor binding sites within the human AFP promoter and 
enhancer sequences were identified using PROMO34,35. Six CpG sequences were identified, with 
each sequence overlapping with a known transcriptional regulatory element by only one base 
pair. The non-overlapping base pair was changed to remove the CpG, with purines exchanged for 
purines (G to A) and pyrimidines for pyrimidines (C to T).  
Final CpG free plasmids were constructed by cloning CpG free sr39, into a completely 
CpG free pCpGfree-mcs backbone with the included CpG free EF1-CMV promoter (CpGf CMV 
sr39) or replacing that promoter with the engineered CpG free AFP promoter and enhancer 
(CpGf AFP sr39). Control plasmids with CpG-containing sr39 sequence and regulatory 
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sequences were designed in a control CpG containing pCpGrich-mcs backbone. These control 
plasmids containing CpG are referred to as “unmodified” CMV-sr39 and AFP-sr39. 
To assess the effect of removing CpG on plasmid immunogenicity, HEK Blue reporter 
cells for human TLR-9 activation were incubated with CpG-containing or CpG free sr39 
plasmids. Both CMV-sr39 and AFP-sr39 DNA containing CpG caused dose-dependent elevated 
TLR9 activation (Figure 5.3C, D). The CpG free versions of these plasmids did not cause any 
detectable TLR9 activation, demonstrating that removal of CpG sequences reduces the innate 
immune response to these therapeutic plasmids. To evaluate the effect of CpG on promoter 
strength, Hep3b cells were transfected with each sr39 plasmid using PBAE 536 NPs and qRT-
PCR was performed on isolated mRNA. Both CMV-sr39 and CpGf-CMV-sr39 promoted robust 
sr39 expression, with no detrimental effect from removing the CpG sequences (Figure 5.3E). 
AFP-sr39 also showed significant expression but had a significant decrease in expression 
following removal of CpG sequences. This result highlights the importance of balancing the 
decrease on immunogenicity with possible decreased efficacy when utilizing CpG free vectors. 
Despite differences in relative promoter strength, Hep3b cells transfected with each sr39 
formulation with 4 days of GCV treatment showed a significant decrease in viability, with 
maximal effect at a DNA dose of 900 ng per well (Figure 5.3F). Under these conditions, cell 
viability was reduced to 25 ± 1% and 57 ± 1% with CpGf-CMV-sr39 and CpGf-AFP-sr39, 
respectively. Additionally, CpGf-CMV-sr39 maintained superior cell killing effect to wild-type 
HSV-TK, despite extensive modifications to the coding sequence (Figure 5.4). The optimal 
concentration of GCV for in vitro cell killing was determined to be 1.25 μg/mL due to the strong 
therapeutic effect in sr39-transfected cells with no toxicity to cells transfected with control GFP 
NPs (Figure 5.5).  
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To evaluate transcriptional targeting in heterogeneous populations, several cell lines were 
tested for sr39 cell killing in vitro. Huh7 and Hep-3b are AFP-producing HCC cells, SK-HEP-1 
is a non-AFP-producing HCC cell line, PC3 is a non-AFP-producing prostate cancer cell line, 
and THLE-3 is a healthy human hepatocyte cell line43. AFP expression was confirmed by flow 
cytometry (Figure 5.6A). Each cell line was transfected with a GFP reporter gene using PBAE 
536 NPs and screened for expression to determine transfection rates. All cancer cell lines showed 
significantly elevated transfection of 40-60%, compared with 12% in healthy hepatocytes 
(Figure 5.6B). This result was expected, as PBAE 536 NPs were optimized by screening for 
high transfection rates in HCC cell lines and low transfection in hepatocytes32. All transfected 
cell lines maintained > 80% viability (Figure 5.6C).  
Next, each cell line was transfected with CpG free sr39 plasmids using PBAE 536 NPs, 
treated with GCV, and viability was measured over 9 days (Figure 5.6D-H). In all lines, cells 
transfected with CpGf-CMV-sr39 showed significant cell death, with 3-10% viability by day 9. 
With CpGf-AFP-sr39 transfection, there was also significant cell death in AFP-producing HCC 
cells, with 26 ± 1% and 15 ± 2% viability on Day 9 in Hep3b and Huh 7 cells, respectively. 
However, in all non-AFP-producing cells, viability remained high for the course of the study. 
PC3 and THLE-3 cells were >90% viable, while SK-HEP-1 cells viability dipped to 72 ± 9% by 
Day 9, indicating that there may be limited activity in SK-HEP-1 cells despite no detectable AFP 
production. 
To evaluate the utility of this approach for molecular genetic imaging, transfected cells 
were incubated with 10 μCi/mL 18F-FHBG, and in vitro tracer uptake was measured 1 hour later 
(Figure 5.7A-E). Significant radioactivity was measured in all cells transfected with CpGf-
CMV-sr39, ranging from 1600-7200 pCi/μg protein in cancer cells and 220 pCi/μg protein in 
207 
 
THLE-3 hepatocytes. With CpGf-AFP-sr39 transfection, significant accumulation was only 
measured in AFP-producing HCC cells, with 800 ± 100 and 720 ± 50 pCi/μg protein in Hep3b 
and Huh7, respectively. While not statistically significant, SK-HEP-1 cells transfected with 
CpGf-AFP-sr39 had 220 ± 20 pCi/μg protein, again suggesting low levels of activity. 
Transfection with CpGf-AFP-sr39 resulted in 43 ± 3 and 50 ± 9 fold higher accumulation in 
Huh7 and Hep3b over THLE3, and this HCC-specificity was not observed with CpGf-CMV-sr39 
(Figure 5.7F, G).  
To recapitulate barriers to systemic gene delivery, we employed an orthotopic xenograft 
model of HCC, implanting Hep3b cells in the livers of athymic NU/J mice. When PBAE 536 NP 
harboring fluorescently labeled DNA were administered intravenously in tumor-bearing mice, 
NPs largely accumulated in the liver (Figure 5.8A,B). This is in agreement with biodistribution 
metanalyses of NPs of this size44. Of the major organs, ~7% of total fluorescence signal was 
localized to the tumor. To further probe gene delivery in this model, PBAE 536 NP were used to 
deliver firefly luciferase (fLuc) reporter DNA in tumor-bearing mice (Figure 5.8C, D). 24 hours 
later, transfection was localized to the tumor, with 8-fold higher radiance in the tumor than liver 
on average.  
Next, CpGf-CMV-sr39 and CpGf-AFP-sr39 were administered to tumor-bearing mice to 
probe sr39 expression in vivo using these two vectors. Relative expression of sr39 was 
determined using qRT-PCR 24 hours after NP administration. CpGf-CMV-sr39 promoted sr39 
expression in the tumor, but also off-target expression in the liver and lung (Figure 5.8E). With 
transcriptional targeting, CpGf-AFP-sr39 NPs resulted in highly targeted sr39 expression in the 
tumor alone (Figure 5.8F). On average, sr39 expression was higher in animals treated with 
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CpGf-CMV-sr39 than in those treated with CpGf-AFP-sr39, which is consistent with the in vitro 
analysis of relative promoter strengths. 
To evaluate the therapeutic potential of this approach, tumor-bearing mice were divided 
into treatment groups receiving intravenous injections of fLuc NPs, CpGf-CMV-sr39 NPs, or 
CpGf-AFP-NPs. Each animal received 4 NP injections spaced 4 days apart, then were sacrificed 
16 days after the start of treatment. All animals received 50 mg/kg GCV daily by intraperitoneal 
injection. When tumors were measured at the end of the study, animals treated with CpGf-AFP-
sr39 NPs had an average tumor area of 27 ± 4 mm2 compared with 71 ± 8 mm2 and 79 ± 16 mm2 
for fLuc NP and CpGf-CMV-sr39 treated animals respectively (Figure 5.9A, 7B). This 
represents a significant decrease of 62% compared to fLuc NP treated tumors. Markedly smaller 
tumor size is also evident in representative MRI scans of mice treated with CpGf-AFP-sr39 
(Figure 5.10). At the end of the study, serum liver enzymes ALT and AST were not elevated 
compared with untreated controls for any NP group (Figure 5.11). Additionally, there were no 
signs of abnormalities or toxicities in tissues harvested at the end of this study, as determined by 
histopathology of hematoxylin and eosin-stained paraffin tissue sections (Figure 5.12).  
Next, this system was tested for in vivo PET imaging. Four weeks after tumor 
implantation, animals were divided into treatment groups to receive a single intravenous 
injection of fLuc NPs, CpGf-CMV-sr39 NPs, or CpGf-AFP-NPs. The following day, the mice 
received a 150 µCi injection of 18F-FHBG and were imaged 2 hours later with PET and T2-
weighted MRI (Figure 5.9C). Activity was observed in the tumor in animals treated with CpGf-
AFP-sr39, but not in animals treated with fLuc or CpGf-CMV-sr39 NPs (Figure 5.13). 
Following imaging, organs were harvested, and 18F activity was measured in major organs 
(Figure 5.9D) Animals treated with CpGf-AFP-NPs showed significant and specific activity in 
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tumor tissue. Interestingly, CpGf-CMV-sr39 showed lower activity in the tumor and no 
significant off-target transfection. This result is in agreement with the results of the therapeutic 
study, which surprisingly showed no therapeutic effect from CpGf-CMV-sr39 NPs, despite 
significantly stronger activity in vitro. This may be due to silencing mediated by the innate 
immune system, which has been shown to affect strong ubiquitous viral promoters such as CMV 
and EF1 more strongly than tissue-specific promoters, particularly in the liver45–47.  
5.4 Discussion 
Suicide gene therapy has shown promise but ultimately has faced several hurdles in 
clinical translation for patients with HCC. In a 2010 phase I study, a thymidine kinase-based 
adenoviral gene therapy was well-tolerated, showing potential for safe use in humans48. 
However, transgene expression was not detectable with repeated administrations of viral 
particles, indicating rapid immune recognition and silencing, leading to a modest overall median 
survival time of 5 months48. This highlights the need for alternative delivery strategies with 
lower immunogenicity and improved targeting. Here we advanced such a strategy using: 1) a 
safe, non-viral delivery vehicle, 2) AFP promoter for transcriptional targeting, and 3) completely 
CpG free plasmids to reduce TLR9 activation. 
PBAE NPs offer several advantages for DNA delivery to solid tumors. A large library of 
PBAE polymers may be synthesized rapidly using combinatorial chemistry to formulate a library 
of polymers with wide structural diversity12. Small changes in properties including 
hydrophobicity, molecular weight, and effective pKa can dramatically affect cellular uptake and 
transfection efficacy of NPs 49–51. Additionally, next generation PBAE polymers incorporating 
bioreducible, branched, and carboxylated structures have enabled delivery of siRNA, miRNA, 
and protein therapeutics52–54. PBAE NPs have low toxicity and no risk of insertional 
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mutagenesis, clear benefits over viral delivery strategies. This study is the first use of PNAE NPs 
for systemic DNA delivery, which enables the use of orthotopic tumor models and is a more 
clinically relevant intravenous route of administration, particularly for treating metastases, 
compared with intratumoral injection. Despite modest levels of NP accumulation within tumor 
tissue, PBAE 536 enabled expression of a reporter gene as well as theranostic sr39 genes in 
orthotopic HCC tumors with a high degree of specificity, which ultimately resulted in effective 
tumor cell killing and tumor imaging. 
This specificity is further enhanced by incorporating the AFP promoter and enhancer for 
transcriptional targeting, safeguarding against systemic toxicity from systemic administration. In 
this study, the AFP promoter and enhancer restricted sr39 expression to AFP-producing HCC 
cell lines, with no off-target cell killing or radiotracer accumulation in non-HCC cells, including 
healthy human hepatocytes. This specificity also translated in vivo, where systemically 
administered CpGf-AFP-sr39 NPs transfected the tumor but not liver or other healthy mouse 
tissues. Overall, this clearly demonstrates the specificity of this platform for AFP-producing 
HCC cells. Interestingly, despite reduced promoter strength, CpGf-AFP-sr39 showed improved 
therapeutic activity over CpGf-CMV-sr39 in vivo. This may be due to transcriptional silencing 
of the strong ubiquitous CMV/EF1 promoter45–47. Alternatively, the non-targeted platform may 
result in off-target transfection and killing of Kupffer cells, significantly altering the liver and 
tumor microenvironments and potentially affecting tumor growth55. While CpGf-AFP-sr39 NPs 
showed high potency in vivo, improving the strength of this promoter should be investigated to 
maximize therapeutic potential. Employing a two-step transcriptional amplification (TSTA) 




A novel CpG free version of the sr39 gene was developed and utilized in two theranostic 
plasmids: CpGf-CMV-sr39 and CpGf-AFP-sr39. Methylated CpG dinucleotides have been 
shown to stimulate cytokine production and reduce the duration of transgene expression27. This 
is the first reported use of a completely CpG free sr39 gene and AFP promoter, which we 
showed reduces TLR9 activation while maintaining cell killing and molecular genetic imaging 
functionality in vitro and in vivo, despite extensive sequence alterations. We noted that removing 
CpG dinucleotides from the AFP promoter and enhancer sequences resulted in reduction of sr39 
expression and activity. This highlights the importance of balancing the safety concerns of CpG 
sequences and promoter strength for therapeutic gene expression. Nonetheless, CpGf-AFP-sr39 
showed impressive therapeutic efficacy in vivo, with a 62% reduction in tumor size compared 
with controls. Studies have also shown significant T cell involvement in thymidine kinase gene 
therapy57, raising the possibility for further enhanced therapeutic benefit in a syngeneic model.   
Overall, this approach improves upon clinically tested adenoviral TK-gene therapy by: 1) 
employing a safe, biodegradable non-viral polymer DNA delivery system rather than 
immunogenic viral vectors, 2) removing CpG sequences to reduce TLR-9 activation, which has 
been linked to gene silencing and inflammation in vivo, 3) using sr39, a mutant form of HSV-TK 
with higher affinity for GCV and improved efficacy, and 4) employing AFP transcriptional 
targeting for highly specific expression in cancer cells. Altogether, these advancements improve 
the clinical compatibility of the system and improve its translational potential and have the 






1. Golabi, P, Fazel, S, Otgonsuren, M, Sayiner, M, Locklear, CT and Younossi, ZM (2017). 
Mortality assessment of patients with hepatocellular carcinoma according to underlying 
disease and treatment modalities. Medicine (Baltimore). 96. 
2. El–Serag, HB and Rudolph, KL (2007). Hepatocellular Carcinoma: Epidemiology and 
Molecular Carcinogenesis. Gastroenterology 132: 2557–2576. 
3. Shaw, JJ and Shah, SA (2011). Rising incidence and demographics of hepatocellular 
carcinoma in the USA: what does it mean? Expert Rev. Gastroenterol. Hepatol. 5: 365–
370. 
4. Bruix, J, Boix, L, Sala, M and Llovet, JM (2004). Focus on hepatocellular carcinoma. 
Cancer Cell 5: 215–219. 
5. Park, J, Chen, M, Colombo, M, Roberts, LR, Schwartz, M, Chen, P, et al. (2015). Global 
patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE 
Study. Liver Int. 35: 2155–2166. 
6. Huang, Y-S, Chiang, J-H, Wu, J-C, Chang, F-Y and Lee, S-D (2002). Risk of hepatic 
failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: 
predictive value of the monoethylglycinexylidide test. Am. J. Gastroenterol. 97: 1223–
1227. 
7. Yang, JD, Hainaut, P, Gores, GJ, Amadou, A, Plymoth, A and Roberts, LR (2019). A 
global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. 
Rev. Gastroenterol. Hepatol. 16: 589–604. 
8. Karlsson, J, Vaughan, HJ and Green, JJ (2018). Biodegradable Polymeric Nanoparticles 
213 
 
for Therapeutic Cancer Treatments. Annu. Rev. Chem. Biomol. Eng. 9: 105–127. 
9. Lundstrom, K (2018). Viral Vectors in Gene Therapy. Dis. (Basel, Switzerland) 6: 42. 
10. Phillips, AJ (2001). The challenge of gene therapy and DNA delivery. J. Pharm. 
Pharmacol. 53: 1169–1174. 
11. Zhou, Z, Liu, X, Zhu, D, Wang, Y, Zhang, Z, Zhou, X, et al. (2017). Nonviral cancer gene 
therapy: Delivery cascade and vector nanoproperty integration. Adv. Drug Deliv. Rev. 
115: 115–154. 
12. Green, JJ, Langer, R and Anderson, DG (2008). A combinatorial polymer library 
approach yields insight into nonviral gene delivery. Acc. Chem. Res. 41: 749–759. 
13. Guerrero-Cázares, H, Tzeng, SY, Young, NP, Abutaleb, AO, Quiñones-Hinojosa, A and 
Green, JJ (2014). Biodegradable Polymeric Nanoparticles Show High Efficacy and 
Specificity at DNA Delivery to Human Glioblastoma in Vitro and in Vivo. ACS Nano 8: 
5141–5153. 
14. Wilson, DR, Rui, Y, Siddiq, K, Routkevitch, D and Green, JJ (2019). Differentially 
Branched Ester Amine Quadpolymers with Amphiphilic and pH-Sensitive Properties for 
Efficient Plasmid DNA Delivery. Mol. Pharm. 16: 655–668. 
15. Eltoukhy, AA, Siegwart, DJ, Alabi, CA, Rajan, JS, Langer, R and Anderson, DG (2012). 
Effect of molecular weight of amine end-modified poly (β-amino ester) s on gene delivery 
efficiency and toxicity. Biomaterials 33: 3594–3603. 
16. Maeda, H, Wu, J, Sawa, T, Matsumura, Y and Hori, K (2000). Tumor vascular 
permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. 
Release 65: 271–284. 
17. Kang, H, Rho, S, Stiles, WR, Hu, S, Baek, Y, Hwang, DW, et al. (2020). Size-Dependent 
214 
 
EPR Effect of Polymeric Nanoparticles on Tumor Targeting. Adv. Healthc. Mater. 9: 
1901223. 
18. Robson, T and Hirst, DG (2003). Transcriptional targeting in cancer gene therapy. Biomed 
Res. Int. 2003: 110–137. 
19. Qiao, J, Doubrovin, M, Sauter, B V, Huang, Y, Guo, ZS, Balatoni, J, et al. (2002). Tumor-
specific transcriptional targeting of suicide gene therapy. Gene Ther. 9: 168–175. 
20. Abdul-Ghani, R, Ohana, P, Matouk, I, Ayesh, S, Ayesh, B, Laster, M, et al. (2000). Use of 
transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective 
killing of cancer cells. Mol. Ther. 2: 539–544. 
21. Su, Z-Z, Sarkar, D, Emdad, L, Duigou, GJ, Young, CSH, Ware, J, et al. (2005). Targeting 
gene expression selectively in cancer cells by using the progression-elevated gene-3 
promoter. Proc. Natl. Acad. Sci. 102: 1059–1064. 
22. Yu, D, Chen, D, Chiu, C, Razmazma, B, Chow, Y-H and Pang, S (2001). Prostate-specific 
targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 8: 628–635. 
23. Park, JH, Kim, K Il, Lee, YJ, Lee, TS, Kim, KM, Nahm, S-S, et al. (2011). Non-invasive 
monitoring of hepatocellular carcinoma in transgenic mouse with bioluminescent imaging. 
Cancer Lett. 310: 53–60. 
24. Ahn, B-C, Ryu, MJ, Ahn, SJ, Yoon, SM, Choi, SH, Yoo, J, et al. (2006). Construction of 
a highly hepatoma specific adenoviral vector system carrying NIS gene activated by AFP 
enhancer. J. Nucl. Med. 47: 409P-409P. 
25. Bauer, S, Kirschning, CJ, Häcker, H, Redecke, V, Hausmann, S, Akira, S, et al. (2001). 
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif 
recognition. Proc. Natl. Acad. Sci. 98: 9237 LP – 9242. 
215 
 
26. Wagner, H (2004). The immunobiology of the TLR9 subfamily. Trends Immunol. 25: 
381–386. 
27. Hodges, BL, Taylor, KM, Joseph, MF, Bourgeois, SA and Scheule, RK (2004). Long-
term Transgene Expression from Plasmid DNA Gene Therapy Vectors Is Negatively 
Affected by CpG Dinucleotides. Mol. Ther. 10: 269–278. 
28. Scheule, RK (2000). The role of CpG motifs in immunostimulation and gene therapy. 
Adv. Drug Deliv. Rev. 44: 119–134. 
29. Davies, LA, Hyde, SC, Nunez-Alonso, G, Bazzani, RP, Harding-Smith, R, Pringle, IA, et 
al. (2012). The use of CpG-free plasmids to mediate persistent gene expression following 
repeated aerosol delivery of pDNA/PEI complexes. Biomaterials 33: 5618–5627. 
30. Takahashi, Y, Nishikawa, M and Takakura, Y (2012). Development of safe and effective 
nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector. Front. 
Biosci. S 4: 133–141. 
31. Hyde, SC, Pringle, IA, Abdullah, S, Lawton, AE, Davies, LA, Varathalingam, A, et al. 
(2008). CpG-free plasmids confer reduced inflammation and sustained pulmonary gene 
expression. Nat. Biotechnol. 26: 549–551. 
32. Zamboni, CG, Kozielski, KL, Vaughan, HJ, Nakata, MM, Kim, J, Higgins, LJ, et al. 
(2017). Polymeric nanoparticles as cancer-specific DNA delivery vectors to human 
hepatocellular carcinoma. J. Control. Release 263: 18–28. 
33. Black, ME, Kokoris, MS and Sabo, P (2001). Herpes simplex virus-1 thymidine kinase 
mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor 
cell killing. Cancer Res. 61: 3022–3026. 
34. Farré, D, Roset, R, Huerta, M, Adsuara, JE, Roselló, L, Albà, MM, et al. (2003). 
216 
 
Identification of patterns in biological sequences at the ALGGEN server: PROMO and 
MALGEN. Nucleic Acids Res. 31: 3651–3653. 
35. Messeguer, X, Escudero, R, Farré, D, Nuñez, O, Martı́nez, J and Albà, MM (2002). 
PROMO: detection of known transcription regulatory elements using species-tailored 
searches. Bioinformatics 18: 333–334. 
36. Schmittgen, TD and Livak, KJ (2008). Analyzing real-time PCR data by the comparative 
C T method. Nat. Protoc. 3: 1101. 
37. Castanares, MA, Mukherjee, A, Chowdhury, WH, Liu, M, Chen, Y, Mease, RC, et al. 
(2014). Evaluation of Prostate-Specific Membrane Antigen as an Imaging Reporter. J. 
Nucl. Med.  55: 805–811. 
38. Ponde, DE, Dence, CS, Schuster, DP and Welch, MJ (2004). Rapid and reproducible 
radiosynthesis of [18F] FHBG. Nucl. Med. Biol. 31: 133–138. 
39. Fillat, C, Carrio, M, Cascante, A and Sangro, B (2003). Suicide gene therapy mediated by 
the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of 
application. Curr. Gene Ther. 3: 13–26. 
40. Yaghoubi, SS and Gambhir, SS (2006). PET imaging of herpes simplex virus type 1 
thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and 
humans using [18 F] FHBG. Nat. Protoc. 1: 3069. 
41. Tjuvajev, JG, Doubrovin, M, Akhurst, T, Cai, S, Balatoni, J, Alauddin, MM, et al. (2002). 
Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET 
imaging of HSV1-tk gene expression. J. Nucl. Med. 43: 1072–1083. 
42. Surana, S, Shenoy, AR and Krishnan, Y (2015). Designing DNA nanodevices for 




43. Kaneko, S, Hallenbeck, P, Kotani, T, Nakabayashi, H, McGarrity, G, Tamaoki, T, et al. 
(1995). Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-
specific gene expression. Cancer Res. 55: 5283–5287. 
44. Wilhelm, S, Tavares, AJ, Dai, Q, Ohta, S, Audet, J, Dvorak, HF, et al. (2016). Analysis of 
nanoparticle delivery to tumours. Nat. Rev. Mater. 1: 16014. 
45. Herweijer, H, Zhang, G, Subbotin, VM, Budker, V, Williams, P and Wolff, JA (2001). 
Time course of gene expression after plasmid DNA gene transfer to the liver. J. Gene 
Med. 3: 280–291. 
46. Harms, JS and Splitter, GA (1995). Interferon-γ Inhibits Transgene Expression Driven by 
SV40 or CMV Promoters but Augments Expression Driven by the Mammalian MHC I 
Promoter. Hum. Gene Ther. 6: 1291–1297. 
47. Löser, P, Jennings, GS, Strauss, M and Sandig, V (1998). Reactivation of the Previously 
Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: 
Involvement of NFκB. J. Virol. 72: 180 LP – 190. 
48. Sangro, B, Mazzolini, G, Ruiz, M, Ruiz, J, Quiroga, J, Herrero, I, et al. (2010). A phase I 
clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular 
carcinoma. Cancer Gene Ther. 17: 837–843. 
49. Bishop, CJ, Kozielski, KL and Green, JJ (2015). Exploring the role of polymer structure 
on intracellular nucleic acid delivery via polymeric nanoparticles. J. Control. Release 219: 
488–499. 
50. Bishop, CJ, Ketola, T-M, Tzeng, SY, Sunshine, JC, Urtti, A, Lemmetyinen, H, et al. 
(2013). The Effect and Role of Carbon Atoms in Poly(β-amino ester)s for DNA Binding 
218 
 
and Gene Delivery. J. Am. Chem. Soc. 135: 6951–6957. 
51. Routkevitch, D, Sudhakar, D, Conge, M, Varanasi, M, Tzeng, SY, Wilson, DR, et al. 
(2020). Efficiency of Cytosolic Delivery with Poly(β-amino ester) Nanoparticles is 
Dependent on the Effective pKa of the Polymer. ACS Biomater. Sci. Eng. 6: 3411–3421. 
52. Kozielski, KL, Ruiz-Valls, A, Tzeng, SY, Guerrero-Cázares, H, Rui, Y, Li, Y, et al. 
(2019). Cancer-selective nanoparticles for combinatorial siRNA delivery to primary 
human GBM in vitro and in vivo. Biomaterials 209: 79–87. 
53. Lopez-Bertoni, H, Kozielski, KL, Rui, Y, Lal, B, Vaughan, H, Wilson, DR, et al. (2018). 
Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating 
miRNAs inhibit glioblastoma growth and prolong survival. Nano Lett. 18: 4086–4094. 
54. Rui, Y, Wilson, DR, Choi, J, Varanasi, M, Sanders, K, Karlsson, J, et al. (2019). 
Carboxylated branched poly(β-amino ester) nanoparticles enable robust cytosolic protein 
delivery and CRISPR-Cas9 gene editing. Sci. Adv. 5: eaay3255. 
55. Kelley, SK, Harris, LA, Xie, D, DeForge, L, Totpal, K, Bussiere, J, et al. (2001). 
Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related 
apoptosis-inducing ligand in humans: characterization of in vivo efficacy, 
pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299: 31–38. 
56. Iyer, M, Wu, L, Carey, M, Wang, Y, Smallwood, A and Gambhir, SS (2001). Two-step 
transcriptional amplification as a method for imaging reporter gene expression using weak 
promoters. Proc. Natl. Acad. Sci. 98: 14595–14600. 
57. Kuriyama, S, Kikukawa, M, Masui, K, Okuda, H, Nakatani, T, Akahane, T, et al. (1999). 
Cancer gene therapy with HSV-tk/GCV system depends on t-cell-mediated immune 






Figure 5.1 A schema describing a tumor-targeted theranostic approach for the treatment of 
HCC. PBAE NPs are synthesized with transcriptionally targeted plasmid encoding for sr39 gene. 





Figure 5.2. PBAE 536 NPs transfect liver cancer cells with a reporter gene in vitro A. 
Structure of polymer PBAE 536 B. TEM image of PBAE 536 NPs C. In vitro transfection 
efficacy and D. cell viability of Hep3b cells transfected with varying doses of GFP DNA. PBAE 
NPs were synthesized with PBAE 536 at a polymer:DNA mass ratio of 25 (w/w). Mean ± SE are 
shown (n=3). Statistically significant transfection was calculated by one-way ANOVA with 
Dunnett’s multiple comparison test compared to the control.  E. Fluorescence micrographs of 
GFP expression in transfected Hep3b cells. Scale bar = 500 μm. *P < 0.05; **P < 0.01; ***P < 





Figure 5.3. CpG free sr39 plasmids induce sr39tk expression in vitro without elevated 
TLR9 activation (A and B) Plasmid maps are shown for CMV-sr39 and AFP-sr39. (C)  hTLR-9 
activation in HEK-blue reporter cells after exposure to CpG-containing and CpG-free CMV-sr39 
and (D) AFP-sr39 plasmid DNA. Statistically significant differences in TLR9 activation between 
unmodified and CpG free plasmids were determined by two-way ANOVA and Sidak’s multiple 
comparison test. (D) qRT-PCR analysis of sr39 expression in transfected cells. F. Hep3b cellular 
viability 5 days after transfection with sr39 NPs and treatment with 1.25 μg/mL GCV. 
Statistically significant differences among DNAs were determined by two-way ANOVA and 
Sidak’s multiple comparison test. Mean ± SE are shown for all graphs (n=3) *P < 0.05; **P < 
























Figure 5.4 CpG-free SR39 has superior cell killing effect compared with wild-type HSV-
TK. Hep3b cells were transfected with NPs harboring GFP, HSVTK, or CpGf-CMV-SR39 DNA 
and treated with 1.25 µg/mL GCV on days 1, 3, 5, 7, and 9. Significant differences between 
groups were calculated for each time point by two-way ANOVA with Dunnett’s multiple 
comparisons. Mean ± SE are shown (n=3) ****P < 0.0001. 
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Figure 5.5 SR39-mediated cell death with varying GCV doses. Hep3b cells were transfected 
with NPs harboring GFP or SR39 plasmids, then treated with GCV 1 and 3 days after 
transfection. Viability was measured 5 days after transfection by MTS assay. Significant 
differences between groups were calculated for each time point by two-way ANOVA with 




Figure 5.6 AFP transcriptional targeting restricts sr39-mediated cell death to AFP-
producing HCC cells (A) AFP expression in fixed and permeabilized Huh7, Hep 3b, SK-HEP-
1, PC-3, and THLE-3 cells measured by flow cytometry. (B and C) Transfection efficacy and 
viability of cell lines transfected with 600 ng/well GFP DNA using PBAE 536 NPs. Statistically 
significant differences between cell lines were determined using one-way ANOVA with Tukey’s 
multiple comparison’s test. (D-H) Viability time course of cells transfected with CpG free CMV-
sr39 and AFP-sr39 DNA and treated with 1.25 ug/mL GCV. Statistically significant loss in 
viability for each DNA was calculated by two-way ANOVA with Dunnett’s multiple 
comparisons between each timepoint and Day 1. Mean ± SE are shown for all graphs (n=3) *P < 






Figure 5.7 sr39 NPs enable specific accumulation of 18F-FHBG in target HCC cells (A-E). 
Cellular radioactivity in transfected cells incubated with 10 μCi 18F-FHBG for 1 hour, 
normalized to total protein content. Statistically significant differences were calculated by one-
way ANOVA with Dunnett’s multiple comparison test between treatment groups and controls. 
(F,G) Fold radioactivity accumulation in cancer cells normalized to THLE3 cells treated with the 
same NP. Mean ± SE are shown for all graphs (n=3) *P < 0.05; **P < 0.01; ***P < 0.001; 






Figure 5.8 Intravenously Administered NPs Efficiently Transfect Orthotopic HCC Tumors 
A. Average radiance (p/s/cm2/sr) of major organs 1 hours after fluorescent NP administration and 
B. representative image of organs. Significant differences between organ radiance were 
calculated by Kruskal-Wallis nonparametric test and Dunn’s test for multiple comparisons. *P < 
0.05 Data shown as mean ± SE (n=3). C. Average radiance and D. representative images of 
orthotopic tumor and liver transfected with fLuc-NPs administered by tail vein injection. 
Statistically significant differences in radiance between liver and tumor tissue were determined 
by a ratio-paired t test between average radiance over the region of interest. *P < 0.05 Data 
shown as mean ± SE (n=3). E. Fold sr39 expression in organs after IV administration of CMV-
sr39 NPs or F. AFP-sr39 NPs by qRT-PCR. Significant differences between tumor and healthy 
tissue were calculated by Ordinary one-way ANOVA and Dunnett’s test for multiple 






Figure 5.9 CpGf-sr39 NP treatment significantly inhibits tumor growth and enables 
monitoring by PET/CT. Mice with orthotopic xenograft Hep3b tumors were treated with IV 
administration of fLuc NPs (n = 11), CpGf-CMV-sr39 NPs (n = 10), or CpGf-AFP-sr39 NPs (n 
= 8) with systemic GCV. A. After 16 days, tumors treated with CpGf-AFP-sr39 had significantly 
smaller tumors than the other two groups. Mean ± SE are shown. Significant differences between 
treatment groups were determined by one-way ANOVA with Tukey posttests among the three 
groups. *P < 0.05 B. Representative images show differences in tumor size. C. Representative 
PET/MRI imaging shows intratumoral 18F-FHBG activity in a tumor-bearing mouse treated with 
CpGf-AFP-sr39. D. Activity in major organs with fLuc (n=2), CpGf-CMV-sr39 (n=2), or CpGf-
AFP-sr39 (n=3) NPs and subsequent 18F-FHBG injection. Activity was calculated per mass of 
tissue, then normalized to activity in the control group (fLuc NP). Significant differences 
between treatment groups were determined by two-way ANOVA and Tukey posttest. ***P < 





Figure 5.10 T2-weighted MRI scans of the liver and HCC tumors on Day 16. Arrows point 





Figure 5.11 Liver enzyme levels in serum after 16 days of NP + GCV treatment A. ALT 
levels and B. AST levels for untreated animals (n = 3), and tumor-bearing mice treated with fLuc 
NPs (n = 6), CpGf-CMV-sr39 (n = 5), and CpGf-AFP-sr39 (n = 3). Mean ± SE are shown. 
 
Figure 5.12 Representative histopathology after 16 days of NP + GCV treatment Formalin-
fixed and paraffin-embedded tissue sections from the liver, tumor, spleen, kidney, heart, and 





Figure 5.13 Representative PET/MRI imaging of Hep3b orthotopic tumor-bearing mice treated 








 While there have been many advances in cancer treatment over the past decades, the 
efficacy of a novel therapy in a particular patient’s tumor remains unpredictable1,2. With the 
advent of nanomedicines for cancer treatment, small differences in tumor biology, vascularity 
and immune microenvironment can have a large impact on the efficacy of a particular 
therapeutic3,4. Therefore, there is growing interest in developing approaches which incorporate 
agents with therapeutic efficacy as well as capabilities for monitoring the location and activity of 
the therapeutic agent. Gene delivery, in particular, can enable such promising theranostic 
approaches. There is great interest in developing gene therapies for many disease indications, 
including cancer. However, successful delivery of nucleic acids to tumor cells is a major 
challenge, and in vivo efficacy is difficult to predict. Cancer theranostics is an approach 
combining anti-tumor therapy with imaging or diagnostic capabilities, with the goal of 
monitoring successful delivery and efficacy of a therapeutic agent in a tumor. Successful 
theranostics must maintain a high degree of anticancer targeting and efficacy while incorporating 
high-contrast imaging agents that are nontoxic and compatible with clinical imaging modalities. 
This review highlights recent advancements in theranostic strategies, including imaging 
technologies and genetic engineering approaches (Figure 6.1). 
6.2 Multifunctional Nanoparticles 
 
This chapter contains material modified from the following article in press: 
Vaughan, H.J., Green J.J.; Recent Advances in Gene Therapy for Theranostic Cancer Medicine. (2021). Current 
Opinion in Biomedical Engineering. In Press. 
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Multifunctional nanoparticles incorporate two or more biological or chemical 
modifications for enhanced functionality5–7. This may include targeting ligands, bioresponsive 
chemistries, and multiple encapsulated agents which serve therapeutic or diagnostic functions. 
By incorporating an imaging agent into a nanoparticle, it is possible to monitor tissue-level 
biodistribution and functional molecular interactions within the tumor. Imaging agents can be 
linked to nucleic acid cargo through direct covalent conjugation or incorporation into 
supramolecular NPs which also include biomaterials, such as lipids, polymers, and peptides to 
aid in nucleic acid encapsulation and release. Several types of imaging agents have been 
successfully incorporated in therapeutic nanoparticles, with varying sensitivity, resolution, and 
clinical compatibility.  
6.2.1 MR and CT Imaging 
Inorganic materials are popular choices for imaging nanoparticles, as they have desirable 
properties for detection under a range of clinical imaging modalities8. In particular, 
superparamagnetic iron oxide (SPIO) nanoparticles have magnetic properties well suited for MR 
imaging9. SPIO nanoparticles may be coated in polymer or lipid materials to allow nucleic acid 
encapsulation as well as surface functionalization and targeting10. For further spatial targeting, an 
external magnetic force may be used to localize nanoparticles in the tumor tissue and aid in gene 
delivery in a process called magnetofection11. Recent work by Cui and colleagues demonstrated 
that polymer nanoparticles loaded with SPIO showed successful localized transfection of 
primary hippocampal neurons in vivo under an external magnetic field, providing evidence for 
the safety and efficacy of this approach12. 
Gold nanoparticles have also been investigated for dual imaging and nucleic acid 
delivery. Gold nanoparticles have a high degree of X-ray attenuation, generating contrast on a 
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CT scan13. As a delivery material, gold is attractive because it can be functionalized with 
chemical and biological ligands through gold - sulfur (Au-S) bonding14. Thiolated 
oligonucleotides may be conjugated directly to the surface of gold nanoparticles, and work by 
Mirkin and coworkers shows that dense nucleic acid conjugation prevents nuclease degradation 
and improves cellular uptake15. Gold nanoparticles can also be encapsulated in ultrasound 
responsive microbubbles for spatially controlled disruption of cellular membranes, which has 
been shown to enhance intracellular delivery of nucleic acid cargo16–18. 
6.2.2 Optical Imaging and Sensing 
Fluorescent dyes and quantum dots have also been used to enable in vivo tracking by 
optical imaging19. These optical imaging strategies are advantageous because they are sensitive, 
versatile, and enable multiplexing of different agents. The limitations of optical imaging 
strategies are significant background fluorescence and shallow penetration depth (Table 6.1). 
Recently there has been much focus on the development of NIR-IIb (1500–1700 nm) fluorescent 
probes, which are compatible with in vivo imaging due to low tissue autofluorescence and photo-
scattering. Inorganic agents, including quantum dots20, rare-earth nanoprobes21, and carbon 
nanotubes22 have all shown promise in imaging at wavelengths > 1500 nm. A new technology 
termed aggregation-induced emission lumigens (AIEgens) has shown promise as an organic 
probe in the NIR II range23.  
To probe molecular interactions in target cells, biosensors may be incorporated into 
therapeutic nanoparticles by chemical conjugation24,25 or encapsulation26. Sensors can be 
designed to emit a signal in response to the presence of nucleic acids, proteins, or other 
hallmarks of a particular disease27. Typically, these sensors undergo a conformational change in 
the presence of a target molecule or environmental change, and this conformational change 
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affects the spatial position of a fluorophore to change its proximity to a quencher or another 
fluorophore. Sensors have been designed to detect environmental changes such as pH 
change28,29, reactive oxygen30, and ion concentrations31. Sensors have also been developed to 
detect biological activity including enzyme activity32–34 and expression of specific nucleic acid 
sequences35,36. 
6.3 Co-expression of Genetically Encoded Therapeutic and Diagnostic Agents 
 Nonviral nanoparticle delivery vehicles have the potential to deliver multiple nucleic acid 
sequences in a combinatorial manner through simple mixing during particle fabrication37. 
Theranostic functionality can be achieved by either delivering a plasmid that encodes an enzyme 
with both therapeutic and diagnostic function38,39 or by co-delivering nucleic acids encoding for 
diagnostic and therapeutic agents. Therapeutic and diagnostic sequences may be placed in a 
single plasmid under the control of the same promoter in a bicistronic vector40,41 or using a 
bidirectional promoter42,43.  Alternatively, two or more different plasmids or RNA sequences 
may be co-encapsulated, allowing the ratio of each component to be controlled.  
6.3.1 Genetically Encoded Diagnostic Agents 
A. Optical Imaging 
 Encoded fluorescent proteins are powerful tools for monitoring the dynamics of gene 
expression. Protein engineering strategies have been employed to increase chromophore 
brightness, improve stability, and shift the excitation and emission wavelengths44. Specifically, 
longer wavelength fluorescent proteins have been developed which are less susceptible to 
absorption and scattering from tissue45. Additionally, there have been advancements in 
genetically encoded fluorescent biosensors, including optimized sensors for FRET, dimerization, 
translocation, complementation, and fluorescence-modulated single fluorescent protein sensors44. 
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Optoacoustic imaging measures the conversion of optical photon energy to ultrasound 
waves by thermoelastic expansion of a material. This enables measurements to be obtained from 
deeper within the tissue than fluorescence-based methods. Endogenous chromophores include 
melanin and hemoglobin. Stritzker et al. used vaccinia virus to genetically manipulate tumor 
cells to overproduce the polymerized melanin, enabling optoacoustic imaging as well as 
photothermal therapy of tumors46.  
B. MRI 
To create contrast in MRI imaging, the expressed protein or peptide must interfere with 
nuclear spins of surrounding tissue47,48. Much of this work has focused on the development of 
proteins that bind and sequester contrast agents that are endogenous to the target tissue or are 
systemically administered. Ferritin is an iron storage molecule that augments iron uptake in cells 
where it is overexpressed, and engineered ferritin proteins have been developed for enhanced 
imaging properties49,50. More recently, a family of prokaryotic nano compartments called 
encapsulins were expressed in human cells and showed high levels of nontoxic iron 
sequestration51. Encoded proteins have also been designed to sequester intravenously 
administered contrast, including Gd3+ agents52.  
Engineered proteins capable of proton exchange with surrounding molecules are 
detectable by chemical exchange saturation transfer (CEST) MRI53. Gilad et al developed a 
genetically encoded lysine-rich peptide (LRP) reporter with high amide proton exchange rate 
which enables frequency-selective contrast with CEST MRI54. 9L xenograft brain tumors 
expressing the LRP exhibited significant differences in signal-intensity change by CEST MRI 
compared with contralateral control tumors. 
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Finally, genetically encoded agents have been developed to alter cell and tissue water 
content for local MRI contrast. One elegant approach by Mukherjee et al. demonstrates that 
overexpression of the water channel protein aquaporin 1 enables tumor imaging by diffusion-
weighted MRI by changing the cellular permeability to water55. Alternative proteins have also 
been explored in a similar approach, including a pH-sensitive bacterial channel56 and a urea 
transporters57. Similarly, vasoactive peptides or proteins may be locally expressed to increase 
local blood flow and induce contrast changes detectable by MRI58. 
C. Ultrasound 
 Gas bubbles in the form of injected microbubbles are a well-established contrast agent for 
ultrasound59. In recent work by Farhadi et al, researchers engineered genes from waterborne 
microbes to express gas vesicles in mammalian cells (Figure 6.2) 60. Expression of these 
mammalian acoustic reporter genes (mARGs) result in the intracellular production of gas-filled 
nanocompartments, allowing for genetic expression of ultrasound contrast in vitro and in vivo.  
6.3.2 Therapeutic Nucleic Acids 
Many different strategies have been employed to genetically induce cancer cell death61. 
One strategy is to overexpress pro-apoptotic genes in tumor cells, including sequences that 
induce apoptosis62–64, mediate cell cycle arrest65,66, and regulate DNA damage response67. The 
most prominent of these genes in clinical trials is p53, a transcription factor that controls cellular 
stress response and is dysregulated in a majority of human tumors68. Adenovirus expressing p53 
has been tested in many tumor types in clinical trials, including hepatocellular carcinoma, non-
small cell lung cancer, and squamous cell carcinoma69. These trials show the feasibility, safety, 
and antitumor efficacy of this approach, which has led to the approval of the AAV product 
Gendicine in China70. However, no p53 gene therapy has been approved in the US71. 
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Immunotherapy approaches have shown promise in reprograming the immune system to 
destroy tumor cells72. Genetic cancer vaccines deliver nucleic acids encoding for tumor antigen 
to antigen presenting cells for a systemic immune response73–75. Potent antitumor responses have 
also been achieved with the delivery of cytokines to tumors, recruiting pro-inflammatory 
immune cells to the immunosuppressive tumor microenvironment76–78. Cell therapies are a new 
promising category of cancer therapeutic, and much work has been focused on imaging 
technologies for tracking and monitoring adoptively transferred cells in vivo. Prior to adoptive 
transfer, therapeutic cells may be transduced or transfected with genetically encoded imaging 
agents, including fluorescent and luminescent proteins. These imaging strategies have been used 
to study migration, persistence, and proliferation of adoptively transferred cells79. Minn and 
colleagues recently developed chimeric antigen receptor (CAR) T cells expressing a reporter 
transgene with prostate-specific membrane antigen (PSMA), a cancer-specific biomarker 
targeted by a number of radiotracer ligands (Figure 6.3)80. Engineered anti-CD19 CAR T cells 
(CD19-tPSMA(N9Del)) were tracked in vivo using [18F]DCFPyL PET in a model of acute 
lymphoblastic leukemia, showing infiltration in bone marrow metastases as well as the primary 
tumor. Importantly, the PSMA-transduced CAR T cells maintained antitumor efficacy, 
indicating that incorporating this tracking strategy does not impair T cell function. 
Advances in siRNA and miRNA delivery have enabled the targeting of alternative 
pathways involved in cancer progression. siRNAs serve to transiently silence oncogene 
expression in a sequence-dependent manner81. In cancer therapy, targets for siRNA therapy 
include genes involved in proliferation82, survival83,84, and migration85. miRNAs are 
multifunctional sequences which are important for gene expression and regulation and are often 
dysregulated in tumor cells. Recent work to target miRNAs to tumor cells has shown preclinical 
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efficacy, either through delivery of anti-tumor miRNAs86 or anti-miR sequences which target 
destruction of pro-cancer miRNAs87. 
6.4 Expression of Dual-function Theranostic Protein 
Gene-directed enzyme prodrug therapy (GDEPT) utilizes a single enzyme with dual 
substrates for combination therapeutic and diagnostic functions88. One enzyme of this type with 
therapeutic promise is Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK), which converts 
the prodrug ganciclovir into a toxic nucleoside analog89. The same enzyme phosphorylates the 
radiotracer 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU) and 
causes accumulation which is detectable by PET imaging. Thus, the expression in HSV-TK 
alone in tumor cells enables cancer killing and monitoring using imaging. A mutant form of 
HSV-TK termed SR39 was developed by Black et al for enhanced prodrug sensitivity90. Both the 
mutant and wild-type forms have been tested in humans for clinical efficacy91–93 and PET 
imaging94. 
Similarly, nitroreductase enzyme converts the prodrug CB1954 into a bifunctional 
alkylating agent, which induces apoptosis in tumor cells by crosslinking DNA95. This system is 
advantageous over HSV-TK/GCV because it is cell cycle-independent. Substrates for 
nitroreductase include both PET96 and optical97 imaging agents. Additional enzyme/prodrug 
combinations include cytochrome P450/cyclophosphamide98,99 and cytosine deaminase/5-
Fluorocytosine (5-FC) 100–102, although radiotracer substrates for these enzymes have been 
limited103. While these enzymes are paired with a therapeutic prodrug and separate tracer 
molecule, sodium and iodide symporter gene therapy enables both imaging and radiotherapy 
with the administration of radioiodine alone104. This symporter actively transports iodine 
isotopes into the cell, effectively concentrating the radiotracer105. These dual function theranostic 
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strategies that utilize a single enzyme encoded by a delivered gene therapy plasmid are 
advantageous by simplifying manufacturing as well as enabling tight correlation between the 
activity of the therapeutic and the diagnostic imaging read out. 
6.5 Clinical Translation 
While most of the approaches described in this review are in early stages of development, 
there has been early-stage progress in translating theranostic technologies to patients (Table 6.2). 
Nanoparticle imaging agents, including radiolabeled colloids for PET and iron oxide 
nanoparticles for MRI, have been clinically approved to improve contrast in certain solid tumors 
or surrounding lymph nodes106,107. True theranostic strategies remain in early stage clinical 
development. HSV-TK therapy has been the most commonly explored genetically encoded 
theranostic approach, with several Phase I/II trials completed. The major hurdle in translation 
remains improving intratumoral transgene expression108. While viral vectors historically have 
shown improved delivery efficacy over non-viral methods, there are safety concerns and reduced 
efficacy with repeated administrations due to the vector immunogenicity. Additionally, achieving 
improved targeting would improve local concentrations of therapeutics while reducing off-target 
dose-limiting toxicities. Taken together, improving delivery technologies is critical to the clinical 
success of all gene therapies, including theranostic approaches.  
6.6 Conclusions 
Nucleic acid therapeutics have incredible potential for innovative molecular therapy, 
improved cancer specificity, and the ability to disrupt multiple cancer mechanisms 
simultaneously. This review highlights the recent progress that has been made in gene delivery 
systems to monitor biodistribution and activity.  Relevant imaging modalities span from PET and 
MRI to optical and ultrasound. Delivery remains a major barrier to translation of cancer gene 
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therapy, with key improvements needed in tumor targeting and robust transfection throughout 
heterogeneous tumors109,110. Additionally, improved technology and analysis of data is needed to 
better correlate theranostic imaging to clinical prognosis in order to fully realize the potential of 
the theranostic approach. By monitoring therapeutic efficacy in a comprehensive way, it 
becomes possible to better understand the interactions of next-generation nucleic acid therapies 
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6.8 Figures and Tables 
 
Figure 6.1 Theranostic strategies allow for simultaneous therapeutic nucleic acid delivery and 
imaging. MRI: Magnetic Resonance Imaging. PET: Positron Emission Tomography, US: 
Ultrasound. MRI image adapted from ref. 111 Figure 5 B with permission from the Turkish 
Society of Radiology. PET image adapted from ref. 112 Figure 1 with permission from the World 
Academy of Sciences. US image adapted from ref. 113 Figure 4 B with permission from the 
World Federation for Ultrasound in Medicine & Biology. Optical image adapted from ref. 114 1 E 




Figure 6.2. Genetically encoded gas vesicles (mARGs) enable ultrasound imaging of gene 
expression in vivo A. Schematic and B. timeline of subcutaneous tumor implantation and 
doxycycline included expression on mARGs and mCherry in contralateral tumors. C. 
Representative image of mARGs-related ultrasound contrast (heat map) overlayed on B-mode 
imaging showing tumor anatomy. D. Representative image of a control tumor expressing 
mCherry. E. Sequential slices spaced 1 mm apart showing mARG expression in the tumor. 
Adapted from ref. 60 Figure 4 A-E with permission from the American Association for the 





Figure 6.3. PSMA-transduced CAR T cells enable in vivo tracking and extend survival. A. 
Tumor burden on Day 0 and Day 11 of treatment is shown using bioluminescence imaging 
(BLI), and CD19-tPSMA(N9Del) cell tracking in bone marrow metastases (Day 5) and primary 
tumor (Day 12) by PET imaging. B. PSMA-transduced CD19-tPSMA(N9Del) cells extend survival 
compared with negative controls, with efficacy similar to CD19-EGFRt positive control cells. 
Adapted from ref. 80 Figure 4 B and 2 D with permission from the American Association for the 
Advancement of Science. 
 
Modality Resolution Imaging Depth Advantages Drawbacks 
MR 50-500 µm Full Body Excellent resolution, 













PET 0.3-3 mm Full Body Functional imaging Radiation exposure 





Table 6.1 Common imaging modalities and properties115,116. MR: Magnetic resonance, CT: 






Modality Select Product(s) Trial Phase Trial 
Identifier(s) 
Radiolabeled Colloids 99mTc-labeled sulfur colloid  Approved NCT01668914 


















ThermoDox® (LTLD) Phase III NCT00617981 
Gene-directed enzyme 
prodrug therapy (GDEPT) 





GL-ONC1 Phase I NCT00794131 
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Duke University (2012 - 2016)  
- B.S. in Biomedical Engineering, Concentration in Cell and Tissue Engineering 
- Graduation with Departmental Distinction  
- Cum Laude 
 
Peer-reviewed Publications 
1. Vaughan, H.J., Zamboni, C.G.; Radant, N.P.; Bhardwaj P.; Mease, R.C.; Pomper, M.G.; Green, 
J.J.; Polymeric Nanoparticles for Transcriptionally Targeted Theranostic Gene Delivery to 
Hepatocellular Carcinoma. (2021). Manuscript In Preparation 
2. Vaughan, H.J., Green J.J.; Recent Advances in Gene Therapy for Theranostic Cancer Medicine. 
(2021). Current Opinion in Biomedical Engineering. In Press. 
3. Kim, J.*, Vaughan, H.J.*, Zamboni, C.G., Sunshine, J.C., Green, J.J., High-throughput 
Screening of Polymer Structure on Tissue-targeted Gene Expression In Vivo Using Barcoded 
Plasmid DNA. (2021) Journal of Controlled Release. In Press. 
4. Vaughan, H.J., Zamboni, C.G., Radant, N.P., Bhardwaj, P. Hassan, L., Green, J.J., 2021. 
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander 
effect to treat liver cancer. Molecular Therapy: Oncolytics. 
5. Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020). Cancer‐Targeting Nanoparticles for 
Combinatorial Nucleic Acid Delivery. Advanced Materials, 32(13), 1901081.  
6. Karlsson, J.*, Vaughan, H.J.* ,and Green, J.J., 2018. Biodegradable polymeric nanoparticles for 
therapeutic cancer treatments. Annual review of chemical and biomolecular engineering, 9, 
pp.105-127. 
7. Zamboni, C.G., Kozielski, K.L., Vaughan, H.J., Nakata, M.M., Kim, J., Higgins, L.J., Pomper, 
M.G. and Green, J.J., 2017. Polymeric nanoparticles as cancer-specific DNA delivery vectors to 
human hepatocellular carcinoma. Journal of Controlled Release, 263, pp.18-28. 
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8. Lopez-Bertoni, H., Kozielski, K.L., Rui, Y., Lal, B., Vaughan, H.J., Wilson, D.R., Mihelson, N., 
Eberhart, C.G., Laterra, J. and Green, J.J., 2018. Bioreducible Polymeric Nanoparticles 
Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and 
Prolong Survival. Nano letters, 18(7), pp.4086-4094. 
9. Kozielski, K.L., Ruiz-Valls, A., Tzeng, S.Y., Guerrero-Cázares, H., Rui, Y., Li, Y., Vaughan, 
H.J., Gionet-Gonzales, M., Vantucci, C., Kim, J. and Schiapparelli, P., 2019. Cancer-selective 
nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in 
vivo. Biomaterials. 
 
*These authors contributed equally  
 
Patents  
1. Green, J.J., Pomper, M.G., Zamboni, C.G., Vaughan, H.J. and Minn, I., Johns Hopkins 
University, 2020. Transcriptionally targeted and cpg-free plasmid for theranostic gene therapy. 
U.S. Patent Application 16/589,647.  
 
Awards and Recognition  
- Principal Investigators Meeting: NCI Alliance for Nanotechnology in Cancer Outstanding Poster Award 
- Ruth L. Kirchstein F31 NIH National Research Service Award Fellowship, National Cancer Institute 
(2020-present) 
- NIH Cancer Nanobiotechnology Training Center Fellowship recipient (2017)  
- Pathways in Technology Early College High Schools at Dunbar Mentor (2016-present) 
- NSF GRFP Honorable Mention (2016)  
 
Oral Presentations and Posters 
1. Vaughan, H.J., Zamboni, C.G.; Radant, N.P.; Bhardwaj P.; Mease, R.C.; Pomper, M.G.; Green, 
J.J.; Polymeric Nanoparticles for Transcriptionally Targeted Theranostic Gene Delivery to 
Hepatocellular Carcinoma. Presentation. (2020). American Society for Cell and Gene Therapy 
Annual Meeting, Boston, MA (Virtual) 
2. Vaughan, H.J., Sarker, R.; Rui Y.; Zachos N. C.; Donowitz M.; Green J. J.; Polymer-Peptide 
Nanoparticle Targets Intracellular NHE3 Transporter Implicated in Diarrhea. Presentation. (2019) 
Biomedical Engineering Society Annual Meeting, Philadelphia, PA 
3. Vaughan, H.J., Zamboni C.G.; Radant N.P.; Bhardwaj P.; Francisco D.H.; Green J.J.; Polymer 
Nanoparticles for Secreted TRAIL Cancer Therapy. Presentation. (2019) Society for Biomaterials 
Annual Meeting, Seattle, WA 
4. Vaughan, H.J., Zamboni C.G.; Pomper M.G.; Green J.J.; Poly(beta-amino ester) Nanoparticles 
for Therapeutic Gene Delivery to Hepatocellular Carcinoma. Poster. (2018) NIH/NCI Nano 
Alliance PI Meeting, Rockville, MD Outstanding Poster Award 
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5. Vaughan, H.J., Zamboni C.G.; Mease R.C.; Radant N.P.; Bhardwaj P.; Pomper M.G.; Green J.J.; 
Transcriptionally Targeted Biodegradable Polymeric Nanoparticles for Selective Theranostic 
Gene Delivery to Hepatocellular Carcinoma. Poster. (2018) Controlled Release Society Annual 
Meeting, New York, NY 
6. Vaughan, H.J., Zamboni C.G.; Mease R.C.; Radant N.P.; Bhardwaj P.; Pomper M.G.; Green J.J.; 
Transcriptionally Targeted Biodegradable Polymeric Nanoparticles for Selective Theranostic 
Gene Delivery to Hepatocellular Carcinoma. Poster. (2018) Johns Hopkins University Institute 




1. Kim J; Zamboni, C.G.; Vaughan, H.J.; Wilson, D.R.; Green, J.J. High-throughput In Vivo 
Evaluation of Nanobiomaterial-mediated Tissue Targeting of Polymeric Gene Delivery Vectors 
Using DNA Barcodes. Presentation. (2017) Biomedical Engineering Society Annual Meeting, 
Phoenix, AZ 
2. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.J.; Laterra, J.; Green, J.J. MicroRNA 
delivery via poly(beta-amino ester) nanoparticles as a treatment for human glioblastoma. 
Presentation. (2016) 10th World Biomaterials Congress, Montreal, QC Canada.  
3. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.J.; Laterra, J.; Green, J.J. 
Environmentally triggered miRNA nanoparticles as a treatment for human glioblastoma. Poster. 
(2016)  
4. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.J.; Laterra, J.; Green, J.J. 
Environmentally triggered miRNA nanoparticles as a treatment for human glioblastoma. 
Presentation. (2015) US-Japan Symposium on Drug Delivery Systems, Lahaina, HI.  
5. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.J.; Laterra, J.; Green, J.J. Nanoparticles 
for miRNA Delivery as a Potent and Combinatorial Treatment for Glioblastoma. Presentation. 
(2015) Biomedical Engineering Society Annual Meeting, Tampa, FL.  
6. Kozielski, K.L.; Vaughan, H.J.; Kim, B.H.; Tzeng, S.Y.; Magraviti, A.M.; Wang, Y.; Guerrero-
Cazares, H.; Quinones-Hinojosa, A.; Brem, H.; Tyler, B.; Green, J.J.: Poly(beta-amino ester) 
nanoparticles for selective and combinatorial delivery of siRNA and DNA to brain cancer. 
Presentation. (2015) 6th Annual Advanced Study Institute on Global Healthcare Challenges, 
Izmir, Turkey.  
7. Kozielski, K.L.; Vaughan, H.J.; Kim, B.H.; Tzeng, S.Y.; Guerrero-Cazares, H.; Quinones-
Hinojosa, A.; Green, J.J.: Poly(beta-amino ester) nanoparticles for selective and combinatorial 
delivery of siRNA to brain cancer. Presentation. (2015) Society for Biomaterials, Charlotte, NC.  
8. Kozielski, K.L.; Vaughan, H.J.; Kim, B.H.; Tzeng, S.Y.; Guerrero-Cazares, H.; Quinones-
Hinojosa, A.; Green, J.J.: Environmentally triggered nanoparticles for efficient and cancer-
specific DNA and siRNA delivery to glioblastoma. Presentation. (2015) Johns Hopkins School 
of Medicine Neurooncology Monthly Research Meeting, Baltimore, MD.  
9. Kozielski, K.L.; Vaughan, H.J.; Kim, B.H.; Tzeng, S.Y.; Mangraviti, A.; Wang, Y.; Guerrero-
Cazares, H.; Quinones-Hinojosa, A.; Brem, H.; Tyler, B.; Green, J.J. Poly(β-amino ester) 
nanoparticles for selective and combinatorial delivery of siRNA and DNA to brain cancer. 
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Poster. (2015) Johns Hopkins University Institute for Nanobiotechnology Annual Symposium, 
Baltimore, MD. 
10. Kozielski, K.L.; Vaughan, H.J.; Kim, B.; Tzeng, S.Y.; Guerrero-Cazares, H.; Quinones-
Hinojosa, A.; Green, J.J.: Bioreducible nanoparticles for efficient and combinatorial siRNA 
delivery to primary human glioblastoma. Presentation. (2014) Johns Hopkins University Institute 
for Nanobiotechnology Mini Symposium, Baltimore, MD.  
 
Research Experience  
 
Johns Hopkins University Biomedical Engineering, Advisor: Dr. Jordan Green (2016-present)  
- Developed DNA barcodes and qPCR methods for in vivo screening of polymer (PBAE) nanoparticles, 
resulting in a 5X increase in screening throughput  
- With collaborators in Nuclear Medicine, co-invented a transcriptionally targeted CpG-free plasmid 
DNA for theranostic suicide gene expression, enabling liver cancer cell death and radiotracer 
accumulation 
- Applied nucleic acid design principles to develop innovative cancer-targeted therapeutic plasmid DNAs, 
incorporating principles such as transcriptional targeting, codon optimization, and CpG-free sequences 
- Designed and executed in vivo studies of candidate nanoparticles to assess biodistribution, transfection 
targeting, and anti-tumor efficacy and safety in a range of rodent liver tumor (hepatocellular carcinoma) 
models 
- In the first therapeutic application of PBAE polymer nanoparticles for liver cancer, developed employed 
an engineered secretable TRAIL gene therapy, enabling >90% cancer cell death and  
 
 
Duke University, Biomedical Engineering, Advisor: Dr. George Truskey (2014-2016) 
- Created in vitro tissue engineered models of human vasculature to recapitulate structure and physiology 
of blood vessels  
- Developed co-culture models to recapitulate interactions between endothelial cells and smooth muscle 
cells 
- Used immunohistochemistry to verify adequate cellular adhesions and overall tissue morphology 
- Developed a mechanical injury model to mimic endothelial trauma from catheter or stent 
placement 
 
Johns Hopkins University Biomedical Engineering, Advisor: Dr. Jordan Green (Summer 2014) 
- Optimized and characterized combinatorial delivery of siRNA and miRNA to human 
glioblastoma cells using PBAE nanoparticles 
 




- Performed in vitro transcription and RNA purification to support research to solve the 
structure of highly conserved 5’ leader of HIV-1 genome by NMR 
 
Extracurricular and Volunteer Experience 
 
Pathways in Technology Early College High Schools (P-TECH) at Dunbar (2016-Present) 
 
P-TECH is a national organization whose mission is to support high school students in achieving 
Associates degrees in high-demand technical fields while still in high school. As a P-TECH mentor in 
Baltimore, I supported a student from his freshman year of high school through graduation. This involved 
setting up regular one-on-one meetings, participating in career development workshops, and advising my 
student on his career trajectory and education as he pursues a degree in physical therapy. 
 
BME Extramural Development in Graduate Education (EDGE) Director of Internships (2020-Present) 
 
BME EDGE is a student-led organization dedicated to exposing students to non-academic careers and 
preparing them to excel in their chosen career path. Along with my co-director, I assisted PhD students in 
finding, applying to, and completing internships in biotech, pharma, consulting, and finance. In the 2020-
2021 academic year, we placed 8 students in internships. We also built connections with companies in 
order to offer more opportunities in the future. 
 
BME Application Assistance Program Volunteer (2020-2021) 
 
I served as a mentor to a student from an underrepresented background applying to the BME PhD 
program. I met with the student to discuss her application, offered feedback on her materials, and 
provided support throughout the application process.  
 
 
Teaching Assistant Experience 
 
Cellular Engineering (2018, 2020) 
This is an upper-level undergraduate and graduate course which focuses on principles and applications of 
cellular engineering, including modeling cellular processes, genetic engineering, and drug delivery. I held 
weekly office hours, graded homework and exams, and assisted the professors with course organization 
and structure. 
 
Cell and Tissue Engineering Lab: Gene Delivery Lab Module (2018)  
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This is a laboratory-based course where students learn hand-on techniques related to cell and tissue 
engineering. I was responsible for preparing all lab materials, explaining transfection protocols, and 




Pranshu Bhardwaj (2016-2017) 
Pranshu was an undergraduate student at Johns Hopkins University majoring in Cellular and Molecular 
Biology. I worked with Pranshu throughout his senior year He assisted with cloning, cell culture, and 
animal experiments in the lab. He is finishing his second year of medical school at University of Florida. 
 
Nicholas Radant (2016-2019) 
Nick was a Biomedical Engineering undergraduate student at Johns Hopkins University, and he worked 
in the lab with me for three years. During this time, he worked on several projects involving targeted gene 
delivery and treatment for liver cancer. He completed a postbaccalaureate program at NIH and is starting 
an MD/PhD at Marshall University. 
 
David Francisco (2018-2019) 
David is an undergraduate student at Johns Hopkins University majoring in Biomedical Engineering and 
Computer Science. David worked with me for his sophomore year optimizing cell culture and transfection 
protocols. Since this experience, he had the opportunity to work at the Max Planck institute in Germany 
and the Applied Physics Laboratory.  
 
Laboni Hassan (2019-present) 
Laboni is a Biomedical Engineering student at Johns Hopkins University. She worked with me in the lab 
for 2 years and assisted with several projects developing targeted therapeutics for liver cancer. She is 
graduating this spring and starting a Master’s program in Biomedical Engineering at Boston University 
starting Summer 2021. 
 
 
 
